NICE — Íàöèîíàëüíûé èíñòèòóò çäîðîâüÿ è êëèíè÷åñêîãî ñîâåðøåíñòâîâàíèÿ (êà÷åñòâà ìåäèöèíñêîé ïîìîùè) Âåëèêîáðèòàíèè (National Institute for Health and Clinical Excellence)
NK — åñòåñòâåííûå êëåòêè-êèëëåðû (natural killer)
NMDA — N-ìåòèë-D-àñïàðòàò (N-methyl-D-aspartate)
NMDA — N-ìåòèë-D-àñïàðòàòíûå ðåöåïòîðû
NNT — ÷èñëî áîëüíûõ, êîòîðûõ íåîáõîäèìî ïðîëå÷èòü, ÷òîáû äîñòè÷ü êàêîãî-òî óêàçàííîãî ýôôåêòà (Number Need to Treatment)
OR — îòíîøåíèå øàíñîâ (odds ratio)
paCO2 — ïàðöèàëüíîå äàâëåíèå óãëåêèñëîãî ãàçà â àðòåðèàëüíîé êðîâè
PALS — êóðñû ðàñøèðåííûõ ðåàíèìàöèîííûõ ìåðîïðèÿòèé â ïåäèàòðèè (Pediatric Advanced Life Support)
PANDAS — àóòîèììóííîå íåéðîïñèõèàòðè÷åñêîå ðàññòðîéñòâî â äåòñêîì âîçðàñòå, àññîöèèðîâàííîå ñî ñòðåïòîêîêêîâîé èíôåêöèåé (Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
 õîäå ïîäãîòîâêè ñòàòåé ïî èíôåêöèîííûì çàáîëåâàíèÿì â ïåäèàòðèè äëÿ ïîëüçîâàòåëåé ñàéòà ÌåäÓíèâåð èñïîëüçîâàíû òðóäû ñëåäóþùèõ àâòîðîâ:
Banerjee R, Teng CB, Cunningham SA, et al: Randomized. trial of rapid multiplex polymerase chain reaction–based. blood culture identification and susceptibility testing, Clin Infect Dis 69(7):1071–1080, 2015.
Baron EJ, Miller M, Weinstein MP, et al: A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM), Clin Infect Dis 57(4):e22, 2013.
Buchan BW, Ledeboer NA: Advances in identification of clinical yeast isolates by use of matrix-assisted. laser desorption ionization-time of flight mass spectrometry, J Clin Microbiol 51:1359–1366, 2013.
Buss SN, Leber A, Chapin K, et al: Multicenter evaluation of the BioFireFilmArray gastrointestinal panel for etiologic diagnosis of infectious gastroenteritis, J Clin Microbiol 53:915–920, 2015.
Caliendo AM, Hodinka RL: A CRISPR way to diagnose infectious diseases, N Engl J Med. 377(17):1685–1687, 2017. Dien Bard J, McElvania T, Kippe E: Diagnosis of bloodstream infections in children, J Clin Microbiol 54:1418–1424, 2016.
Doern CD, Richardson SE: Diagnosis of urinary tract infections in children, J Clin Microbiol 54:2233–2242, 2016.
Esparcia O, Montemayor M, Ginovart G, et al: Diagnostic accuracy of a 16S ribosomal DNA gene-based. molecular technique (RT-PCR, microarray, and sequencing) for bacterial meningitis, early-onset neonatal sepsis, and spontaneous bacterial peritonitis, Diagn Microbiol Infect Dis 69:153–160, 2011.
Gould LH, Bopp . C, Strockbine N, et al; Centers for Disease Control and Prevention: Recommendations for diagnosis of Shiga toxin–producing Escherichia coli infections by clinical laboratories, MMWR Recomm Rep 58(RR–12):1–14, 2013.
Holcomb ZE, Tsalik EL, Woods CW, McClain MT: Host-based. peripheral blood gene expression analysis for diagnosis of infectious diseases, J Clin Microbiol 55:360–368, 2017.
Herberg JA, Kaforou M, Wright VJ, et al: Diagnostic test accuracy of a 2-transcript host RNA signature for discriminating bacterial vs viral infection in febrile children, JAMA 316(8):835–845, 2016.
Leber AL, Everhart K, Balada-Llasat JM, et al: Multicenter evaluation of BioFireFilm Array meningitis/encephalitis panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens, J Clin Microbiol 54:2251–2261, 2016.
Mahajan P, Kuppermann N, Mejias A, et al: Assocition of RNA biosignatures with bacterial infections in febrile infants aged. 60 days or younger, JAMA 316(8):846–857, 2016.
Miller JM, Binnicker MJ, Campbell S, et al: A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology, Clin Infect Dis 67(6):e1–e94, 2018.
Patel R: MALDI-TOF mass spectrometry: transformative proteomics for clinical microbiology, Clin Chem 59:340–342, 2013.
Popowitch EB, O’Neill SS, Miller MB: Comparison of the BioFireFilmArray RP, Genmarke Sensor, Luminex xTAG RVP1, and Luminex xTAG RVP fast multiplex assays for detection of respiratory viruses, J Clin Microbiol 51:1528–1533, 2013.
Pritt BS, Patel R, Kirn TJ, Thomson RB Jr: Point-counterpoint: a nucleic acid amplification test for Streptococcus pyogenes should replace antigen detection and culture for detection of bacterial pharyngitis, J Clin Microbiol 54:2413–2419, 2016.
Razonable RR, ?sberg A, Rollag H, et al: Virologic suppression measured. by a cytomegalovirus (CMV) DNA test calibrated. to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients, Clin Infect Dis 56:1546–1553, 2013.
Srugo I, Klein A, Stein M, et al: Validation of a novel assay to distinguish bacterial and viral infections, Pediatrics 140(4):e20163453, 2017.
Tsalik EL, Henao R, Nichols M, et al: Host gene expression classifiers diagnose acute respiratory illness etiology, Sci Transl Med. 8(322):322ra11, 2016.
Albenberg L, Kelsen J: Advances in gut mictobione research and relevance to pediatric diseases, J Pediatr 178:16–23, 2016.
Amenyogbe N, Kollmann TR, Ben-Othman R: Early-life host–microbiome interphase: the key frontier for immune development, Front Pediatr 5:111, 2017.
Arrieta M-C, Stiemsma LT, Amenyogbe N, et al: The intestinal microbiome in early life: health and disease, Front Immunol 5:427, 2014.
Brumbaugh DE, De Zoeten EF, Pyo-Twist A, et al: An intragastric fecal microbiota transplantation program for treatment of recurrent Clostridium difficile in children is efficacious, safe, and inexpensive, J Pediatr 194:123–127.e1, 2018.
Byrd AL, Belkaid Y, Segre JA: The human skin microbiome, Nat Rev Microbiol 16(3):143–155, 2018.
Fettweis JM, Brooks JP, Serrano MG, et al: Differences in vaginal microbiome in African American women versus women of European ancestry, Microbiology 160:2272–2782, 2014.
Foster JA, Rinaman L, Cryan JF: Stress and the gut-brain axis: regulation by the microbiome, Neurobiol Stress 11:291–301, 2017.
Gaufin T, Tobin NH, Aldrovandi GM: The importance of the microbiome in pediatrics and pediatric infectious diseases, Curr Opin Pediatr 30:117–124, 2018.
McCann JR, Mason SN, Auten RL, et al: Early-life intranasal colonization with nontypeable Haemophilus influenzae exacerbates juvenile airway disease in mice, Infect Immun 84:2022–2030, 2016.
Nash MJ, Frank DN, Friedman JE: Early microbes modify immune system development and metabolic homeostasis—the “restaurant” hypothesis revisited, Front Endocrinol (Lausanne) 8:349, 2017.
Nishida A, Inoue R, Inatomi O, et al: Gut microbiota in the pathogenesis of inflammatory bowel disease, Clin J Gastroenterol 11(1):1–10, 2018.
Panigrahi P, Parida S, Nanda NC, et al: A randomized. synbiotic trial to prevent sepsis among infants in rural India, Nature 548:407–412, 2017.
Ahmed. F, Temte JL, Campos-Outcalt D, et al: Methods for developing evidence-based. recommendations by the Advisory Committee on Immunization Practices of the U.S. Centers for Disease Control and Prevention, Vaccine 29: 9171-9176, 2011.
American Academy of Pediatrics Committee on Practice and Ambulatory Medicine and Council on Community Pediatrics: Policy statement: increasing immunization coverage, Pediatrics 125: 1295-1304, 2010.
Atahasoff S, Ryan T, Lightfoot R, Johann-Liang R: Shoulder injury related. to vaccine administration (SIRVA), Vaccine 28: 8049-8052, 2010.
Atkinson W, Kroger A, Wolfe C, et al, editors: Epidemiology and prevention of vaccine preventable diseases, ed. 13, Washington, DC, 2015, Public Health Foundation.
Supplement found at: https://www.cdc.gov/vaccines/pubs/pinkbook/supplement.html. (Accessed. Feb 10, 2019).
Baxter R, Bakshi N, Fireman B, et al: Lack of association of Guillain-Barr? syndrome with vaccinations, Clin Infect Dis 57(2): 197-207, 2013.
Berberich FR, Landman Z: Reducing immunization discomfort in 4- to 6-year-old children: a randomized. clinical trial, Pediatrics 124: e203-e209, 2009.
Bernstein HH, Bocchini JA: Practical approaches to optimize adolescent immunization, committee on infectious diseases, Pediatrics 139(3): 2017.
Briere EC: Food and Drug Administration approval for use of Hiberix as a 3-dose primary Haemophilus influenza type b (Hib) vaccination series, MMWR 65: 418-419, 2016.
Briere EC, Rubin L, Moro PL, et al; Centers for Disease Control and Prevention: Prevention and control of Haemophilus influenzae type b disease: recommendations of the Advisory Committee on Immunization Practices, MMWR Recomm Rep 63(RR-01): 1-14, 2014.
Bryant KA, Block SL, Baker SA, et al: Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine, Pediatrics 125: 866-875, 2010.
Centers for Disease Control and Prevention: Vaccine preventable deaths and the global immunization vision and strategy, 2006-2015, JAMA 295: 2840-2842, 2006.
Centers for Disease Control and Prevention: General recommendations on immunization, MMWR 60(2): 3-61, 2011.
Centers for Disease Control and Prevention: Updated. recommendations for use of tetanus toxoid, reduced. diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010, MMWR 60(1): 13-15, 2011.
Centers for Disease Control and Prevention: Infant meningococcal vaccination: Advisory Committee on Immunization Practices recommendations and rationale, MMWR 62(3): 52-54, 2013.
Centers for Disease Control and Prevention: National, state, and local area vaccination coverage among children aged. 19-35 months — United. States, 2012, MMWR 62: 733-740, 2013.
Centers for Disease Control and Prevention: Updated. recommendations for use of tetanus toxoid, reduced. diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women — Advisory Committee on Immunization Practices, 2012, MMWR 62(7): 131-135, 2013.
Centers for Disease Control and Prevention: Updated. recommendations for use of VariZIG — United. States, 2013, MMWR 62(28): 574-576, 2013.
Centers for Disease Control and Prevention: Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged. 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices, MMWR 62(25): 521-524, 2013.
Centers for Disease Control and Prevention: Tetanus, diphtheria, pertussis vaccination coverage before, during, and after pregnancy — 16 states and New York City, 2011, MMWR 64(19): 522-526, 2015.
Centers for Disease Control and Prevention: Use of 9-valent human papillomavirus (HPV) vaccine: updated. HPV vaccination recommendations of the Advisory Committee on Immunization Practices, 2015, MMWR 64(11): 300-304, 2015.
Centers for Disease Control and Prevention: Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015, MMWR 64(41): 1171-1176, 2015.
Centers for Disease Control and Prevention: Administration error involving a meningococcal conjugate vaccine — United. States, March 1, 2010 — September 22, 2015, MMWR 65: 161-162, 2016.
Centers for Disease Control and Prevention: Recommendations for use of meningococcal conjugate vaccines in HIV-infected. persons — Advisory Committee on Immunization Practices, 2016, MMWR 65(43): 1189-1194, 2016.
Centers for Disease Control and Prevention: Use of a 2-dose schedule for human papillomavirus vaccination — updated. recommendations of the Advisory Committee on Immunization Practices, 2016, MMWR 65(49): 1405-1408, 2016.
Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices: ACIP recommendations. Centers for Disease Control and Prevention: Tdap vaccination coverage during Pregnancy-selected. sites, United. States, 2006-2015, MMWR Morb Mortal Wkly Rep 66(41): 1105-1108, 2017.
Centers for Disease Control and Prevention: General Best Practice Guidelines for Immunization, 2018.
Centers for Disease Control and Prevention: Vaccination coverage among children aged. 19-35 months — United. States, 2017, MMWR Morb Mortal Wkly Rep 67(40): 1123-1128, 2018.
Centers for Disease Control and Prevention: Prevention of pertussis, tetanus, and diphtheria with vaccines in the United. States: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Morb Mortal Wkly Rep 67(2): 1-44, 2018.
Committee on Infectious Diseases: Recommended. childhood and adolescent immunization schedules — United. States, 2019, Pediatrics 143(3): e20190065, 2019.
Cohn A.C., MacNeil J.R., Clark T.A., et al; Centers for Disease Control and Prevention: Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, MMWR Recomm Rep 62(RR-2): 1-28, 2013.
Committee on Infectious Diseases: Recommended. childhood and adolescent immunization schedule — United. States, 2017, Pediatrics 140: e20164007, 2017.
Committee on Practice and Ambulatory Medicine, Committee on Infectious Diseases, Committee on State Government Affairs, Council on School Health, Section on Administration and Practice Management: Medical versus nonmedical immunization exemptions for child care and school attendance, Pediatrics 138: e20162145, 2016.
Diekema DS: American Academy of Pediatrics Committee on Bioethics: responding to refusals of immunization of children, Pediatrics 115: 1428-1431, 2005.
Edwards KM, Hackell JM, Committee on Infectious Diseases, Committee on Practice and Ambulatory Medicine: Countering vaccine hesitancy, Pediatrics 138(3): 2016.
FDA approves first seasonal influenza vaccine containing an adjuvant, FDA News Release, Nov 24, 2015.
Goldblatt D, Miller E: Nonspecific effects of vaccines, JAMA 311: 804-805, 2014.
Griffin MR, Zhu Y, Moore MR, et al: U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination, N Engl J Med. 369(2): 155-163, 2013.
Grohskopf LA, Sokolow LZ, Broder KR, et al; Centers for Disease Control and Prevention: Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices — United. States, 2016-17
Grohskopf LA, Sokolow LZ, Broder KR, et al: Prevention and control of seasonal influenza with vaccine: recommendations of the Advisory Committee on Immunization Practices –United. States. 2018-2019
Grohskopf LA, Sokolow LZ, Fry AM, et al: Update: ACIP recommendations for the use of quadrivalent live attenuated. influenza vaccine (LAIV4) — United. States, 2018-19 influenza season, MMWR Morb Mortal Wkly Rep 67: 643-645, 2018.
Johnson MG, Bradley KK, Mendus S, et al: Vaccine-preventable disease among omeschooled. children: two cases of tetanus in Oklahoma, Pediatrics 132: e1686-e1689, 2013.
Kelso JM, Li JT: Adverse reactions to vaccines, Ann Allergy Asthma Immunol 103: S1-S14, 2009.
Kim DK, Hunter P: Advisory committee on immunization practices recommended. immunization schedule for adults aged. 19 years or older — United. States, 2019, MMWR Morb Mortal Wkly Rep 68: 115-118, 2019.
Kim DK, Riley LE, Harriman KH, et al: Advisory Committee in Immunization Practices recommended. immunization schedule for adults aged. 19 years or older — United. States, 2017, MMWR 66: 136-138, 2017.
Kimberlin D.W., Brady M.T., Jackson M.A., Long S.S., editors: Red. book 2018: report of the Committee on Infectious Diseases, ed. 31, Elk Grove Village, IL, 2018, American Academy of Pediatrics.
Kobayashi M, Bennett NM, Gierke R, et al; Centers for Disease Control and Prevention: Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices, MMWR 64(34): 944-947, 2015.
Lateef TM, Johann-Liang R, Kaulas H, et al: Seizures, encephalopathy, and vaccines: experience in the National Vaccine Injury Compensation Program, J Pediatr 166: 576-581, 2015.
Lee G, Carr W: Updated. framework for development of evidence-based. recommendations by the Advisory Committee on Immunization Practices, MMWR Morb Mortal Wkly Rep 67: 1271-1272, 2018.
MacNeil J.R., Rubin L, MacNamara L, et al; Centers for Disease Control and Prevention: Use of MenACWY-CRM vaccine in children aged. 2 through 23 months at increased. risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013, MMWR (24): 2014.
Maglione MA, Das L, Raaen L, et al: Safety of vaccines used. for routine immunization of US children: a systematic review, Pediatrics 134: 325-337, 2014.
Markowitz LE, Hariri S, Lin C, et al: Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United. States, National Health and Nutrition Examination Surveys, 2003–2010, J Infect Dis 208(3): 385-393, 2013.
McCauley MM, Kennedy A, Basket M, Sheedy K: Exploring the choice to refuse or delay vaccines: a national survey of parents of 6- through 23-month-olds, Acad Pediatr 12(5): 375-383, 2012.
McClure CC, Cataldi JR, O’Leary ST: Vaccine hesitance: where we are and where we are going, Clin Ther 39(8): 1550-1562, 2017.
McLean HQ, Fiebelkorn AP, Temte JL, et al; Centers for Disease Control and Prevention: Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices, MMWR Recomm Rep 62(RR-4): 1-34, 2013.
The Medical Letter: Adult immunization, Med. Lett 60: 73-82, 2018.
The Medical Letter: Vaccines and pregnancy, Med. Lett Drugs Ther 53: 94-95, 2011.
The Medical Letter: Vaccines for travelers, Med. Lett 56: 115120, 2014.
Munoz FM, Bond NH, Maccato M, et al: Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants, JAMA 311: 1760-1769, 2014.
Nuorti JP, Whitney CG, Centers for Disease Control and Prevention: Prevention of pneumococcal disease among infants and children — use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine — recommendations of the Advisory Committee on Immunization Practices, MMWR Recomm Rep 59(RR-11): 1-18, 2010.
Omer SB, Salmon DA, Orenstein WA, et al: Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases, N Engl J Med. 360: 1981-1988, 2009.
Patton ME, Stephens D, Moore K, MacNeil J.R.: Updated. recommendations for use of MenB-FHbp serogroup B meningoccal vaccine — Advisory Committee on Immunization Practices, 2016, MMWR Morb Mortal Wkly Rep 66: 509-513, 2017.
Pickering LK, Orenstein WA: Development of pediatric vaccine recommendations and policies, Semin Pediatr Infect Dis 13(3): 148-154, 2002.
Plotkin SA, Gilbert PB: Nomenclature for immune correlates of protection after vaccination, Clin Infect Dis 54(11): 1615-1617, 2012.
Quinn P, Gold M, Royle J, et al: Recurrence of extensive injection site reactions following DTPa or dTpa vaccine in children 4-6 years old, Vaccine 29: 4230-4237, 2011.
Robinson CL, Romero JR, Kempe A, et al: Advisory Committee on Immunization Practices recommended. immunization schedule for children and adolescents aged. 18 years or younger—United. States, 2017, MMWR 66: 134-135, 2017.
Robinson CL, Bernstein H, Romero JR, Szilagyi P: Advisory Committee on Immunization Practices recommended. immunization schedule for children and adolescents aged. 18 years or younger — United. States, 2019, MMWR Morb Mortal Wkly Rep 68: 112-114, 2019.
Rolfe A, Sheikh A: Measles, mumps, and rubella vaccination in a child with suspected. egg allergy, BMJ 343: d4536, 2011.
Rubin LG, Levin MJ, Ljungman P, et al: 2013 IDSA clinical practice guideline for vaccination of the immunocompromised. host, Clin Infect Dis 58: 309- 318, 2014.
Schillie S, Harris A, Link-Gelles R, et al: Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant, MMWR Morb Mortal Wkly Rep 67: 455-458, 2018.
Smith JC, Snider DE, Pickering LK: Immunization policy development in the United. States: the role of the Advisory Committee on Immunization Practices, Ann Intern Med. 150(1): 45-49, 2009.
Turner PJ, Southern J, Andrews NJ, et al: Safety of live attenuated. influenza vaccine in young people with egg allergy: multicenter prospective cohort study, BMJ 351: h6291, 2015.
Varricchio F, Iskander J, Destefano F, et al: Understanding vaccine safety information from the Vaccine Adverse Event Reporting System, Pediatr Infect Dis J 23: 287-294, 2004.
Verbeek NE, Jansen FE, Vermeer-de Bondt PE, et al: Etiologies for seizures around the time of vaccination, Pediatrics 134(4): 658-666, 2014.
Witt MA, Arias L, Katz P, et al: Reduced. risk of pertussis among persons ever vaccinated. with whole cell pertussis vaccine compared. to recipients of acellular pertussis vaccines in a large U.S. cohort, Clin Infect Dis 56(9): 1248-1254, 2013.
Zafack JG, De Serres G, Kiely M, et al: Risk of recurrence of adverse events following immunization: a systematic review, Pediatrics 140(3): e20163707, 2017.
Zimmerman RK: Size of the needle for infant vaccination: longer needles reduce incidence of local reactions, BMJ 333: 563-564, 2006.
American Academy of Pediatrics Committee on Infectious Diseases: Recommended. childhood and adolescent immunization schedule—United. States, 2013, Pediatrics 131: 397-398, 2013.
Atkinson W, Hamborsky J, McIntyre L, editors: Epidemiology and prevention of vaccine-preventable diseases, ed. 9, Washington, DC, 2006, Public Health Foundation. Centers for Disease Control and Prevention: Recommended. adult immunization schedule, United. States, October 2006 — September 2007, MMWR 55: Q1-Q4, 2006.
Centers for Disease Control and Prevention: Update: Guillain-Barr? syndrome among recipients of Menactra meningococcal conjugate vaccine — United. States, June 2005 — September 2006, MMWR 55: 1120-1124, 2006.
Centers for Disease Control and Prevention: General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices, MMWR 55: Q1-Q3, 2007.
Centers for Disease Control and Prevention: Progress in global measles control and mortality reduction, 2000-2015, MMWR 65(44): 1228-1233, 2016.
Centers for Disease Control and Prevention: Vaccine preventable deaths and the global immunization vision and strategy, 2006-2015, JAMA 295: 2840-2842, 2006.
Clark HF, Offit PA, Plotkin SA, et al: The new pentavalent rotavirus vaccine composed. of bovine (strain WC3) human rotavirus reassortments, Pediatr Infect Dis J 25: 577-582, 2006.
Cohn A.C., Broder KR, Pickering LK: Immunizations in the US: a rite of passage, Pediatr Clin North Am 52: 669-693, 2005.
Diekema DS: American Academy of Pediatrics Committee on Bioethics: responding to refusals of immunization of children, Pediatrics 115: 1428-1431, 2005.
Omer SB, Pan WKY, Halsey NA, et al: Nonmedical exemptions to school immunization requiremets: secular trends and association of state policies with pertussis incidence, JAMA 296: 1757-1763, 2006.
Orenstein WA, Douglas RG, Rodewald LE, et al: Immunizations in the US: success, structure and stress, Health Aff (Millwood) 24: 559-610, 2005.
O’Ryan M, Matson DO: New rotavirus vaccines: renewed. optimism, J Pediatr 149: 448-451, 2006.
Pickering LK, Baker CJ, Kimberlin D.W., et al, editors: Red. book: 2015 report of the Committee on Infectious Diseases, ed. 30, Elk Grove Village, IL, 2015, American Academy of Pediatrics, pp . 1-107.
Plotkin SA, Orenstein WA, editors: Vaccines, ed. 5, Philadelphia, 2007, Elsevier. Varricchio F, Iskander J, Destefano F, et al: Understanding vaccine safety information from the Vaccine Adverse Event Reporting System, Pediatr Infect Dis J 23: 287-294, 2004.
World Health Organization: Progress in global measles control and mortality, 2000-2010, Wkly Epidemiol Rec 87: 45-52, 2012.
Bratzler D.W., Dellinger EP, Olsen K.M., et al: Clinical practice guidelines for antimicrobial prophylaxis in surgery, Am J Health Syst Pharm 70: 195-283, 2013.
Climo MW, Yokoe DS, Warren DK, et al: Effect of daily chlorhexidine bathing on hospital-acquired. infection, N Engl J Med. 368 :533-542, 2013.
Joint Commission on Hospital Accreditation: 2017 Hospital National Patient Safety Goals.
Kerkering TM, Grifasi ML, Baffoe-Bonnie AW, et al: Early clinical observation in prospectively followed. patients with fungal meningitis related. to contaminated epidural steroid injections, Ann Intern Med. 158: 154-161, 2013.
Marschall J, Mermel LA, Fakih M, et al: Strategies to prevent central line–associated bloodstream infections in acute care hospitals: 2014 update, Infect Control Hosp Epidemiol 35: 753-771, 2014.
Pollack LA, Srinivasan A: Core elements of hospital antibiotic stewardship programs from the Centers for Disease Control and Prevention, Clin Infect Dis 59(Suppl 3): S97-S100, 2014
Schutze GE, Willoughby RE, Committee on Infectious Diseases, American Academy of Pediatrics: Clostridium difficile infection in infants and children, Pediatrics 131: 196-200, 2013.
Siegel JD, Rhinehart E, Jackson M, et al: The Healthcare Infection Control Practices Advisory Committee: Management of multidrug-resistant organisms in healthcare settings, 2006. www.cdc.gov/hicpac/pdf/MDRO/MDROguideline2006.pdf.
Sommerstein R, R?egg C, Kohler P, et al: Transmission of Mycobacterium chimaera from heater-cooler units during cardiac surgery despite an ultraclean air ventilation system, Emerg Infect Dis 22: 1008-1013, 2016.
Verbeek JH, Ijaz S, Mischke C, et al: Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated. body fluids in healthcare staff, Cochrane Database Syst Rev (4): CD011621, 2016.
Aliabadi N, Tate JE, Haynes AK, et al: Sustained. decrease in laboratory detection of rotavirus after implementation of routine vaccination — United. States, 2000–2014, MMWR Morb Mortal Wkly Rep 64(13):337–342, 2015.
American Academy of Pediatrics (AAP): American Public Health Association: Caring for our children: National Health and Safety Performance Standards: guidelines for early care and early education programs, ed. 3, Elk Grove Village, IL, 2011, AAP.
Aronson SS, Shope TR, editors: Managing infectious diseases in child care and schools, ed. 4, Elk Grove Village, IL, 2017, AAP.
Bernstein DI, Munoz FM, Callahan TS: Safety and efficacy of a cytomegalovirus glycoprotein (gB) vaccine in adolescent girls: a randomized. clinical trial, Vaccine 34:313–319, 2016.
Centers for Disease Control and Prevention: Methicillin-resistant Staphylococcus aureus.
Dehoog M, Venekamp RP, van der Ent CK, et al: Impact of early daycare on healthcare resource use related. to upper respiratory tract infections during childhood: prospective WHISTLER cohort study, BMC Med. 12:107–114, 2014.
Griffiths C, Drews SJ, Marchant DJ: Respiratory syncytial virus: infection, detection, and new options for prevention and treatment, Clin Microbiol Rev 30:277–319, 2017.
Grohskopf LA, Sokolow LZ, Broder KR, et al: Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices—United. States, 2018–19 Influenza Season, MMWR Recomm Rep 67(RR–3):1–20, 2018. doi:10.15585/mmwr.rr6703a1.
Iwamoto M, Mu Y, Lynfield R, et al: Trends in invasive methicillin-resistant Staphylococcus aureus infections, Pediatrics 132(4): e817–e824, 2013.
Kimberlin D.W., Brady M.T., Jackson M.A., Long S.S., editors: Red. Book 2018–2021: Report of the Committee on Infectious Diseases, ed. 31, Elk Grove Village, IL, 2018, American Academy of Pediatrics.
Laughlin L: Who’s minding the kids? Child care arrangements: spring 2011, 2013, US Census Bureau.
McGirr A, Fisman DN: Duration of pertussis immunity after DTaP immunization: a meta-analysis, Pediatrics 135(2):331–434, 2014.
Moore RM, Link-Gelles R, Schaffner W, et al: Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched. case-control study, Lancet Respir Med. 4(5):399–406, 2016.
Morinz ED, Hanson BM, Kates AE: Molecular characteristics of Staphylococcus aureus isolated. from employees, children, and environmental surfaces in Iowa child daycare facilities, Am J Infect Control 43:482–488, 2015.
Morrissey TW: Multiple child care arrangements and common communicable illnesses in children aged. 3 to 54 months, Matern Child Health J 17:1175–1184, 2013.
Zomer TP, Erasmus V, Vlaar N, et al: A hand hygiene intervention to decrease infections among children attending day care centers: design of a cluster randomized controlled. trial, BMC Infect Dis 13:259, 2013.
Ashkenazi S, Schwartz E, O’Ryan M: Travelers’ diarrhea in children: what have we learnt?, Pediatr Infect Dis J 35:698–700, 2016.
Barnett E: Pediatric travel medicine: challenges for the primary care and travel medicine specialist, Curr Infect Dis Rep 15:216–222, 2013.
Centers for Disease Control and Prevention (CDC): International travel with infants and children, Yellow Book 2016. Weinberg N, Weinberg M, Maloney SA: Traveling safely with infants & children.
Dagan R, Amir J, Mijalovsky A, et al: Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody, Pediatr Infect Dis J 19:1045–1052, 2000.
Fhogartaigh CN, Sanford C, Behrens RH: Preparing young travelers for low resource destinations, BMJ 345:e7179, 2012.
Hagmann S, LaRocque RC, Rao SR, et al: Pre-travel health preparation of pediatric international travelers: analysis from the Global TravEpiNet Consortium, J Pediatr Infect Dis Soc 2:327–334, 2013.
Hagmann S, Neugebauer R, Schwartz E, et al: Illness in children after international travel: analysis from the GeoSentinel Surveillance Network, Pediatrics 125(5):e1072–e1080, 2010.
Han P, Yanni E, Jentes ES, et al: Health challenges of young travelers visiting friends and relative compared. with those traveling for other purposes, Pediatr Infect Dis J 31:915–919, 2012.
Harvey K, Esposito DH, Han P, et al; Centers for Disease Control and Prevention: Surveillance for travel-related. disease—GeoSentinel surveillance system, United. States, 1997–2011, MMWR Surveill Summ 62:1–23, 2013.
Kantele A, L??veri T, Mero S, et al: Antimicrobials increase travelers’ risk of colonization by extended-spectrum beta-lactamase-producing Enterobacteriaceae, Clin Infect Dis 60:837–846, 2015.
Ladhani S, Aibara RJ, Riordan FA, et al: Imported. malaria in children: a review of clinical studies, Lancet Infect Dis 7:349–357, 2007.
Leder K, Torresi J, Brownstein JS, et al: Travel-associated. illness trends and clusters, 2000–2010, Emerg Infect Dis 19:1049–1057, 2013.
Leder K, Torresi J, Libman M, et al: GeoSentinel surveillance of illness in returned. travelers, 2007–2011, Ann Intern Med. 158(6):456–468, 2013.
Mackell S: Traveler’s diarrhea in the pediatric population: etiology and impact, Clin Infect Dis 41:S547–S552, 2005.
The Medical Letter: Advice for travelers, Med. Lett 57(1466):52–58, 2015.
The Medical Letter: Vaccines for travelers, Med. Lett 56(1456):115–120, 2014.
The Medical Letter on Drugs and Therapeutics: Insect repellents, JAMA 316:766–767, 2016.
Myers AL, Christenson JC: Approach to immunization for the traveling child, Infect Dis Clin North Am 29:745–757, 2015.
Nelson NP, Link-Gelles R, Hofmeister MG, et al: Update: recommendations of the Advisory Committee on Immunization Practices for use of hepatitis A vaccine for postexposure prophylaxis and for preexposure prophylaxis for international travel, MMWR 67:1216–1220, 2018.
Neumann K: Family travel: an overview, Travel Med. Infect Dis 4:202–217, 2006.
Nield LS: Health implications of adolescent travel, Pediatr Ann 40:358–361, 2011.
Nuorti JP, Whitney CG, Centers for Disease Control and Prevention: Prevention of pneumococcal disease among infants and children: use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine, MMWR Recomm Rep 59(RR–11):1–18, 2010.
Pitzinger B, Steffen R, Tschopp . A: Incidence and clinical features of traveler’s diarrhea in infants and children, Pediatr Infect Dis J 10(10):719–723, 1991.
Rupprecht CE, Briggs D, Brown CM, et al; Centers for Disease Control and Prevention: Use of reduced. (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the Advisory Committee on Immunization Practices, MMWR Recomm Rep 59(RR–2):1–9, 2010.
Stauffer W, Christenson JC, Fischer PR: Preparing children for international travel, Travel Med. Infect Dis 6:101–113, 2008.
Strysko JP, Mony V, Cleveland J, et al: International travel is a risk factor for extendedspectrum ?-lactamase-producing Enterobacteriaceae acquisition in children: a case-control study in an urban US hospital, Traved. Med. Infect Dis 14:568–571, 2016.
Thwaites GE, Day NPJ: Approach to fever in the returning traveler, N Engl J Med. 376:548–560, 2017.
Wilson M.E., Weld LH, Bogglid A, et al: Fever in returned. travelers: results from the GeoSentinel Surveillance Network, Clin Infect Dis 4(12):1560–1568, 2007.
Zafren K: Prevention of high altitude illness, Travel Med. Infect Dis 12:29–39, 2014.
Adam H: Fever: measuring and managing, Pedimat Rev 34:368, 2013.
American Academy of Pediatrics Subcommittee on Febrile Seizures: Febrile seizures: guideline for the neurodiagnostic evaluation of the child with a simple febrile seizure, Pediatrics 127:38, 2011.
Biondi EA, Byington CL: Evaluation and management of febrile, well-appearing young infants, Infect Dis Clin North Am 29:575–585, 2015.
Flatties CM: The onset of fever: new insights into its mechanism, Prog Brain Res 162:3–14, 2007.
Case WB, Nucci AT, Cho S: Extreme hyperpyrexia in childhood: prevention similar to hemorrhagic shock and encephalopathy, Clin Pediatr (Phila) 28(2):76–80, 1989.
Chiappini E, Venturini E, Remashi G, et al: 2016 update of the Italian Pediatric Society guidelines for management of fever in children, J Pediatr 180:177–183, 2017.
Cunha BA: The clinical significance of fever patterns, Infect Dis Clin North Am 1:33–44, 1996.
Dinarello CA: Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed, J Endotoxin Res 10(4):201–222, 2004.
Filha EM, de Carvalho WB: Current management of occult bactermia in infants, J Pediatr (Rio J) 91:561–566, 2015.Gomez B, Bressan S, Mintegi S, et al: Diagnostic value of procalcitonin in well-appearing young febrile infants, Pediatrics 130:815–822, 2012.
Hanna CM, Greene DS: How much tachycardia in infants can be attributed. to fever? Ann Emerg Med. 43(6):699–705, 2004.
Purssell E, While AE: Does the use of antipyretics in children who have acute infections prolong febrile illness? A systematic review and meta-analysis, J Pediatr 163:822–827, 2013.
Sherman JM, Sood SK: Current challenges in the diagnosis and management of fever, Curr Opin Pediatr 24:400–406, 2012.
Trautner BW, Caviness AC, Gerlacher GR, et al: Prospective evaluation of the risk of serious bacterial infection in children who present to the emergency department with hyperpyrexia (temperatures of 106°F or higher), Pediatrics 118:34–40, 2006.
Van den Bruel A, Thompson MJ, Haj-Hassan T, et al: Diagnostic value of laboratory tests in identifying serious infections in febrile children: systematic review, BMJ 342: d3082, 2011.
Wang D: Complementary, holistic, and integrative medicine: fever, Pediatr Rev 30:75–8, 2009.
American Academy of Pediatrics: Herpes simplex. In Kimberlin DW, Brady MT, Jackson MA, et al, editors: Red book: 2015 report of the Committee on Infectious Diseases, ed 30, Elk Grove Village, IL, 2015, AAP, pp 432–445.
Aronson PL, Thurm C, Alpern ER, et al: Variation in care of the febrile young infant <90 days in US pediatric emergency departments, Pediatrics 134(4):667–677, 2014.
Aronson PL, Thurm C, Williams DJ, et al: Association of clinical practice guidelines with emergency department management of febrile infants ?56 days of age, J HospMed 10(6):358–365, 2015.
Baker MD, Avner JR: Management of fever in young infants: evidence versus common practice, Pediatrics 138(6):2016.
Baker MD, Bell LM, Avner JR: Outpatient management without antibiotics of fever in selected infants, N Engl J Med 329(20):1437–1441, 1993.
Baraff LJ, Bass JW, Fleisher GR, et al: Practice guideline for the management of infants and children 0 to 36 months of age with fever without source, Agency for Health Care Policy and Research, Ann Emerg Med 22(7):1198–1210, 1993.
Baskin MN, O’Rourke EJ, Fleisher GR: Outpatient treatment of febrile infants 28 to 89 days of age with intramuscular administration of ceftriaxone, J Pediatr 120(1): 22–27, 1992.
Bedford H, de Louvois J, Halket S, et al: Meningitis in infancy in England and Wales: follow up at age 5 years, BMJ Clin Res 323(7312):533–536, 2001.
Bhansali P, Wiedermann BL, Pastor W, et al: Management of hospitalized febrile neonates without CSF analysis: a study of US pediatric hospitals, Hosp Pediatr 5(10):528–533, 2015.
Biondi E, Evans R, Mischler M, et al: Epidemiology of bacteremia in febrile infants in the United States, Pediatrics 132(6):990–996, 2013.
Biondi EA, Byington CL: Evaluation and management of febrile, well-appearing young infants, Infect Dis Clin North Am 29(3):575–585, 2015.
Biondi EA, Mischler M, Jerardi KE, et al: Blood culture time to positivity in febrile infants with bacteremia, JAMA Pediatr 168(9):844–849, 2014.
Bonadio W: Pediatric lumbar puncture and cerebrospinal fluid analysis, J Emerg Med 46(1):141–150, 2014.
Bonadio W, Maida G: Urinary tract infection in outpatient febrile infants younger than 30 days of age: a 10-year evaluation, Pediatr Infect Dis J 33(4):342–344, 2014.
Brizzi K, Hines EM, McGowan KL, Shah SS: Diagnostic accuracy of cerebrospinal fluid Gram stain in children with suspected bacterial meningitis, Pediatr Infect Dis J 31(2):195–197, 2012.
Brower L, Schondelmeyer A, Wilson P, Shah SS: Testing and empiric treatment for neonatal herpes simplex virus: challenges and opportunities for improving the value of care, Hosp Pediatr 6(2):108–111, 2016.
Burstein B, Dubrovsky AS, Greene AW, Quach C: National survey on the impact of viral testing for the ED and inpatient management of febrile young infants, HospPediatr 6(4):226–233, 2016.
Cabrerizo M, Trallero G, Pena MJ, et al: Comparison of epidemiology and clinical characteristics of infections by human parechovirus vs. those by enterovirus during the first month of life, Eur J Pediatr 174(11):1511–1516, 2015.
Chua KP, Neuman MI, McWilliams JM, Aronson PL: Association between clinical outcomes and hospital guidelines for cerebrospinal fluid testing in febrile infants aged 29-56 days, J Pediatr 167(6):1340–1346, e1349, 2015.
Cioffredi L, Jhaveri R: Evaluation and management of febrile children: a review, JAMA Pediatr 170(8):794–800, 2016.
Dagan R, Sofer S, Phillip M, Shachak E: Ambulatory care of febrile infants younger than 2 months of age classified as being at low risk for having serious bacterial infections, J Pediatr 112(3):355–360, 1988.
Dien Bard J, McElvania TeKippe E: Diagnosis of bloodstream infections in children, J Clin Microbiol 54(6):1418–1424, 2016.
Doan Q, Enarson P, Kissoon N, et al: Rapid viral diagnosis for acute febrile respiratory illness in children in the emergency department, Cochrane Database Syst Rev (9):CD006452, 2014.
England JT, Del Vecchio MT, Aronoff SC: Use of serum procalcitonin in evaluation of febrile infants: a meta-analysis of 2317 patients, J Emerg Med 47(6):682–688, 2014.
Glissmeyer EW, Korgenski EK, Wilkes J, et al: Dipstick screening for urinary tract infection in febrile infants, Pediatrics 133(5):e1121–e1127, 2014.
Gomez B, Bressan S, Mintegi S, et al: Diagnostic value of procalcitonin in well-appearing young febrile infants, Pediatrics 130(5):815–822, 2012.
Gomez B, Mintegi S, Benito J: A prospective multicenter study of leukopenia in infants younger than ninety days with fever without source, Pediatr Infect Dis J 35(1):25–29, 2016.
Gomez B, Mintegi S, Bressan S, et al: Validation of the “step-by-step” approach in the management of young febrile infants, Pediatrics 138(2):2016.
Greenhow TL, Hung YY, Herz AM, et al: The changing epidemiology of serious bacterial infections in young infants, Pediatr Infect Dis J 33(6):595–599, 2014.
Herberg JA, Kaforou M, Wright VJ, et al: Diagnostic test accuracy of a 2-transcript host RNA signature for discriminating bacterial vs viral infection in febrile children, JAMA 316(8):835–845, 2016.
Irwin AD, Wickenden J, Le Doare K, et al: Supporting decisions to increase the safe discharge of children with febrile illness from the emergency department: a systematic review and meta-analysis, Arch Dis Child 101(3):259–266, 2016.
Kotzbauer D, Andresen D, Doelling N, Shore S: Clinical and laboratory characteristics of central nervous system herpes simplex virus infection in neonates and young infants, Pediatr Infect Dis J 33(11):1187–1189, 2014.
Kuppermann N, Mahajan P: Role of serum procalcitonin in identifying young febrile infants with invasive bacterial infections: one step closer to the Holy Grail?, JAMA Pediatr 170(1):17–18, 2016.
Leazer R, Perkins AM, Shomaker K, Fine B: A meta-analysis of the rates of Listeria monocytogenes and Enterococcus in febrile infants, Hosp Pediatr 6(4):187–195, 2016.
Mahajan P, Kuppermann N, Mejias A, et al: Association of RNA biosignatures with bacterial infections in febrile infants aged 60 days or younger, JAMA 316(8):846–857, 2016.
Martinez E, Mintegi S, Vilar B, et al: Prevalence and predictors of bacterial meningitis in young infants with fever without a source, Pediatr Infect Dis J 34(5):494–498, 2015.
Milcent K, Faesch S, Gras-Le Guen C, et al: Use of procalcitonin assays to predict serious bacterial infection in young febrile infants, JAMA Pediatr 170(1):62–69, 2016.
Mintegi S, Bressan S, Gomez B, et al: Accuracy of a sequential approach to identify young febrile infants at low risk for invasive bacterial infection, Emerg Med J 31(e1):e19–e24, 2014.
Nigrovic LE, Mahajan PV, Blumberg SM, et al: The Yale observation scale score and the risk of serisou bacterial infections in febrile infants, Pediatrics 140(1):e20170695, 2017.
Srinivasan L, Shah SS, Padula MA, et al: Cerebrospinal fluid reference ranges in term and preterm infants in the neonatal intensive care unit, J Pediatr 161(4):729–734, 2012.
Stocker M, van Herk W, el Helou S, et al: Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPins), Lancet 390:871–881, 2017.
Verboon-Maciolek MA, Nijhuis M, van Loon AM, et al: Diagnosis of enterovirus infection in the first 2 months of life by real-time polymerase chain reaction, ClinInfect Dis 37(1):1–6, 2003.
Wallace SS, Lopez MA, Caviness AC: Impact of enterovirus testing on resource use in febrile young infants: a systematic review, Hosp Pediatr 7(2):96, 2017.
Woll C, Neuman MI, Pruitt CM, et al: Epidemiology and etiology of invasive bacterial infection in infants ?60 days old treated in emergency departments, J Pediatr 200:210–217, 2018.
Agyeman P.K.A., Schlapbach L.J., Giannoni E., et al: Epidemiology of blood culture-proven bacterial sepsis in children in Switzerland: a population-based. cohort study, Lancet Child Adolesc Health 1:124–133, 2017.
American Academy of Pediatrics, Subcommittee on Urinary Tract Infection: Reaffirmation of AAP clinical practice guideline: the diagnosis and management of the initial urinary tract infection in febrile infants and young children 2-24 months of age, Pediatrics 138(6):2016.
Bradley JS, Byington CL, Shah SS, et al: The management of community-acquired. pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America, Clin Infect Dis 53(7):e25–e76, 2011.
Carstairs KL, Tanen DA, Johnson AS, et al: Pneumococcal bacteremia in febrile infants presenting to the emergency department before and after the introduction of the heptavalent pneumococcal vaccine, Ann Emerg Med. 49(6):772–777, 2007.
Farnham AC, Zimmerman CM, Papadouka V, et al: Invasive pneumococcal disease following the introduction of 13-valent conjugate vaccine in children in New York City from 2007 to 2012, JAMA Pediatr 169(7):646–652, 2015.
Finnell SM, Carroll AE, Downs SM, American Academy of Pediatrics, Subcommittee on Urinary Tract Infection: Technical report. Diagnosis and management of an initial UTI in febrile infants and young children, Pediatrics 128(3):e749–e770, 2011.
Hoberman A, Paradise JL, Rockette HE, et al: Shortened. antimicrobial treatment for acute otitis media in young children, N Engl J Med. 375(25):2446–2456, 2016.
Hsiao AL, Chen L, Baker MD: Incidence and predictors of serious bacterial infections among 57- to 180-day-old infants, Pediatrics 117(5):1695–1701, 2006.
Irwin AD, Drew RJ, Marshall P, et al: Etiology of childhood bacteremia and timely antibiotics administration in the emergency department, Pediatrics 135(4):635–642, 2015.
Irwin AD, Grant A, Williams R, et al: Predicting risk of serious bacterial infections in febrile children in the emergency department, Pediatrics 140(2):e20162853, 2017.
Joffe MD, Alpern ER: Occult pneumococcal bacteremia: a review, Pediatr Emerg Care 26(6):448–454, 2010.
Martinon-Torres F, Salas A, Rivero-Calle I, et al: Life-threatening infections in children in Europe (the EUCLIDS Project): a prospective cohort study, Lancet Child Adolesc Health 2:404–414, 2018.
Roberts KB, American Academy of Pediatrics, Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management: Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months, Pediatrics 128(3):595–610, 2011.
Shulman ST, Bisno AL, Clegg HW, et al: Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America, Clin Infect Dis 55(10):e86–e102, 2012.
Spiro DM, Tay KY, Arnold DH, et al: Wait-and-see prescription for the treatment of acute otitis media: a randomized. controlled. trial, JAMA 296(10):1235–1241, 2006.
Weiss SL, Fitzgerald JC, Balamuth F, et al: Delayed. antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis, Crit Care Med. 42(11):2409–2417, 2014.
American Academy of Pediatrics: Fever and antipyretic use in children, Pediatrics 127:580–587, 2011.
Baker MD, Bell LM, Avner JR: The efficacy of routine outpatient management without antibiotics of fever in selected. infants, Pediatrics 103:627–631, 1999.
Baraff LJ, Schriger DL, Bass JW, et al: Practice guideline for the management of infants and children 0 to 36 months of age with fever without source, Ann Emerg Med. 22:1196–1210, 1993.
Biondi E, Evans R, Mischler M, et al: Epidemiology of bacteremia in febrile infants in the United. States, Pediatrics 132:990–996, 2013.
Brauner M, Goldman M, Kozer E: Extreme leucocytosis and the risk of serious bacterial infections in febrile children, Arch Dis Child 95:209–212, 2010.
Colvin JM, Muenzer JT, Jaffe DM, et al: Detection of viruses in young children with fever without focus an apparent source, Pediatrics 130:e1455–e1462, 2012.
Craig JC, Williams GJ, Jones M, et al: The accuracy of clinical symptoms and signs for the diagnosis of serious bacterial infection in young febrile children: prospective cohort study of 15,781 febrile illnesses, BMJ 340:1594, 2010.
Dawes M: Identifying sick children on primary care, Lancet 375:784–785, 2010.
Galetto-Lacour A, Zamora SA, Andreola B, et al: Validation of a laboratory risk index score for the identification of severe bacterial infection in children with fever without focus, Arch Dis Child 95:968–973, 2010.
Gomez B, Bressan S, Mintegi S, et al: Diagnostic value of procalcitonin in well-appearing young febrile infants, Pediatrics 130:815, 2012.
Gomez B, Mintegi S, Benito J, et al: Blood culture and bacteremia predictors in infants less than three months of age with fever without source, Pediatr Infect Dis J 29:43–47, 2010
Greenhow TL, Hung YY, Herz AM: Changing epidemiology of bacteremia in infants aged. 1 week to 3 months, Pediatrics 129:e590–e596, 2012.
Horowitz HW: Fever of unknown origin or fever of too many origins?, N Engl J Med. 368:197–199, 2013.
Huppler AR, Eickhoff JC, Wald ER: Performance of low-risk criteria in the evaluation of young infants with fever: review of the literature, Pediatrics 125:228–233, 2010.
Mahajan P, Ramilo O, Kuppermann N: The future possibilities of diagnostic testing for the evaluation of febrile infants, JAMA Pediatr 167:888–898, 2013.
Oliveira CF, Botoni FA, Oliveira CRA, et al: Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized. trial, Crit Care Med. 41:2336–2343, 2013.
Segal I, Ehrlichman M, Urbach J, Bar-Meir M: Use of time from fever onset improves the diagnostic accuracy of C-reactive protein in identifying bacterial infections, Arch Dis Child 99:974–978, 2014.
Statler VA, Marshall GS: Characteristics of patients referred. to a pediatric infectious diseases clinic with unexplained. fever, J Pediatr Infect Dis 5:249–256, 2016.
Thompson MJ, van den Bruel A: Diagnosing serious bacterial infection in young febrile children, BMJ 340:c2062, 2010.
Van den Bruel A, Haj-Hassan T, Thompson M, et al: Diagnostic value of clinical features at presentation to identify serious infection in children in developed. countries: a systematic review, Lancet 375:834–844, 2010.
Vidwan G, Geis G: Evaluation, management, and outcome of focal bacterial infections (FBIs) in nontoxic infants under two months of age, J Hosp Med. 5:76–82, 2010.
Yo CH, Hsieh PS, Lee SH, et al: Comparison of the test characteristics of procalcitonin to C-reactive protein and leukocytosis for the detection of serious bacterial infections in children presenting with fever without source: a systematic review and meta-analysis, Ann Emerg Med. 60:591–600, 2012.
American Academy of Pediatrics: Active and passive immunization. In Kimberlin D.W., Brady M.T., Jackson M.A., Long S.S., editors: Red. book: 2015 report of the Committee on Infectious Diseases, ed. 30, Elk Grove Village, IL, 2015, American Academy of Pediatrics, pp. 1–107.
Buckley RH: Primary immunodeficiency disease due to defects in lymphocytes, N Engl J Med. 343:1313–1324, 2000.
Chiu SN, Shao PL, Wang JK, et al: Severe bacterial infection in patients with heterotaxy syndrome, J Pediatr 164:99–104, 2014.
Picard C, Al-Herz W, Bousfiha A, et al: Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency, J Clin Immunol 35:696–726, 2015.
Blumberg EA, Danziger-Isakov L, Kumar D, et al, editors: Infectious diseases guidelines, ed. 3, Am J Transplant 13(Suppl 4):1–371, 2013.
Castagnola E, Fontana V, Caviglia I, et al: A prospective study on the epidemiology of febrile episodes during chemotherapy induced. neutropenia in children with cancer or after hematopoietic stem cell transplantation, Clin Infect Dis 45:1296–1304, 2007.
Freifeld AG, Bow EJ, Sepkowitz KA, et al: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America, Clin Infect Dis 52:e56–e93, 2011.
Lehrnbecher T, Phillips R, Alexander S, et al: Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation, J Clin Oncol 30:4427–4438, 2012.
Palazzi DL: The use of antimicrobial agents in children with fever during hemotherapyinduced. neutropenia, Pediatr Infect Dis J 30:887–890, 2011.
Phillips R, Hancock B, Graham J, et al: Prevention and management of neutropenic sepsis in patients with cancer: summary of NICE guidance, BMJ 345:47–49, 2012.
Pizzo PA, Robichaud KJ, Wesley R, et al: Fever in the pediatric and young adult patient with cancer: a prospective study of 1001 episodes, Medicine (Baltimore) 61:153–165, 1982.
Blumberg EA, Danziger-Isakov L, Kumar D, et al, editors: Infectious diseases guidelines, ed. 3, Am J Transplant 13(Suppl 4):1–371, 2013.
Freifeld AG, Bow EJ, Sepkowitz KA, et al: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the
Infectious Diseases Society of America, Clin Infect Dis 52:e56–e93, 2011.
Lehrnbecher T, Phillips R, Alexander S, et al: Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation, J Clin Oncol 30:4427–4438, 2012.
Chopra V, Saint S: Vascular catheter infections: time to get technical, Lancet 386: 2034–2036, 2015.
Downes KJ, Metlay JP, Bell LM, et al: Polymicrobial bloodstream infections among children and adolescents with central venous catheters evaluated. in ambulatory care, Clin Infect Dis 46:387–394, 2008.
Fulkerson DH, Sivaganesan A, Hill JD, et al: Progression of cerebrospinal fluid cell count and differential over a treatment course of shunt infection, J Neurosurg Pediatr 8:613–619, 2011.
Hooton TM, Bradley SF, Cardenas DD, et al: Diagnosis, prevention, and treatment of catheter-associated. urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America, Clin Infect Dis 50:625–663, 2010.
Marsh N, Webster J, Mihala G, Rickard CM: Devices and dressings to secure peripheral venous catheters: a Cochrane systematic review and meta-analysis, Int J Nurs Stud 67:12–19, 2017.
Mermel LA, Allon M, Bouza E, et al: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related. infection: 2009 update by the Infectious Diseases Society of America, Clin Infect Dis 49:1–45, 2009.
Mimoz O, Lucet JC, Kerforne T, et al: Skin antisepsis with chlorhexidine-alcohol versus povidone iodine-alcohol, with and without skin scrubbing, for prevention of intravascular-catheter-related. infection (CLEAN): two-by-two factorial trial, Lancet 386:2069–2077, 2015.
O’Grady NP, Alexander M, Burns LA, et al: Guidelines for the prevention of intravascular catheter-related. infections, Am J Infect Control 39:S1–S34, 2011.
Osmon DR, Berbari EF, Berendt AR, et al: Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America, Clin Infect Dis 56:e1–e25, 2013.
Prusseit J, Simon M, von der Brelie C, et al: Epidemiology, prevention and management of ventriculoperitoneal shunt infections in children, Pediatr Neurosurg 45:325–336, 2009.
Shenep MA, Tanner MR, Sun Y, et al: Catheter-related. complications in children with cancer receiving parenteral nutrition: change in risk is moderated. by catheter type, JPEN J Parenter Enteral Nutr 41(6):1063–1071, 2017.
Simon TD, Hall M, Riva-Cambrin J, et al: Infection rates following initial cerebrospinal fluid shunt placement across pediatric hospitals in the United. States, J Neurosurg Pediatr 4:156–165, 2009.
Sobel JD, Kauffman CA, McKinsey D, et al: Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group, Clin Infect Dis 30:19–24, 2000.
Tunkel AR, Hasbun R, Bhimraj A, et al: 2017 Infectious Diseases Society of America’s clinical practice guidelines for healthcare-associated. ventriculitis and meningitis, Clin Infect Dis 64(6):e34–e65, 2017.
Warady BA, Bakkaloglu S, Newland J, et al: Consensus guidelines for the prevention and treatment of catheter-related. infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update, Perit Dial Int 32(Suppl 2):S32–S86, 2012.
Wolf J, Curtis N, Worth LJ, et al: Treatment of central-line associated. bloodstream infections in children: an update, Pediatr Infect Dis J 32:905–910, 2013.
Zegers B, Uiterwaal C, Kimpen J, et al: Antibiotic prophylaxis for urinary tract infections in children with spina bifida on intermittent catheterization, J Urol 186:2365–2370, 2011.
Assis LM, Nedeljkovi? M, Dessen A: New strategies for targeting and treatment of multi-drug resistant Staphylococcus aureus, Drug Resist Updat 31:1–14, 2017.
Dulhunty JM, Roberts JA, Davis JS, et al: A multicenter randomized. trial of continuous versus intermittent ?-lactam infusion in severe sepsis, Am J Respir Crit Care Med 192(11):1298–1305, 2015.
Feldman EA, McCulloh RJ, Myers AL, et al: Empiric antibiotic use and susceptibility in infants with bacterial infections: a multicenter retrospective cohort study, Hosp Pediatr 2017. pii: hpeds.2016-0162. doi:10.1542/hpeds.2016-0162. PMID: 28729240.
Flokas ME, Karanika S, Alevizakos M, Mylonakis E: Prevalence of ESBL-producing Enterobacteriaceae in pediatric bloodstream infections: a systematic review and meta-analysis, PLoS ONE 12:e0171216, 2017.
Gonzalez D, Bradley JS, Blumer J, et al: Dalbavancin pharmacokinetics and safety n children 3 months to 11 years of age, Pediatr Infect Dis J 36:645–653, 2017.
Harris PNA, Tambyah PA, Lye DC, et al: Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance, JAMA 320(10):984–994, 2018.
Holmes AH, Moore LSP, Sundsfjord A, et al: Antimicrobials: access and sustainable effectiveness 2, Lancet 387:176–187, 2016.
Janelle SJ, Kallen A, de Mans T, et al: New Delhi metallo-?-lactamase-producing carbapenem-resistant Enterobacteriaceae identified. in patients without known health care risk factors—Colorado, 2014–2016, MMWR Morb Mortal Wkly Rep 65(49):1414–1415, 2016.
Kaye KS, Gales AC, Dubourg G: Old antibiotics for multidrug-resistant pathogens:from in vitro activity to clinical outcomes, Int J Antimicrob Agents 49:542–548, 2017.
Ling LL, Schneider T, Peoples AJ, et al: A new antibiotic kills pathogens without detectable resistance, Nature 517:455–459, 2015.
Logan LK, Weinstein RA: The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace, J Infect Dis 215(Suppl 1):S28–S36, 2017.
The Medical Letter: Alternatives to fluoroquinolones, Med. Lett Drugs Ther 58(1496): 75–76, 2016.
Nakagawa N, Ochi N, Yamane H, et al: Ceftriaxone-associated. pancreatitis captured. on serial computed. tomography scans, Radiol Case Rep 13:43–46, 2018.
Roberts JA, Abdul-Aziz MH, Davis JS, et al: Continuous versus intermittent ?-lactam infusion in severe sepsis, Am J Respir Crit Care Med. 194(6):681–691, 2016.
Satlin MJ, Chen L, Patel G, et al: Bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE): a multicenter clinical and molecular epidemiologic analysis in the nation’s epicenter for CRE, Antimicrob Agents Chemother 61(4):2018.
Smith MJ, Gerber JS, Hersh AL: Inpatient antimicrobial stewardship in pediatrics: a systematic review, J Pediatric Infect Dis Soc 4:e127–e135, 2015.
Syrogiannopoulos GA, Michoula AN, Petinaki E, Grivea IN: Daptomycin use in children: experience with various types of infection and age groups, Pediatr Infect Dis J 36:962–966, 2017.
Thompson G, Barker CI, Folgori L, et al: Global shortage of neonatal and paediatric antibiotic trials: rapid review, BMJ Open 7(10):e016293, 2017.
US Food and Drug Administration: Fluoroquinolone antibacterial drugs for systemic use: drug safety communication—warnings updated. due to disabling side effects, 2016.
Von Martels JZH, van de Meeberg EK: Pseudolithiasis after recent use of ceftriaxone: an unexpected. diagnosis in a child with abdominal pain, Am J Emerg Med. 31: 1294.e5–1294.e6, 2013.
Yim J, Molloy LM, Newland JG: Use of ceftaroline fosamil in children: review of current knowledge and its application, Infect Dis Ther 6:57–67, 2017.
Brade KD, Rybak JM, Rybak MJ: Oritavancin: a new lipoglycopeptide antibiotic in the treatment of gram-positive infections, Infect Dis Ther 5:1–15, 2016.
Bradley J, Glasser C, Patino H, et al: Daptomycin for complicated. skin infections: a randomized. trial, Pediatrics 139(3):2017.
Fritz SA, Hogan PG, Hayek G, et al: Household versus individual approaches to eradication of community-associated. Staphylococcus aureus in children: a randomized. trial, Clin Infect Dis 54:743–751, 2012.
Hamdy Hb, Hsu AJ, Stockmann C, et al: Epidemiology of methicillin-resistant Staphylococcus aureus bacteremia in children, Pediatrics 139(6):e20170183, 2017.
Hersh AL, Lee BR, Hedican EB, et al: Linezolid use in hospitalized. children, Pediatr Infect Dis J 33:e14–e18, 2014.
Holland TL, Fowler VG Jr: Rifampicin for Staphylococcus aureus bacteraemia: give it ARREST, Lancet 391:634–636, 2018.
Iwamoto M, Mu Y, Lynfield R, et al: Trends in invasive methicillin-resistant Staphylococcusaureus infections, Pediatrics 132(4):e817–e824, 2013.
Jackson KA, Bohm MK, Brooks JT, et al: Invasive methicillin-resistant Staphylococcus aureus infections among persons who inject drugs: six sites, 2005–2016, MMWR Morb Mortal Wkly Rep 67(22):625–628, 2018.
Liu C, Bayer A, Cosgrove SE, et al: Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children, Clin Infect Dis 52(3):e18–e55, 2011.
Missiakas D, Schneewind O: Staphylococcus aureus vaccines: deviating from the carol, J Exp Med. 213:1645–1653, 2016.
Oestergaard LB, Christiansen MN, Schmiegelow MD, et al: Familial clustering of Staphylococcus aureus bacteremia in first-degree relatives, Ann Intern Med. 165(6):390–398, 2016.
Ray SM: Preventing methicillin-resistant Staphylococcus aureus (MRSA) disease in urban US hospitals—now for the hard part: more evidence pointing to the community as the source of MRSA acquisition, J Infect Dis 215:1631–1633, 2017.
Smith JR, Roberts KD, Rybak MJ: Dalbavancin: a novel lipoglycopeptide antibiotic with extended. activity against gram-positive infections, Infect Dis Ther 4(3):245–258, 2015.
Walrath JJ, Hennrikus WL, Zalonis C, et al: The prevalence of MRSA nasal carriage in preoperative pediatric orthopaedic patients, Adv Orthop 2016:5646529, 2016.
Zervou FN, Zacharioudakis IM, Ziakas PD, Mylonakis E: MRSA colonization and risk of infection in the neonatal and pediatric ICU: a meta-analysis, Pediatrics 133(4):e1015–e1023, 2014.
Chan KH, Kraai TL, Richter GT, et al: Toxic shock syndrome and rhinosinusitis in children, Arch Otolaryngol Head Neck Surg 135:538–542, 2009.
DeVries AS, Lesher L, Schlievert PM, et al: Staphylococcal toxic shock syndrome 2000–2006: epidemiology, clinical features, and molecular characteristics, PLoS ONE 6:e22997, 2011.
Zimbelman J, Palmer A, Todd JK: Improved. outcome of clindamycin compared. with beta-lactam antibiotics treatment of invasive Streptococcus pyogenes infection, Pediatr Infect Dis J 18:1096–1100, 1999.
German GJ, Wang B, Bernard K, et al: Staphylococcus lugdunensis: low prevalence and clinical significance in a pediatric microbiology laboratory, Pediatr Infect Dis J 32:87–89, 2013.
Gkentzi D, Kolyva S, Spiliopoulou I, et al: Treatment options for persistent coagulase negative staphylococcal bacteremia in neonates, CurrPediatr Rev 12:199–208, 2016.
Mermel LA, Allon M, Bouza E, et al: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related. infection: 2009 update by the Infectious Diseases Society of America, Clin Infect Dis 49:1–45, 2009.
Pogorzelska-Maziarz M: The use and effectiveness of bundles for prevention of central line-associated. bloodstream infections in neonates: a review of the literature, J Perinat Neonatal Nurs 30:148–159, 2016.
Pardo J, Klinker KP, Borgert SJ, et al: Clinical and economic impact of antimicrobial stewardship interventions with the FilmArray blood culture identification panel, Diagn Microbiol Infect Dis 84:159–164, 2016.
American Academy of Pediatrics: Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23), Pediatrics 126:186–190, 2010.
American Academy of Pediatrics, Committee on Infectious Diseases: Immunization for Streptococcus pneumoniae infections in high-risk children, Pediatrics 134:1230–1233, 2014.
Bradley JS, Byington CL, Shah SS, et al: The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America, Clin Infect Dis 53(7):e25–e76, 2011.
Centers for Disease Control and Prevention: Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—United. States, 1998–2003, MMWR Morb Mortal Wkly Rep 54:893–897, 2005.
Centers for Disease Control and Prevention: Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae—United. States, 2006–2007, MMWR Morb Mortal Wkly Rep 57:1353–1357, 2008.
Centers for Disease Control and Prevention: Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children: Advisory Committee on Immunization Practices, MMWR Morb Mortal Wkly Rep 59:1–18, 2010.
Centers for Disease Control and Prevention: Pink book: pneumococcal disease epidemiology and prevention of vaccine-preventable diseases, ed. 12, Washington, DC, 2012, Public Health Foundation, pp . 233–248.
Centers for Disease Control and Prevention: Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory
Gadsby NJ, Russell CD, McHugh MP, et al: Comprehensive molecular testing for respiratory pathogens in community-acquired. pneumonia, Clin Infect Dis 62:817–823, 2016.
Gaschingnard J. Levy C, Chrabieh M, et al: Invasive pneumococcal disease in children can reveal a primary immunodeficiency, Clin Infect Dis 59:244–251, 2014.
Gona P, Van Dyke RB, Williams PL, et al: Incidence of opportunistic and other infections in HIV-infected. children in the HAART era, JAMA 296:292–300, 2006.
Halasa NB, Shankar SM, Talbot TR, et al: Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine, Clin Infect Dis 44:1428–1433, 2007.
Hampton LM, Farley MM, Schaffner W, et al: Prevention of antibiotic-nonsusceptible Streptococcus pneumonia with conjugate vaccines, J Infect Dis 205:401–411, 2012.
Hsu HE, Shutt KA, Moore MR, et al: Effect of pneumococcal conjugate vaccine on pneumococcal meningitis, N Engl J Med. 360:244–256, 2009.
Ingels H, Schejbel L, Lundstedt AC, et al: Immunodeficiency among children with recurrent invasive pneumococcal disease, Pediatr Infect Dis J 34(6):644–651, 2015.
Jones RN, Sader HS, Mendes RE, et al: Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United. States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998–2011), Diagn Microbiol Infect Dis 75(1):107–109, 2013.
Kaplan SL, Barson WJ, Lin PL, et al: Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine, Pediatr Infect Dis J 32(3):203–207, 2013.
Kaplan SL, Center KJ, Barson WJ, et al: Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era, Clin Infect Dis 60:1339–1345, 2015.
Kimberlin D.W., Brady M.T., Jackson M.A., Long S.S., editors: Red. book: 2015 report of the Committee on Infectious Diseases, ed. 30, Elk Grove Village, IL, 2015, American Academy of Pediatrics, pp . 626–637.
Leber AL, Everhart K, Balada-Llasat JM, et al: Multicenter evaluation of BioFire FilmArray meningitis/encephalitis panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens, J Clin Microbiol 54:2251–2261, 2016.
Lynch JP, Zhanel GG: Streptococcus pneumoniae: does antimicrobial resistance matter?, Semin Respir Crit Care Med. 30:210–238, 2009.
Lynch JP 3rd, Zhanel GG: Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention, Semin Respir Crit Care Med. 30:189–209, 2009.
Lynch JP, Zhanel GG: Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines, CurrOpinPulm Med. 16:217–225, 2010.
McCavit TL, Quinn CT, Techasaensiri C, et al: Increase in invasive Streptococcus pneumoniae infections in children with sickle cell disease since pneumococcal conjugate vaccine licensure, J Pediatr 158(3):505–507, 2011.
Miller E, Andrews NJ, Waight PA, et al: Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine, Vaccine 29(49):9127–9131, 2011.
Moore MR, Link-Gelles R, Schaffner W, et al: Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched. case-control study, Lancet Respir Med. 4:399–406, 2016.
Moore MR, Link-Gelles R, Schaffner W, et al: Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the US: analysis of multisite, population-based. surveillance, Lancet Infect Dis 15:301–309, 2015.
Morens DM, Taubenberger JK, Fauci AS: Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness, J Infect Dis 198:962–970, 2008.
Neuman MI, Harper MB: Time to positivity of blood cultures for children with Streptococcus pneumoniae bacteremia, Clin Infect Dis 33:1324–1328, 2001.
O’Brien KL, Wolfson LJ, Watt JP, et al: Burden of disease caused. by Streptococcus pneumoniae in children younger than 5 years: global estimates, Lancet 374:893–902, 2009.
Olarte L, Ampofo K, Stockmann C, et al: Invasive pneumococcal disease in infants younger than 90 days before and after introduction of PCV7, Pediatrics 132:e17–e24, 2013.
Olarte L, Barson WJ, Barson RM, et al: Impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in US children, Clin Infect Dis 61:767–775, 2015.
Olarte L, Barson WJ, Barson RM, et al: Pneumococcal pneumonia requiring hospitalization in US children in the 13-valent pneumococcal conjugate vaccine era, Clin Infect Dis 64(12):1699–1704, 2017.
Park SY, Van Beneden CA, Pilishvili T, et al: Invasive pneumococcal infections among vaccinated. children in the United. States, J Pediatr 156:478–483, 2010.
Rello J, Lisbon T, Lujan M, et al: Severity of pneumococcal pneumonia associated with genomic bacterial load, Chest 136:832–840, 2009.
Shigayeva A, Rudnick W, Green K, et al: Invasive pneumococcal disease among immunocompromised. persons: implications for vaccination programs, Clin Infect Dis 62:139–147, 2016.
Spijkerman J, Veenhoven RH, Wijmenga-Monsuur AJ, et al: Immunogenicity of 13-valent pneumococcal conjugate vaccine administered. according to 4 different primary immunization schedules in infants, JAMA 310:930–936, 2013.
Stoecker C, Hamptom LM, Link-Gelles R, et al: Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine, Pediatrics 132:e324–e332, 2013.
Tagarro A, Benito A, Sanchez A, et al: Bacteremic pneumonia before and after withdrawal of 13-valent pneumococcal conjugate vaccine from a public vaccination program in Spain: a case-control study, Pediatrics 171:111–115, 2016.
Ward C, Stocker K, Begum J, et al: Performance evaluation of the Verigene (Nanosphere) and FilmArray (BioFire) molecular assays for identification of causative organisms in bacterial bloodstream infections, Eur J Clin Microbiol Infect Dis 34:487–496, 2015.
Anderson NW, Buchan BW, Mayne D, et al: Multicenter clinical evaluation of the illumigene group A Streptococcus DNA amplification assay for detection of group A Streptococcus from pharyngeal swabs, J Clin Microbiol 51:1473–1477, 2013.
Andreoni F, Zucher C, Tarnutzer A, et al: Clindamycin affects group A Streptococcus virulence factors and improves clinical outcome, J Infect Dis 215:269–277, 2017.
Barash J, Mashiach E, Navon-Elkan P, et al: Differentiation of post-streptococcal reactive arthritis from acute rheumatic fever, J Pediatr 153:696–699, 2008.
Bisno AL, Stevens DL: Streptococcal infections of skin and soft tissues, N Engl J Med. 334:240–245, 1996.
Bowen AC, Lilliebridge RA, Tong SYC, et al: Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole?, J Clin Microbiol 50:4067–4072, 2012.
Bowen AC, Tong SYC, Andrews RM, et al: Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an
Choby BA: Diagnosis and treatment of streptococcal pharyngitis, Am Fam Physician 79:383–390, 2009.
Clegg HW, Giftos PM, Anderson WE, et al: Clinical perineal streptococcal infection in children: epidemiologic features, low symptomatic recurrence rate after treatment, and risk factors for recurrence, J Pediatr 167:687–693, 2015.
Dale JB, Fischetti VA, et al: Group A streptococcal vaccines: paving a path for accelerated. development, Vaccine 31(Suppl 2):B216–B222, 2013.
Gerber M.A., Baltimore R.S., Eaton C.B., et al: Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, Circulation 119:1541–1551, 2009.
Gerber M.A., Shulman ST: Rapid diagnosis of pharyngitis caused. by group A streptococci, Clin Microbiol Rev 17:571–580, 2004.
Henson AM, Carter D, Todd K, et al: Detection of Streptococcus pyogenes using illumigene group A Streptococcus assay, J Clin Microbiol 51:4207–4209, 2013.
Kaul R, McGeer A, Norby-Teglund A, et al: Intravenous immunoglobulin therapy in streptococcal toxic shock syndrome — a comparative observational study, Clin Infect Dis 28:800–807, 1999.
Kurlan R, Kaplan EL: The pediatric autoimmune neuropsychiatric disorders associated. with streptococcal infections (PANDAS) etiology for tics and obsessive-compulsive symptoms: hypothesis or entity? Practical considerations for the clinician, Pediatrics 113:883–886, 2004.
Lennon DR, Farrell E, Martin DR, et al: Once-daily amoxicillin versus twice-daily penicillin V in group A ?-haemolytic streptococcal pharyngitis, Arch Dis Child 93:474–478, 2008.
Malhotra-Kumar S, Lammens C, Coenen S, et al: Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci on healthy volunteers: a randomized, double-blind, placebo-controlled. study, Lancet 369:482–490, 2007.
The Medical Letter: Extended. release amoxicillin for strep throat, Med. Lett Drugs Ther 51:17, 2009.
Navarini S, Erb T, Schaad UB, et al: Randomized, comparative efficacy trial of oral penicillin versus cefuroxime for perianal streptococcal dermatitis in children, J Pediatr 153:799–802, 2008.
Olson D, Edmonson B: Outcomes in children treated. for perineal group A betahemolytic streptococcal dermatitis, Pediatr Infect Dis J 30:933–936, 2011.
Rodriguez-Nuoez A, Dosil-Gallardo S, Jordan I: Clinical characteristics of children with group A streptococcal toxic shock syndrome admitted. to pediatric intensive care unit, Eur J Pediatr 170:639–644, 2011.
Sanderson-Smith M, De Oliveira DM, Guglielmini J, et al; M Protein Study Group: A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development, J Infect Dis 210:1325–1338, 2014.
Shulman ST, Bisno A, Clegg HW, et al: Clinical practice guidelines for the diagnosis and management of group a streptococcal pharyngitis: 2012 update by the Infectious Disease Society of America, Clin Infect Dis 55:1279–1282, 2012.
Shulman ST, Gerber M.A., Tanz RR, et al: Streptococcal pharyngitis: the case for penicillin therapy, Pediatr Infect Dis J 131–137, 1994.
Shulman ST, Tanz RR, Dale JB, et al: Seven-year surveillance of North American pediatric group A streptococcal pharyngitis isolates, Clin Infect Dis 49:78–84, 2009.
Stevens DL: Streptococcal toxic shock syndrome associated. with necrotizing fasciitis, Annu Rev Med. 51:271–288, 2000.
Upton A, Bissessor L, Farrell E, et al: Comparison of illumigene group A Streptococcus assay with culture of throat swabs from children with sore throats in the New Zealand school-based. rheumatic fever prevention program, J Clin Microbiol 54:153–156, 2016.
Carapetis JR, McDonald M, Wilson NJ: Acute rheumatic fever, Lancet 366:155–168, 2005.
Carapetis JR, Steer AC, Mulholland EK, et al: The global burden of group A streptococcal diseases, Lancet Infect Dis 5:685–694, 2005.
Gerber M.A., Baltimore R.S., Eaton C.B., et al: Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, Circulation 119:1541–1551, 2009.
Kerdemelidis M, Lennon DR, Arroll B, et al: The primary prevention of rheumatic fever, J Paediatr Child Health 46:534–548, 2010.
Gewitz MH, Baltimore R.S., Tani LY, et al: Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association, Circulation 131(20):1806–1818, 2015.
Lennon D, Anderson P, Kerdemelidis M, et al: First presentation acute rheumatic fever is preventable in a community setting: a school-based. intervention, Pediatr Infect Dis J 36(12):1113–1118, 2017.
Logan LK, McAulley JB, Shulman ST: Macrolide treatment failure in streptococcal pharyngitis resulting in acute rheumatic fever, Pediatrics 129:e798–e802, 2012.
Marijon E, Ou P, Celermajer DS, et al: Prevalence of rheumatic heart disease detected. by echocardiographic screening, N Engl J Med. 357:470–476, 2007.
Martin JM, Barbadora KA: Continued. high caseload of rheumatic fever in western Pennsylvania: possible rheumatogenic emm types of Streptococcus pyogenes, J Pediatr 149:58–63, 2006.
Milne RJ, Lennon DR, et al: Incidence of acute rheumatic fever in New Zealand children and youth, J Paediatr Child Health 48:685–691, 2012.
Shulman ST, Stollerman G, Beall B, et al: Temporal changes in streptococcal M protein types and the near-disappearance of acute rheumatic fever in the United. States, Clin Infect Dis 42:441–447, 2006.
Tandon R, Sharma M, Chandrashekhar Y, et al: Revisiting the pathogenesis of rheumatic fever and carditis, Nat Rev Cardiol advanced. online publication 10(3):171–177, 2013.
Tani LY, Veasy LG, Minich LL, et al: Rheumatic fever in children younger than 5 years: is the presentation different?, Pediatrics 112:1065–1068, 2003.
Walker AR, Tani LY, Thompson JA, et al: Rheumatic chorea: relationship to systemic manifestations and response to corticosteroids, J Pediatr 151:679–683, 2007.
Baker CJ, Rench MA, McInnes P: Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine, Vaccine 21:3468–3472, 2003.
Berardi A, Rossi C, Lugli L, et al: Group B streptococcus late-onset disease: 2003–2010, Pediatrics 131:e361–e368, 2013.
Brady M.T., Bernstein HH, Byington CL, et al: Policy statement–recommendations for the prevention of perinatal group B streptococcal (GBS) disease, Pediatrics 128:611–616, 2011.
Buser GL, Mato S, Zhang AY, et al: Late-onset infant group B streptococcus infection associated. with maternal consumption of capsules containing dehydrated. placenta—Oregon, 2016, MMWR Morb Mortal Wkly Rep 66(25):677–678, 2017.
Cantoni L, Ronfani L, Da Riol R, et al: Physical examination instead of laboratory tests for most infants born to mother colonized. with group B streptococcus: support for the Centers for Disease Control and Prevention’s 2010 recommendations, J Pediatr 163:568–573, 2013.
Centers for Disease Control and Prevention (CDC): Active bacterial core surveillance (ABCs) report, emerging infectious program network, group B Streptococcus, 2011, 2012, 2013, 2014, 2015.
Libster R, Edwards KM, Levent F, et al: Long-term outcomes of group B meningitis, Pediatrics 130:e8–e15, 2012.
Schrag S.J., Farley MM, Petit S, et al: Epidemiology of early-onset neonatal sepsis, 2005–2014, Pediatrics 138:2016.
Skoff TH, Farley MM, Petit S, et al: Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990–2007, Clin Infect Dis 49:85–92, 2009.
Tazi A, Disson O, Beliais S, et al: The surface protein HvgA mediates group B streptococcus hypervirulence and meningeal tropism in neonates, J Exp Med. 207:2313–2322, 2010.
Van Dyke MK, Phares CR, Lynfield R, et al: Evaluation of universal antenatal screening for group B streptococcus, N Engl J Med. 360:2626–2636, 2009.
Verani J.R., McGee L., Schrag S.J., Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC): Prevention of perinatal group B streptococcal disease—revised. guidelines from CDC 2010, MMWR Recomm Rep 59(RR–10):1–36, 2010.
Brandt CM, Spellerberg B: Human infections due to Streptococcus dysgalactiae subspecies equisimilis, Clin Infect Dis 49:766–772, 2009.
Ikebe T, Okuno R, Sasaki M, et al: Molecular characterization and antibiotic resistance of Streptococcus dysgalactiae subspecies equisimilis isolated. from patients with streptococcal toxic shock syndrome, J Infect Chemother 24:117–122, 2018.
Jensen A, Kilian M: Delineation of Streptococcus dysgalactiae, its subspecies, and its clinical and phylogenetic relationship to Streptococcus pyogenes, J Clin Microbiol 50:113–126, 2012.
Kakuya F, Kinebuchi T, Okubo H, et al: Acute pharyngitis associated. with Streptococcus dysgalactiae subspecies equisimilis in children, Pediatr Infect Dis J 37(6):537–542, 2018.
Watanabe S, Kirikae T, Miyoshi-Akiyama T: Complete genome sequence of Streptococcus dysgalactiae subsp. equisimilis 167 carrying Lancefield group C antigen and comparative genomics of S. dysgalactiae subsp. equisimilis strains, Genome Biol Evol 5:1644–1651, 2013.
Zaoutis T1, Moore LS, Furness K, et al: In vitro activities of linezolid, meropenem, and quinupristin-dalfopristin against group C and G streptococci, including vancomycin-tolerant isolates, Antimicrob Agents Chemother 45:1952–1954, 2001.
Adams DJ, Eberly MD, Goudie A, Nylund CM: Rising vancomycin-resistant enterococcus infections in hospitalized. children in the United. States, Hosp Pediatr 6:404–411, 2016. Arias CA, Murray BE: The rise of the Enterococcus: beyond vancomycin resistance, Nat Rev Microbiol 10:266–278, 2012.
Butler KM: Enterococcal infection in children, Semin Pediatr Infect Dis 17:128–139, 2006. Flokas ME, Karageorgos SA, Detsis M, et al: Vancomycin-resistant enterococci colonisation, risk factors and risk for infection among hospitalized. paediatric patients: a systematic review and meta-analysis, Int J Antimicrob Agents 49:565–572, 2017.
Lake JG, Weiner LM, Milstone AM, et al: Pathogen distribution and antimicrobial resistance among pediatric healthcare-associated. infections reported. to the National Healthcare Safety Network, 2011–2014, Infect Control Hosp Epidemiol 39:1–11, 2018.
Taur Y, Xavier JB, Lipuma L, et al: Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation, Clin Infect Dis 55:905–914, 2012.
Both L, Collins S, De Zoysa A, et al: Molecular and epidemiological review of toxigenic diphtheria infections in England between 2007 and 2013, J Clin Microbiol 53(2):567–572, 2015.
Chagina IA, Borisova O, Mel’nikov VG, et al: [Sensitivity of Corynebacterium diphtheria strains to antibacterial preparations], Zh Mikrobiol Epidemiol Immunobiol 4:8–13, 2014.
De Zoysa A, Efstratiou A, Mann G, et al: Development, validation and implementation of a quadruplex real-time PCR assay for identification of potentially toxigenic corynebacteria, J Med. Microbiol 65(12):1521–1527, 2016.
FitzGerald RP, Rosser AJ, Perera DN: Non-toxigenic penicillin-resistant cutaneous C. diphtheriae infection: a case report and review of the literature, J Infect Public Health 8(1):98–100, 2015.
Hacker E, Antunes CA, Mattos-Guaraldi AL, et al: Corynebacterium ulcerans, an emerging human pathogen, Future Microbiol 11(9):1191–1208, 2016.
Ahn SJ, Ryoo NK, Woo SJ: Ocular toxocariasis: clinical features, diagnosis, treatment, and prevention, Asia Pac Allergy 4(3):134–141, 2014.
Lee RM, Moore LB, Bottazzi ME, Hotez PJ: Toxocariasis in north America: a systematic review, PLoS Negl Trop Dis 8:e3116, 2014.
Macpherson CN: The epidemiology and public health importance of toxocariasis: a zoonosis of global importance, Int J Parasitol 43(12/13):999–1008, 2013.
Padhi TR, Das S, Sharma S, et al: Ocular parasitoses: a comprehensive review, Surv Ophthalmol 62(2):161–189, 2017.
Sircar AD, Abanyie F, Blumberg D, et al: Raccoon roundworm infection associated. with central nervous system disease and ocular disease—six states, 2013–2015, MMWR 65(35):930–933, 2016.
Woodhall DM, Eberhard ML, Parise ME: Neglected. parasitic infections in the United. States: toxocariasis, Am J Trop Med. Hyg 90(5):810–813, 2014.
Faber M, Schink S, Mayer-Scholl A, et al: Outbreak of trichinellosis due to wild boar meat and evaluation of the effectiveness of post exposure prophylaxis, Germany, 2013, Clin Infect Dis 60(12):e98–e104, 2015.
Greene YG, Padovani T, Rudroff JA, et al: Trichinellosis caused. by consumption of wild boar meat—Illinois, 2013, MMWR Morb Mortal Wkly Rep 63(20):451, 2014.
Heaton D, Huang S, Shiau R, et al: Trichinellosis outbreak linked. to consumption of privately raised. raw boar meat—California, 2017, MMWR Morb Mortal Wkly Rep 67(8):247–249, 2018.
Messiaen P, Forier A, Vanderschueren S, et al: Outbreak of trichinellosis related. to eating imported. wild boar meat, Belgium, 2014, Euro Surveill 21(37):2016.
Murrell KD: The dynamics of Trichinella spiralis epidemiology: out to pasture?, Vet Parasitol 231:92–96, 2016.
Pozio E, Zarlenga DS: New pieces of the Trichinella puzzle, Int J Parasitol 43(12/13): 983–997, 2013.
Shimoni Z, Froom P: Uncertainties in diagnosis, treatment and prevention of trichinellosis, Expert Rev Anti Infect Ther 13(10):1279–1288, 2015.
Springer YP, Casillas S, Helfrich K, et al: Two outbreaks of trichinellosis linked. to consumption of walrus meat—Alaska, 2016–2017, MMWR Morb Mortal Wkly Rep 66(26):692–696, 2017.
Wilson NO, Hall RL, Montgomery SP, Jones JL: Trichinellosis surveillance—United. States, 2008–2012, MMWR Surveill Summ 64(1):1–8, 2015.
Bustinduy AL, Thomas CL, Fiutem JJ, et al: Measuring fitness of Kenyan children with polyparasitic infections using the 20-meter shuttle run test as a morbidity metric, PLoS Negl Trop Dis 5:e1213, 2011.
Bustinduy A, Waterhouse D, de Sousa-Figueiredo J, et al: Population pharmacokinetics and pharmacodynamics of praziquantel in Ugandan children with intestinal schistosomiasis: higher dosages are required. for maximal efficacy, MBio 7(4):e00227–16, 2016.
Carod-Artal FJ: Neurological complications of Schistosoma infection, Trans R Soc Trop Med. Hyg 102:107–116, 2008.
Centers for Disease Control and Prevention: Schistosomiasis. http://www.cdc.gov/parasites/schistosomiasis/index.html.
Colley DG, Bustinduy AL, Secor WE, et al: Human schistosomiasis, Lancet 383: 2253–2264, 2014.
Friedman JF, Kanzaria HK, McGarvey ST: Human schistosomiasis and anemia: the relationship and potential mechanisms, Trends Parasitol 21:386–392, 2005.
Hegertun IE, Sulheim Gundersen KM, Kleppa E, et al: S. haematobium as a common cause of genital morbidity in girls: a cross-sectional study of children in South Africa, PLoS Negl Trop Dis 7:e2104, 2013.
Kjetland EF, Leutscher PD, Ndhlovu PD: A review of female genital schistosomiasis, Trends Parasitol 28:58–65, 2012.
The Medical Letter: Drugs for parasitic infections, Med. Lett Drugs Ther 11(Suppl):e1–e31, 2013.
Mutapi F: Changing policy and practice in the control of pediatric schistosomiasis, Pediatrics 135(3):536–544, 2015.
Stothard JR, Sousa-Figueiredo JC, Betson M, et al: Schistosomiasis in African infants and preschool children: let them now be treated!, Trends Parasitol 29:197–205, 2013.
Andrews RH, Sithithaworn P, Petney TN: Opisthorchis viverrini: an underestimated. parasite in world health, Trends Parasitol 24:497–501, 2008.
Mas-Coma S, Valero MA, Bargues MD: Chapter 2. Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control, Adv Parasitol 69:41–146, 2009.
The Medical Letter: Drugs for parasitic infections, Med. Lett Drugs Ther 11(Suppl):e1–e31, 2013.
Millan JC, Mull R, Freise S, et al: The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection, Am J Trop Med. Hyg 63:264–269, 2000.
Zarrin-Khameh N, Citron DR, Stager CE, et al: Pulmonary paragonimiasis diagnosed. by fine-needle aspiration biopsy, J Clin Microbiol 46:2137–2140, 2008.
Anantaphruti MT, Yamasaki H, Nakao M, et al: Sympatric occurrence of Taenia solium, T. saginata, and T. asiatica, Thailand, Emerg Infect Dis 13:1413–1416, 2007.
Cabada MM, Morales ML, Lopez M, et al: Hymenolepis nana impact among children in the highlands of Cusco-Peru: an emerging neglected. parasite infection, Am J Trop Med. Hyg 95:1031–1036, 2016.
Scholz T, Garcia HH, Kuchta R, et al: Update on the human broad tapeworm (genus Diphyllobothrium), including clinical relevance, Clin Microbiol Rev 22:146–160, 2009.
Del Brutto OH: Neurocysticercosis in infants and toddlers: report of seven cases and review of published. patients, Pediatr Neurol 48:432–435, 2013.
Del Brutto OH, Nash TE, White AC Jr, et al: Revised. diagnostic criteria for neurocysticercosis, J Neurol Sci 372:202–210, 2017.
Garcia HH, Nash TE, Del Brutto OH: Clinical symptoms, diagnosis, and treatment of neurocysticercosis, Lancet Neurol 13(12):1202–1215, 2014.
Garcia HH, Gonzales I, Lescano AG, et al: Efficacy of combined. antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomized. controlled. trial, Lancet Infect Dis 14(8):687–695, 2014.
Ndimubanzi PC, Carabin H, Budke CM, et al: A systematic review of the frequency of neurocysticercosis with a focus on people with epilepsy, PLoS Negl Trop Dis 4(11):e870, 2010.
O’Keefe KA, Eberhard ML, Shafir SC, et al: Cysticercosis-related. hospitalizations in the United. States, 1998–2011, Am J Trop Med. Hyg 92:354–359, 2015.
O’Neal SE, Flecker RH: Hospitalization frequency and charges for neurocysticercosis, United. States, 2003–2012, Emerg Infect Dis 21(6):969–976, 2015.
Rangel-Castilla L, Serpa JA, Gopinath SP, et al: Contemporary neurosurgical approaches to neurocysticercosis, Am J Trop Med. Hyg 80(3):373–378, 2009.
Serpa JA, Graviss EA, Kass JS, et al: Neurocysticercosis in Houston, Texas, Medicine (Baltimore) 90(1):81–86, 2011.
Zammarchi L, Angheben A, Gobbi F, et al: Profile of adult and pediatric neurocysticercosis cases observed. in five Southern European centers, Neurol Sci 37:1349–1355, 2016.
Zhao B-C, Jiang H-Y, Ma W-Y, et al: Albendazole and corticosteroids for the treatment of solitary cysticercus granuloma: a network meta-analysis, PLoS Negl Trop Dis 10(2):e0004418, 2016.
Brunetti EP, Kern P, Vuitton DA, et al: Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans, Acta Trop 114:1–16, 2010.
Budke CM, Carabin H, Ndimubanzi PC, et al: A systematic review of the literature on cystic echinococcosis frequency worldwide and its associated clinical manifestations, Am J Trop Med Hyg 88:1011–1027, 2013.
Cucher MA, Macchiaroli N, Baldi G, et al: Cystic echinococcosis in South America: systematic review of species and genotypes of Echinococcus granulosussensulato in humans and natural domestic hosts, Trop Med Int Health 21:166–175, 2016.
Kern P, Menezes da Silva A, Akhan O, et al: The echinococcoses: diagnosis, clinical management and burden of disease, Adv Parasitol 96:259–369, 2017.
Siles-Lucas M, Casullix A, Conraths FJ, Muller N: Laboratory diagnosis of Echinococcus spp. in human patients and infected animals, Adv Parasitol 96:159–257, 2017.
Solomon N, Fields PJ, Tamarozzi F, et al: Expert reliability for the World Health Organization standardized ultrasound classification of cystic echinococcosis, Am J Trop Med Hyg 96:686–691, 2017.
Manikyamba D, Satyavani A, Deepa P: Diphtheritic polyneuropathy in the wake of resurgence of diphtheria, J Pediatr Neurosci 10(4):331–334, 2015.
May MLA, McDougall RJ, Robson JM: Corynebacterium diphtheriae and the returned tropical traveler, J Travel Med. 21(1):39–44, 2014.
Moore LS, Leslie A, Meltzer M, et al: Corynebacterium ulcerans cutaneous diphtheria, Lancet Infect Dis 15(9):1100, 2015.
Mothershed. EA, et al: Development of a real-time fluorescence PCR assay for rapid detection of the diphtheria toxin gene, J Clin Microbiol 40(12):4713–4719, 2002.
Notes from the field: respiratory diphtheria-like illness caused. by toxigenic Corynebacterium ulcerans—Idaho, 2010, MMWR Morb Mortal Wkly Rep 60(3):77, 2011.
Schuhegger R, et al: Detection of toxigenic Corynebacterium diphtheriae and Corynebacterium ulcerans strains by a novel real-time PCR, J Clin Microbiol 46(8):2822–2823, 2008.
Sing A, et al: Rapid detection and molecular differentiation of toxigenic Corynebacterium diphtheriae and Corynebacterium ulcerans strains by LightCycler PCR, J Clin Microbiol 49(7):2485–2489, 2011.
Websites Centers for Disease Control and Prevention, Pertussis and Diphtheria Laboratory.
World Health Organization Diphtheria reported. cases.
Moore LS, Leslie A, Meltzer M, et al: Corynebacterium ulcerans cutaneous diphtheria, Lancet Infect Dis 15(9):1100, 2015.
Mothershed. EA, et al: Development of a real-time fluorescence PCR assay for rapid detection of the diphtheria toxin gene, J Clin Microbiol 40(12):4713–4719, 2002.
Notes from the field: respiratory diphtheria-like illness caused. by toxigenic Corynebacterium ulcerans—Idaho, 2010, MMWR Morb Mortal Wkly Rep 60(3):77, 2011.
Schuhegger R, et al: Detection of toxigenic Corynebacterium diphtheriae and
Corynebacterium ulcerans strains by a novel real-time PCR, J Clin Microbiol 46(8):2822–2823, 2008.
Sing A, et al: Rapid detection and molecular differentiation of toxigenic Corynebacterium diphtheriae and Corynebacterium ulcerans strains by LightCycler PCR, J Clin Microbiol 49(7):2485–2489, 2011.
Websites Centers for Disease Control and Prevention, Pertussis and Diphtheria Laboratory.
World Health Organization Diphtheria reported. cases.
Messacar K, Breazeale G, Robinson CC, et al: Potential clinical impact of the film array meningitis encephalitis panel in children with suspected. central nervous system infections, Diagn Microbiol Infect Dis 86:118–120, 2016.
Self JL, Conrad A, Stroika S, et al: Notes from the field. Outbreak of listeriosis associated. with consumption of packaged. salad—United. States and Canada, 2015–2016, MMWR 65:879–881, 2016.
Bartlett AH, Rivera AL, Krishnamurthy R, et al: Thoracic actinomycosis in children: case report and review of the literature, Pediatr Infect Dis J 27:165–169, 2008.
Kononen E, Wade WG: Actinomyces and related organisms in human infections, Clin Microbiol Rev 28:419–442, 2015.
Smego RA: Actinomycosis of the central nervous system, Rev Infect Dis 9:855–865, 1987.
Thacker SA, Healy CM: Pediatric cervicofacial actinomycosis: an unusual cause of head and neck masses, J Pediatric Infect Dis Soc 3:e15–e19, 2014.
Wacharachaisurapol N, Bender JM, Wang L, et al: Abdominal actinomycosis in children, Pediatr Infect Dis J 36:e76–e79, 2017.
Wohlgemuth SD, Gaddy MC: Surgical implications of actinomycosis, South Med J79:1574–1578, 1986.
Fujita T, Ikara J, Watanabe A, et al: Clinical characteristics of pulmonary nocardiosis in immunocompetent patients, J Infect Chemother 22:738–743, 2016.
Girard V, Mailler S, Polsinelli S, et al: Routine identification of Nocardia species by MALDI-TOF mass spectrometry, Diagn Microbiol Infect Dis 87:7–10, 2017.
Haussaire D, Fournier PE, Djiguiba K, et al: Nocardiosis in the south of France over a 10-year period, 2004–2014, Int J Infect Dis 57:13–20, 2017.
McGuinness SL, Whiting SE, Baird R, et al: Nocardiosis in the tropical Northern Territory of Australia, 1997–2014, Open Forum Infect Dis 3(4):ofw208–eCollection, 2016.
McTaggart LR, Doucet J, Witkowska M, et al: Antimicrobial susceptibility among clinical Nocardia species, Antimicrob Agents Chemother 59(1):269–275, 2015.
Minero MV, Marin M, Cercenado E, et al: Nocardiosis at the turn of the century, Medicine (Baltimore) 88(4):250–261, 2009.
Rafiei N, Peri AM, Righi E, et al: Central nervous system nocardiosis in Queensland, Medicine (Baltimore) 95(46):e5255, 2016.
Valdezate S, Garrido N, Carrasco G, et al: Epidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain, J Antimicrob Chemother 72:754–761, 2017.
Woodworth MH, Saullo JL, Lantos PM, et al: Increasing Nocardia incidence associated. with bronchiectasis at a tertiary care center, Ann Am Thorac Soc 14(3):347–354, 2017.
American Academy of Pediatrics Committee on Infectious Diseases: Updated. recommendations on the use of meningococcal vaccines, Pediatrics 134:400–403, 2014.
Basta NE, Mahmoud AAF, Wolfson J, et al: Immunogenicity of a meningococcal B vaccine during a university outbreak, N Engl J Med. 375(3):220–228, 2016.
Borrow R, Alarc?n P, Carlos J, et al: The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection, Expert Rev Vaccines 2016:1–16, 2016.
Bryan P, Seabroke S, Wong J, et al: Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunization in the UK: a prospective surveillance study, Lancet Child Adolesc Health 2:395–402, 2018.
Centers for Disease Control and Prevention: Infant meningococcal vaccination: Advisory Committee on Immunization Practices recommendations and rationale, MMWR Morb Mortal Wkly Rep 62:52–54, 2013.
Centers for Disease Control and Prevention: Serogroup C invasive meningococcal disease among men who have sex with men—New York City, 2010–2012, MMWR Morb Mortal Wkly Rep 61:1048, 2013.
Cohn A.C., MacNeil J.R., Clark T.A., et al: Centers for Disease Control and Prevention: prevention and control of meningococcal disease: recommendations of the Advisory
Committee on Immunization Practices, MMWR Recomm Rep 62(RR–2):1–28, 2013.
Davizon ES, Soeters HM, Miller L, Barnes M: Two cases of meningococcal disease in one family separated. by an extended. period—Colorado, 2015–2016, MMWR
Morb Mortal Wkly Rep 67(12):366–368, 2018.
Chansamouth V, Thammasack S, Phetsouvanh R, et al: The aetiologies and impact of fever in pregnant inpatients in Vientiane, Laos, PLoS Negl Trop Dis 10:e0004577, 2016.
Cross R, Ling C, Day NP, et al: Revisiting doxycycline in pregnancy and early childhood–time to rebuild its reputation?, Expert Opin Drug Saf 15:367–382, 2016.
Marshall GS, for the Tick-Borne Infections in Children Study (TICS) Group: Rickettsia typhi seroprevalence among children in the southeast United. States, Pediatr Infect Dis J 9:1103–1104, 2000.
Murray KO, Evert N, Mayes B, et al: Typhus Group Rickettsiosis, Texas, USA, 2003-2013, Emerg Infect Dis 23(4):645–648, 2017.
Prusinski MA, White JL, Wong SJ, et al: Sylvatic typhus associated. with flying squirrels (Glaucomys volans) in New York State, United. States, Vector Borne Zoonotic Dis 14:240–244, 2014.
Gikas A, Kokkini S, Tsioutis C, et al: Murine typhus in children: clinical and laboratory features from 41 cases in Crete, Greece, Clin Microbiol Infect 15(Suppl 2):211–212, 2009.
Green JS, Singh J, Cheung M, et al: A cluster of pediatric endemic typhus cases in Orange County, California, Pediatr Infect Dis J 30:163–165, 2011.
Tsioutis C, Zafeiri M, Avramopoulos A, et al: Clinical and laboratory characteristics, epidemiology, and outcomes of murine typhus: a systematic review, Acta Trop 166:16–24, 2017.
Walter G, Botelho-Nevers E, Socolovschi C, et al: Murine typhus in returned. travelers: a report of thirty-two cases, Am J Trop Med. Hyg 86:1049–1053, 2012.
Raoult D, Ndihokubwayo JB, Tissot-Dupont H, et al: Outbreak of epidemic typhus associated. with trench fever in Burundi, Lancet 352:353–358, 1998.
Umulisa I, Omolo J, Muldoon KA, et al: A mixed. outbreak of epidemic typhus fever and trench fever in a youth rehabilitation center: risk factors for illness from a case-control study, Rwanda, 2012, Am J Trop Med. Hyg 95:452–456, 2016.
Arnez M, Luznik-Bufon T, Avsic-Zupanc T, et al: Causes of febrile illnesses after a tick bite in Slovenian children, Pediatr Infect Dis J 22:1078–1083, 2003.
Biggs HM, Behravesh CB, Bradley KK, et al: Diagnosis and management of tickborne rickettsial diseases: rocky mountain spotted. fever and other spotted. fever group rickettsioses, ehrlichioses, and anaplasmosis—United. States, MMWR Recomm Rep 65:1–44, 2016.
Berry DS, Miller RS, Hooke JA, et al: Ehrlichial meningitis with cerebrospinal fluid morulae, Pediatr Infect Dis J 18:552–555, 1999.
Buller RS, Arens M, Hmiel SP, et al: Ehrlichia ewingii, a newly recognized. agent of human ehrlichiosis, N Engl J Med. 341:148–155, 1999.
Dahlgren FS, Heitman KN, Drexler NA, et al: Human granulocytic anaplasmosis in the United. States from 2008 to 2012: a summary of national surveillance data, Am J Trop Med. Hyg 93:66–72, 2015.
Dumler JS, Dey C, Meier F, et al: Human monocytic ehrlichiosis: a potentially severe disease in children, Arch Pediatr Adolesc Med. 154:847–849, 2000.
Esbenshade A, Esbenshade J, Domm J, et al: Severe ehrlichia infection in pediatric oncology and stem cell transplant patients, Pediatr Blood Cancer 54:776–778, 2010. Hamburg BJ, Storch GA, Micek ST, et al: The importance of early treatment with doxycycline in human ehrlichiosis, Medicine (Baltimore) 87:53–60, 2008.
Hanson D, Walter AW, Powell J: Ehrlichia-induced. hemophagocytic lymphohistiocytosis in two children, Pediatr Blood Cancer 56:661–663, 2011.
Horowitz HW, Kilchevsky E, Haber S, et al: Perinatal transmission of the agent of human granulocytic ehrlichiosis, N Engl J Med. 339:375–378, 1998.
Krause PJ, Corrow CL, Bakken JS: Successful treatment of human granulocytic ehrlichiosis in children using rifampin, Pediatrics 112:e252–e253, 2003.
Marshall GS, Jacobs Hb, Schutze GE, et al: Ehrlichia chaffeensis seroprevalence among children in the southeast and south-central regions of the United. States, Arch Pediatr Adolesc Med. 156:166–170, 2002.
Moss WJ, Dumler JS: Simultaneous infection with Borrelia burgdorferi and human granulocytic ehrlichiosis, Pediatr Infect Dis J 22:91–92, 2003.
Nichols Heitman K, Dahlgren FS, Drexler NA, et al: Increasing incidence of ehrlichiosis in the United. States: a summary of national surveillance of Ehrlichia chaffeensis and Ehrlichia ewingii infections in the United. States, 2008-2012, Am J Trop Med. Hyg 94:52–60, 2016.
Pritt BS, Sloan LM, Johnson DKH, et al: Emergence of a new pathogenic Ehrlichia species, Wisconsin and Minnesota, 2009, N Engl J Med. 365:422–428, 2011.
Schotthoefer AM, Meece JK, Ivacic LC, et al: Comparison of a real-time PCR method with serology and blood smear analysis for diagnosis of human anaplasmosis: importance of infection time course for optimal test utilization, J Clin Microbiol 51:2147–2153, 2013.
Schutze GE, Buckingham SC, Marshall GS, et al: Human monocytic ehrlichiosis in children, Pediatr Infect Dis J 26:475–479, 2007.
Anderson A, Bijlmer H, Fournier PE, et al: Diagnosis and management of Q fever—United. States, 2013: recommendations from CDC and the Q fever Working Group, MMWR Recomm Rep 62(RR–03):1–30, 2013.
Bart IY, Schabos Y, van Hout RW, et al: Pediatric acute Q fever mimics other common childhood illnesses, PLoS ONE 9:e88677, 2014.
Dahlgren FS, McQuiston JH, Massung Hb, Anderson AD: Q fever in the United. States: summary of case reports from two national surveillance systems, 2000-2012, Am J Trop Med. Hyg 92:247–255, 2015.
Eldin C, M?lenotte C, Mediannikov O, et al: From q fever to Coxiella burnetii infection: a paradigm change, Clin Microbiol Rev 30:115–190, 2017.
Francis JR, Robson J, Wong D, et al: Chronic recurrent multifocal Q fever osteomyelitis in children: an emerging clinical challenge, Pediatr Infect Dis J 35:972–976, 2016.
Hurtado A, Alonso E, Aspiritxaga I, et al: Environmental sampling coupled. with real-time PCR and genotyping to investigate the source of a Q fever outbreak in a work setting, Epidemiol Infect 1-9:2017.
Kobbe R, Kramme S, Kreuels B, et al: Q fever in young children, Ghana, Emerg Infect Dis 14:344–346, 2008.
La Scola B, Maltezou HC: Legionella and Q fever community acquired. pneumonia in children, Paediatr Respir Rev 5(Suppl):S171–S177, 2004.
Maltezou HC, Constantopoulou I, Kallergi C, et al: Q fever in children in Greece, Am J Trop Med. Hyg 70:540–544, 2004.
Million M, Raoult D: No such thing as chronic Q fever, Emerg Infect Dis 23:856–857, 2017.
Million M, Bardin N, Bessis S, et al: Thrombosis and antiphospholipid antibody syndrome during acute Q fever: a cross-sectional study, Medicine (Baltimore) 96:e7578, 2017.
Ravid S, Shahar E, Genizi J: Acute Q fever in children presenting with encephalitis, Neurology 38:44–46, 2008.
Robyn MP, Newman AP, Amato M, et al: Q fever outbreak among travelers to Germany who received. live cell therapy—United. States and Canada, 2014, MMWR 64(38):1071–1073, 2015.
Roest HI, Tilburt JJ, van der Hoek W, et al: The Q fever epidemic in The Netherlands: history, onset, response and reflection, Epidemiol Infect 139:1–12, 2011.
Slok EN, Dijkstra F, de Vries E, et al: Estimation of acute and chronic Q fever incidence in children during a three-year outbreak in the Netherlands and a comparison with international literature, BMC Res Notes 8:456, 2015
Arrieta AC, Maddison P, Groll AH: Safety of micafungin in pediatric clinical trials, Pediatr Infect Dis J 30(6):e97–e102, 2011.
Benjamin DK Jr, Hudak ML, Duara S, Fluconazole Prophylaxis Study Team, et al: Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized. clinical trial, JAMA 311(17):1742–1749, 2014.
Benjamin DK Jr, Smith PB, Arrieta A, et al: Safety and pharmacokinetics of repeat-dose micafungin in young infants, Clin Pharmacol Ther 87(1):93–99, 2010.
Doring M, M?ller C, Johann PD, et al: Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation, BMC Infect Dis 12:263, 2012.
Driscoll TA, Yu LC, Frangoul H, et al: Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised. children and healthy adults, Antimicrob Agents Chemother 55(12):5770–5779, 2011.
Friberg LE, Ravva P, Karlsson MO, Liu P: Integrated. population pharmacokinetic analysis of voriconazole in children, adolescents, and adults, Antimicrob Agents Chemother 56(6):3032–3042, 2012.
Lestner JM, Smith PB, Cohen-Wolkowiez M, et al: Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective, Br J Clin Pharmacol 2012. doi:10.1111/bcp.12025.
Li CC, Sun P, Dong Y, et al: Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients, Antimicrob Agents Chemother 55(5):2098–2105, 2011.
Maertens JA, Madero L, Reilly AF, Caspofungin Pediatric Study Group, et al: A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia, Pediatr Infect Dis J 29(5):415–420, 2010.
Maertens JA, Raad II, Marr KA, et al: Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused. by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial, Lancet 387(10020):760–769, 2016.
Marty FM, Ostrosky-Zeichner L, Cornely OA, et al: VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis, Lancet Infect Dis 16(7):828–837, 2016.
Moon WJ, Scheller EL, Suneja A, et al: Plasma fluoride as a predictor of voriconazoleinduced. periostitis in patients with skeletal pain, Clin Infect Dis 59(9):1237–1245, 2014.
Pappas PG, Kauffman CA, Andes DR, et al: Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America, Clin Infect Dis 62(4):e1–e50, 2016.
Pieper S, Kolve H, Gumbinger HG, et al: Monitoring of voriconazole plasma concentrations in immunocompromised. paediatric patients, J Antimicrob Chemother 67(11):2717–2724, 2012.
Turner K, Manzoni P, Benjamin DK, et al: Fluconazole pharmacokinetics and safety in premature infants, Curr Med. Chem 19(27):4617–4620, 2012.
Welzen ME, Br?ggemann RJ, Van Den Berg JM, et al: A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease, Pediatr Infect Dis J 30(9):794–797, 2011.
Benjamin DK Jr, Stoll BJ, Gantz MG, et al: Neonatal candidiasis: epidemiology, risk factors, and clinical judgment, Pediatrics 126(4):e865–e873, 2010.
Ericson JE, Kaufman DA, Kicklighter SD, et al: Fluconazole prophylaxis for the prevention of candidiasis in premature infants: a meta-analysis using patient-level data, Clin Infect Dis 63(5):604–610, 2016.
Karadag-Oncel E, Kara A, Ozsurekci Y, et al: Candidaemia in a paediatric centre and importance of central venous catheter removal, Mycoses 58(3):140–148, 2015.
Kaufman DA, Coggins SA, Zanelli SA, Weitkamp JH: Congenital cutaneous candidiasis: prompt systemic treatment is associated. with improved. outcomes in neonates, Clin Infect Dis 64(10):1387–1395, 2017.
Lancaster DP, Friedman DF, Chiotos K, Sullivan KV: Blood volume required. for detection of low levels and ultralow levels of organisms responsible for neonatal bacteremia by use of Bactec Peds Plus/F, Plus Aerobic/F Medium, and the BD Bactec FX System: an in vitro study, J Clin Microbiol 53(11):3609–3613, 2015.
Pappas PG, Kauffman CA, Andes DR, et al: Clinical practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America, Clin Infect Dis 62(4):e1–e50, 2016.
Swanson JR, Vergales J, Kaufman DA, Sinkin RA: Cost analysis of fluconazole prophylaxis for prevention of neonatal invasive candidiasis, Pediatr Infect Dis J 35(5):519–523, 2016.
Bonifaz A, Rojas R, Tirado-S?nchez A, et al: Superficial mycoses associated. with diaper dermatitis, Mycopathologia 181(9–10):671–679, 2016.
Wlodek C, Trickey A, de Berker D, Johnson E: Trends in pediatric laboratory-diagnosed. onychomycosis between 2006 and 2014 in the southwest of England, Pediatr Dermatol 33(6):e358–e359, 2016.
Eyre DW, Sheppard AE, Madder H, et al: A Candida auris outbreak and its control in an intensive care setting, N Engl J Med. 379(14):1322–1331, 2018.
Karadag-Oncel E, Kara A, Ozsurekci Y, et al: Candidaemia in a paediatric centre and importance of central venous catheter removal, Mycoses 58(3):140–148, 2015.
Lehrnbecher T, Robinson PD, Fisher BT, et al: Galactomannan, ?-D-glucan, and polymerase chain reaction-based. assays for the diagnosis of invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review and meta-analysis, Clin Infect Dis 63(10):1340–1348, 2016.
Pappas PG, Kauffman CA, Andes DR, et al: Clinical practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America, Clin Infect Dis 62(4):e1–e50, 2016.
Vallabhanemi S, Kallen A, Tsay S, et al: Investigation of the first seven reported. cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus—United. States, May 2013-August 2016, MMWR Morb Mortal Wkly Rep 65(44):1234–1237, 2016.
Whaley SG, Berkow EL, Rybak JM, et al: Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species, Front Microbiol 7:2173, 2016.
Zarei Mahmoudabadi A, Rezaei-Matehkolaei A, Navid M, et al: Colonization and antifungals susceptibility patterns of Candida species isolated. from hospitalized. patients in ICUs and NICUs, J Nephropathol 4(3):77–84, 2015.
Abadi J, Nachman S, Kressel AB, Pirofski L: Cryptococcosis in children with AIDS, Clin Infect Dis 28:309–313, 1999.
Bicanic T, Meintjes G, Rebe K, et al: Immune reconstitution inflammatory syndrome in HIV-associated. cryptococcal meningitis: a prospective study, J Acquir Immune Defic Syndr 51:130–134, 2009.
Chang WC, Tzao C, Hsu HH, et al: Pulmonary cryptococcosis: comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised. patients, Chest 129(2):333–340, 2006.
Leal A, FAganello J, Bassanesi M: Cryptococcus species identification by multiplex PCR, Med. Mycol 46(4):377–383, 2008.
Leggiadro RJ, Barrett FF, Hughes WT: Extrapulmonary cryptococcosis in immunocompromised. infants and children, Pediatr Infect Dis J 11:43–47, 1992.
Leggiadro RJ, Kline MW, Hughes WT: Extrapulmonary cryptococcosis in children with acquired. immunodeficiency syndrome, Pediatr Infect Dis J 10:658–662, 1991.
Lizarazo J, Escandon P, Agudelo CI, Castaneda E: Cryptococcosis in Colombian children and literature review, Mem Inst Oswaldo Cruz 109(6):797–804, 2014.
Loyse A, Wilson D, Meintjes G, et al: Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated. cryptococcal meningitis, HIV AIDS (Auckl) 54:121–128, 2012.
Moncino MD, Gutman LT: Severe systemic cryptococcal disease in a child: review of prognostic indicators predicting treatment failure and an approach to maintenance therapy with oral fluconazole, Pediatr Infect Dis J 9:363–368, 1990.
Perfect JR, Casadevall A: Cryptococcosis, Infect Dis Clin North Am 16:837–874, 2002.
Perfect JR, Dismukes WE, Dromer F, et al: Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America, Clin Infect Dis 50:291–322, 2010.
Sun HY, Alexander BD, Lortholary O, et al: Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis, Clin Infect Dis 49:1721–1728, 2009.
Tenforde MW, Shapiro AE, Rouse B, et al: Treatment for HIV-associated. cryptococcal meningitis (review), Cochrane Database Syst Rev (7):CD005647, 2018.
EyDifonzo EM, Faggi E: Skin diseases associated. with Malassezia species in humans. Clinical features and diagnostic criteria, Parassitologia 50:69–71, 2008.
Hu SW, Bigby M: Pityriasis versicolor: a systematic review of interventions, Arch Dermatol 146(10):1132–1140, 2010.
Morishita N, Sei Y: Microreview of pityriasis versicolor and Malassezia species, Mycopathologia 162:373–376, 2006.
Sepaskhah M, Sadat MS: Comparative efficacy of topical application of tacrolimus and clotrimazole in the treatment of pityriasis versicolor: a single blind, randomized. clinical trial, Mycoses 60(5):338–342, 2017.
Knutsen AP, Bush RK, Demain JG, et al: Fungi and allergic lower respiratory tract diseases, J Allergy Clin Immunol 129(2):280–291, 2012.
Knutsen AP, Slavin RG: Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis, Clin Dev Immunol 2011:843763, 2011.
Denning DW, Cadranel J, Beigelman-Aubry C, et al: Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management, Eur Respir J 47(1):45–68, 2016.
Stevens DA, Melikian GL: Aspergillosis in the ‘nonimmunocompromised’ host, Immunol Invest 40(7–8):751–766, 2011.
Baddley JW, Andes DR, Marr KA, et al: Factors associated. with mortality in transplant patients with invasive aspergillosis, Clin Infect Dis 50:1559–1567, 2010.
Bueid A, Howard SJ, Moore CB, et al: Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009, J Antimicrob Chemother 65:2116–2118, 2010.
Castagnola E, Furfaro E, Caviglia I, et al: Performance of the galactomannan antigen detection test in the diagnosis of invasive aspergillosis in children with cancer or undergoing haemopoietic stem cell transplantation, Clin Microbiol Infect 16: 1197–1203, 2010.
Desai R, Ross LA, Hoffman JA: The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis, Pediatric Infectious Disease Journal 28:283–286, 2009.
Friberg LE, Ravva P, Karlsson MO, et al: Integrated. population pharmacokinetic analysis of voriconazole in children, adolescents, and adults, Antimicrob Agents Chemother 56:3032–3042, 2012.
Ishiguro T, Takayanagi N, Uozumi R, et al: Diagnostic criteria that can most accurately differentiate allergic bronchopulmonary mycosis from other eosinophilic lung diseases: a retrospective, single-center study, Respir Invest 54:264–271, 2016.
Jacobs F, Selleslag D, Aoun M, et al: An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole, European Journal of Clinical Microbiology and Infectious Disease 31:1173–1179, 2012.
Kontoyiannis DP, Marr KA, Park BJ, et al: Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the Transplant-Associated. Infection Surveillance Network (TRANSNET) database, Clin Infect Dis 50:1091–1100, 2010.
Lortholary O, Gangneux JP, Sitbon K, et al: Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007), Clin Microbiol Infect 17: 1882–1889, 2011.
Pascual A, Csajka C, Buclin T, et al: Challenging recommended. oral and intravenous voriconazole doses for improved. efficacy and safety: population pharmacokineticsbased. analysis of adult patients with invasive fungal infections, Clin Infect Dis 55:381–390, 2012.
Patterson TF, Thompson IIIGR, Denning DW, et al: Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America, Clin Infect Dis 63:e1–e60, 2016.
Schauwvlieghe AFAD, Rijnders BJA, Philips R, et al: Invasive aspergillosis in patients admitted. to the intensive care unit with severe influenza: a retrospective cohort study, Lancet Respiratory 6(10):782–792, 2018.
Bahr NC, Antinori S, Wheat LJ, Sarosi GA: Histoplasmosis infections worldwide: thinking outside of the Ohio River valley, Curr Trop Med Rep 2:70–80, 2015.
Hage CA, Azar MM, Bahr N, et al: Histoplasmosis: up-to-date evidence-based approach to diagnosis and management, Semin Respir Crit Care Med 36:729–745, 2015.
Hage CA, Ribes JA, Wengenack NL, et al: A multicenter evaluation of tests for diagnosis of histoplasmosis, Clin Infect Dis 53:448–454, 2011.
Kauffman C: Histoplasmosis: a clinical and laboratory update, Clin Microbiol Rev 20:115–132, 2007.
Koepsell S, Hinrichs S, Iwen P: Applying a real-time PCR assay for Histoplasma capsulatum to clinically relevant formalin-fixed paraffin-embedded human tissue, J Clin Microbiol 50:3395–3397, 2012.
Luckett K, Dummer JS, Miller G, et al: Histoplasmosis in patients with cell-mediated immunodeficiency: human immunodeficiency virus infection, organ transplantation, and tumor necrosis factor-alpha inhibition, Open Forum Infect Dis 2:2015.
Richer SM, Smedema ML, Durkin MM, et al: Improved diagnosis of acute pulmonary histoplasmosis by combining antigen and antibody detection, Clin Infect Dis 62:896–902, 2016.
Vergidis P, Avery RK, Wheat LJ, et al: Histoplasmosis complicating tumor necrosis factor-? blocker therapy: a retrospective analysis of 98 cases, Clin Infect Dis 61:409–417, 2015.
Wheat LJ, Freifeld AG, Kleiman MB, et al: Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America, Clin Infect Dis 45:807–825, 2007.
Alpern JD, Bahr NC, Vazquez-Benitez G, et al: Diagnostic delay and antibiotic overuse in acute pulmonary blastomycosis, Open Forum Infect Dis 3(2):ofw078, 2016.
Brandhorst TT, Roy R, W?thrich M, et al: Structure and function of a fungal adhesion that binds heparin and mimics thrombospondin-1 by blocking T cell activation and effector function, PLoS Pathog 9:e1003464, 2013.
Brown EM, McTaggart LR, Zhang SX, et al: Phylogenetic analysis reveals a cryptic species Blastomyces gilcristii, sp. nov. within the human pathogenic fungus Blastomyces dermatitidis, PLoS ONE 8:2013. e59237.
Chapman SW, Dismukes WE, Proia L, et al: Clinical practice guidelines for the management of blastomycosis: 2008 update by the infectious diseases society of America, Clin Infect Dis 46:1801–1812, 2008.
Connolly P, Hage CA, Bariola JR, et al: Blastomyces dermatitidis antigen detection by quantitative enzyme immunoassay, Clin Vaccine Immunol 19:53–56, 2012.
Fanella S, Skinner S, Trepman E, Embil JM: Blastomycosis in children and adolescents: a 30- year experience from Manitoba, Med. Mycol 49:627–632, 2011.
Fang W, Washington L, Kumar N: Imaging manifestations of blastomycosis: a pulmonary infection with potential dissemination, Radiographics 27:641–655, 2007.
Frost HM, Anderson J, Ivacic L, Meece J: Blastomycosis in children: an analysis of clinical, epidemiological, and genetic features, J Pediatr Infect Dis Soc 6(1):49–56, 2017.
Frost HM, Novicki TJ: Blastomyces antigen detection for diagnosis and management of blastomycosis, J Clin Microbiol 53:3660–3662, 2015.
Marty AJ, Broman AT, Zarnowski R, et al: Fungal morphology, iron homeostasis, and lipid metabolism regulated. by a GATA transcription factor in Blastomyces dermatitidis, PLoS Pathog 11:31004959, 2015.
Nemecek JC, Wuthrich M, Klein BS: Global control of dimorphism and virulence in fungi, Science 312:583–588, 2006.
Saccente M, Woods GL: Clinical and laboratory update on blastomycosis, Clin Microbiol Rev 23:367–381, 2010.
Sterkel AK, Mettelman R, W?thrich M, Klein BS: The unappreciated. intracellular lifestyle of Blastomyces dermatitidis, J Immunol 194:1796–1805, 2015.
American Academy of Pediatrics: Coccidioidomycosis. In Kimberlin D.W., Brady M.T., Jackson M.A., Long S.S., editors: Red. book: 2015 report of the committee on infectious diseases, 30th ed, Elk Grove Village, IL, 2015, American Academy of Pediatrics, pp . 302–305.
Dimitrova D, Ross L: Coccidioidomycosis: experience from a children’s hospital in an area of endemicity, J Pediatric Infect Dis Soc 5:89–92, 2016.
Galgiani JN, Ampel NM, Blair JE: 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis, Clin Infect Dis 63:e112–e146, 2016.
Ho AK, Shrader MW, Falk MN, et al: Diagnosis and initial management of musculoskeletal coccidioidomycosis in children, J Pediatr Orthop 34:571–577, 2014.
Lee JM, Graciano AL, Dabrowski L, et al: Coccidioidomycosis in infants: a retrospective case series, Pediatr Pulmonol 51:858–862, 2016.
Malo J, Holbrook E, Zangeneh T, et al: Enhanced. antibody detection and diagnosis of coccidioidomycosis with the MiraVista IgG and IgM detection enzyme immunoassay, J Clin Microbiol 55:893–901, 2017.
McCarty JM, Demetral LC, Dabrowski L, et al: Pediatric coccidioidomycosis in central California: a retrospective case series, Clin Infect Dis 56:1579–1585, 2013.
Nimer N, Camp T: Coccidioidomycosis, Pediatr Rev 36:181–182, 2015.
Sondermeyer GL, Lee LA, Gilliss D, et al: Epidemiology of pediatric coccidioidomycosis in California, 2000-2012, Pediatr Infect Dis J 35:166–171, 2016.
Stockamp NW, Thompson GR: Coccidioidomycosis, Infect Dis Clin N Am 30:229–246, 2016.
Turabelidze G, Aggu-Sher RK, Jahanpour E, et al: Coccidioidomycosis in a state where it is not known to be endemic—Missouri, 2004-2013, MMWR 64(23):636–638, 2015.
Benard G, Orii NM, Marques HHS, et al: Severe acute paracoccidioidomycosis in children, Pediatr Infect Dis J 13:510–515, 1994.
Blotta MH, Mamoni RL, Oliveira SJ, et al: Endemic regions of paracoccidioidomycosis in Brazil: a clinical and epidemiologic study of 584 cases in the southeast region, Am J Trop Med. Hyg 6:390–394, 1999.
Camacho E, Nino-Vega GA: Paracoccidioides spp.: virulence factors and immuneevasion strategies, Mediators Inflamm 2017:2017. 5313691.
Campos CB, DiBenedette JP, Morais FV, et al: Evidence for the role of calcineurin in morphogenesis and calcium homeostasis during mycelium-to-yeast dimorphism of Paracoccidioides brasiliensis, Eukaryot Cell 7:1856–1864, 2008.
de Almeida SM, Queiroz-Telles F, Teive HA, et al: Central nervous system paracoccidioidomycosis: clinical features and laboratorial findings, J Infect 48:193–198, 2004.
de Bastos Ascenco SR, Gomez FJ, de Almeida SM: Vaccination with heat shock protein 60 induces a protective immune response against experimental Paracoccidioides brasiliensis pulmonary infections, Infect Immun 76:4214–4221, 2008.
de Melo Braga G, Hessel G, Pereira RM: Hepatic involvement in pediatric patients with paracoccidioidomycosis: a clinical and laboratory study, Mycopathologia 176:279–286, 2013.
Gomes GM, Cisalpino PS, Taborda CP, et al: PCR for diagnosis of paracoccidioidomycosis, J Clin Microbiol 38:3478–3480, 2000.
Hahn RC, Fontes CJ, Batista RD, et al: In vitro comparison of activities of terbinafine and itraconazole against Paracoccidioides brasiliensis, J Clin Microbiol 40:2828–2831, 2002.
Mamoni RL, Rossi CL, Camargo ZP, et al: Capture enzyme-linked. immunosorbent assay to detect specific immunoglobulin E in sera of patients with paracoccidioidomycosis, Am J Trop Med. Hyg 65:237–241, 2001.
Martins CV, daSilva DL, Neres AT, et al: Curcumin as a promising antifungal of clinical interest, J Antimicrob Chemother 63:337–339, 2009.
Negroni DM, Montero-Gei F, Castro LG, et al: A Pan-American 5-year study of fluconazole therapy for deep mycoses in immunocompetent host. Pan-American Study Group, Clin Infect Dis 14(Suppl 1):S68–S76, 1992.
Nogueira SA, Guedes AL, Wanke B, et al: Osteomyelitis caused. by Paracoccidioides brasiliensis in a child from the metropolitan area of Rio de Janeiro, J Trop Pediatr 47:311–315, 2001.
Ollague JM, de Zurita AM, Calero G: Paracoccidioidomycosis (South American blastomycosis) successfully treated. with terbinafine: first case report, Br J Dermatol 143:188–191, 2000.
Radisic MV, Linares L, Afeltra J, et al: Acute pulmonary involvement by paracoccioidomycosis disease immediately after kidney transplantation: case report and literature review, Transpl Infect Dis 19(2):2017. doi:10.1111/tid.12655.
Ribeiro AM, Bocca AL, Amaral AC: DNAhsp65 vaccination induces protection in mice against Paracoccidioides brasiliensis infection, Vaccine 27:606–613, 2009.
Shikanai-Yasuda MA, Mendes RP, Colombo AL, et al: Brazilian guidelines for the clinical management of paracoccioidomycosis, Rev Soc Bras Med. Trop 50:715–740, 2017.
Silveira-Gomes F, Sarmento D, Pinto T: Development and evaluation of a latex agglutination test for the serodiagnosis of paracoccidioidomycosis, Clin Vaccine Immunol 18:604–608, 2011.
Travassos L, Taborda C: New advances in the development of a vaccine against paracoccidioidomycosis, Front Microbiol 3:212, 2012.
Barros MB, Costa DL, Schubach TM, et al: Endemic of zoonotic sporotrichosis: profiles of cases in children, Pediatr Infect Dis J 27:246–250, 2008.
Barros MB, Schubach AO, Oliveira RV, et al: Treatment of cutaneous sporotrichosis with Itraconazole: study of 645 patients, Clin Infect Dis 52:e200, 2011.
Bonifaz A, Saul A, Paredes-Solis V, et al: Sporotrichosis in childhood: clinical and therapeutic experience in 25 patients, Pediatr Dermatol 24:369–372, 2007.
Chapman SW, Pappas P, Kauffmann C, et al: Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg/day) in the treatment of cutaneous or lymphocutaneous sporotrichosis, Mycoses 47:62–68, 2004.
Hayfron K, Wiedeman JA: A 7-year-old girl with ulcerative lesion after a rodent bite, Pediatr Infect Dis J 29:185, 2010.
Kauffman CA, Bustamante B, Chapman SW, et al: Clinical practice guidelines for the management of sporotrichosis: update 2007 by the Infectious Diseases Society of America, Clin Infect Dis 45:1255–1265, 2007.
Lindsley MD, Hurst SF, Eqbal NJ, et al: Rapid identification of dimorphic and yeast-like fungal pathogens using specific DNA probes, J Clin Microbiol 39:3505–3511, 2001.
Lyon GM, Zurita S, Casquero J, et al: Population-based. surveillance and a case-control study of risk factors for endemic lymphocutaneous sporotrichosis in Peru, Clin Infect Dis 36:34–39, 2003.
Mario DN, Guarro J, Santurio JM, et al: In vitro and in vivo efficacy of amphotericin B combined. with posaconazole against experimental disseminated. sporotrichosis, Antimicrob Agents Chemother 59:5018–5021, 2015.
Pappas PG, Tellez I, Deep AE, et al: Sporotrichosis in Peru: description of an area of hyperendemicity, Clin Infect Dis 30:65–70, 2000.
Perez A: Terbinafine: broad new spectrum of indications in several subcutaneous and systemic and parasitic diseases, Mycoses 42(Suppl 2):111–114, 1999.
Ramorez Soto MC: Sporotrichosis: the story of an endemic region in Peru over 28 Years (1985 to 2012), PLoS ONE 10(6):e0127924.
Rose NR, editor: Manual of clinical laboratory immunology, ed. 6, Washington DC, 2002, ASM Press, p 579.
Song Y, Yao L, Zhong SX, et al: Infant sporotrichosis in northeast China: a report of 15 cases, Int J Dermatol 50:522–529, 2011.
Abidi MZ, Sohail MR, Cummins N, et al: Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandins-amphotericin combination therapies, Mycoses 57:687–698, 2014.
Cornely OA, Arikan-Akdagli S, Dannaoui E, et al: ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013, Clin Microbiol Infect 20:5–26, 2014.
Jung J, Kim MY, Lee HJ, et al: Comparison of computed. tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis, Clin Microbiol Infect 21:684.e11–684.e18, 2015.
Jung J, Park YS, Sung H, et al: Using immunohistochemistry to assess the accuracy of histomorphologic diagnosis of aspergillosis and mucormycosis, Clin Infect Dis 61:1664–1670, 2015.
Kontoyiannis DP, Yang H, Song J, et al: Prevalence, clinical and economic burden of mucormycosis-related. hospitalizations in the United. States: a retrospective study, BMC Infect Dis 16:730, 2016.
Kyvernitakis A, Torres HA, Jiang Y, et al: Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis, Clin Microbiol Infect 9:811.e1–811.e8, 2016.
Lanternier F, Poiree S, Elie C, et al: Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis, J Antimicrob Chemother 70:3116–3123, 2015.
Marty FM, Ostrosky-Zeichner L, Cornely OA, et al: Isavuconazole treatment for mucormycosis: a single arm open-label trial and case-control analysis, Lancet Infect Dis 16:828–837, 2016.
Pana ZD, Seidel D, Skiada A, et al: Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based. on two registries, BMC Infect Dis 16:667, 2016.
Skiada A, Lanternier F, Groll AH, et al: Diagnosis and treatment of mucormycosis in patients with hematologic malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3), Haematologica 98:492–504, 2013.
Choukri F, Menotti J, Sarfati C, et al: Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia, ClinInfect Dis 51:259–265, 2010
Demasi JM, Cox JA, Leonard D, et al: Intravenous pentamidine is safe and effective as primary Pneumocystis pneumonia prophylaxis in children and adolescents undergoing hematopoietic stem cell transplantation, Pediatr Infect Dis J 32:933–936, 2013
Hughes WT, Leoung G, Kramer F, et al: Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS, N Engl J Med. 328:1521–1527, 1993
Ledergerber B, Mocroft A, Reiss P, et al: Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups, N Engl J Med. 344:168–174, 2001
Martin-Garrido I, Carmona EM, Specks U, et al: Pneumocystis pneumonia in patients treated. with rituximab, Chest 144:258–265, 2013
McIntosh K, Cooper E, Xu J, et al: Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected. with human immunodeficiency virus, Pediatr Infect Dis J 18:432–439, 1999
Mofenson LM, Oleske J, Serchuck L, et al: Treating opportunistic infections among HIV-exposed. and infected. children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America, Clin Infect Dis 40(Suppl 1):S1–S84, 2005
Morgan DJ, Vargas SL, Reyes-Mugica M, et al: Identification of Pneumocystis carinii in the lungs of infants dying of sudden infant death syndrome, Pediatr Infect Dis J 20:306–309, 2001
Morris A, Lundgren JD, Masur H, et al: Current epidemiology of Pneumocystis pneumonia, Emerg Infect Dis 10:1713–1720, 2004
Poulsen A, Demeny AK, Bang Plum C, et al: Pneumocystis carinii pneumonia during maintenance treatment of childhood acute lymphocytic leukemia, Med. Pediatr Oncol 37:20–23, 2001
Thomas CF Jr, Limper AH: Pneumocystis pneumonia, N Engl J Med. 350:2487–2498, 2004
Torres J, Goldman M, Wheat LJ, et al: Diagnosis of Pneumocystis carinii pneumonia in human immunodeficiency virus–infected. patients with polymerase chain reaction: a blinded. comparison to standard methods, Clin Infect Dis 30:141–145, 2000
Vargas SL, Hughes WT, Santolaya ME, et al: Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants, Clin Infect Dis 32:855–861, 2001
Vargas SL, Ponce CA, Hughes WT, et al: Association of primary Pneumocystis carinii infection and sudden infant death syndrome, Clin Infect Dis 29:1489–1493, 1999
Wright TW, Gigliotti F, Finkelstein JN, et al: Immune-mediated. inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia, J Clin Invest 104:1307–1317, 1999
Wright TW, Notter RH, Wang Z, et al: Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia, Infect Immun 69:758–764, 2001
Defresne F, Sokal E: Chronic hepatitis B in children: therapeutic challenges and perspectives, J Gastroenterol Hepatol 32:368–371, 2017.
Haidar G, Singh N: Viral infections in solid organ transplant recipients: novel updates and a review of the classics, Curr Opin Infect Dis 2017. doi:10.1097/ QCO.0000000000000409. PMID: 28984642.
Harris JB, Holmes AP: Neonatal herpes simplex viral infections and acyclovir: an update, J Pediatr Pharmacol Ther 22:88–93, 2017.
Harrison GJ: Current controversies in diagnosis, management, and prevention of congenital cytomegalovirus: updates for the pediatric practitioner, Pediatr Ann 44(5):e115–e125, 2015.
Indolfi G, Thorne C, El Sayed. MH, et al: The challenge of treating children with hepatitis C virus infection, J Pediatr Gastroenterol Nutr 64:851–854, 2017.
Jorquera PA, Tripp . RA: Respiratory syncytial virus: prospects for new and emerging therapeutics, Expert Rev Respir Med. 11:609–615, 2017.
Kimberlin D.W., Jester PM, S?nchez PJ, et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group: Valganciclovir for symptomatic congenital cytomegalovirus disease, N Engl J Med. 372:933–943, 2015.
Lopez-Labrador FX, Berenguer M, Navarro D: Overcoming drug resistance in HSV, CMV, HBV and HCV infection, Future Microbiol 10:1759–1766, 2015.
Muller WJ: Treatment of perinatal viral infections to improve neurologic outcomes, Pediatr Res 81:162–169, 2017.
Yen HL: Current and novel antiviral strategies for influenza infection, Curr Opin Virol 18:126–134, 2016.
Buchanan R, Bonthius DJ: Measles virus and associated. central nervous system sequelae, Semin Pediatr Neurol 19:107–114, 2012.
Centers for Disease Control and Prevention: In Hamborsky J, Kroger A, Wolfe S, editors: Epidemiology and prevention of vaccine-preventable diseases. Measles, ed. 13, Washington D.C., 2015, Public Health Foundation.
Centers for Disease Control and Prevention (CDC): Global control and regional elimination of measles, 2000-2011, MMWR Morb Mortal Wkly Rep 62:27–31, 2013.
Centers for Disease Control and Prevention (CDC): Progress in global measles control, 2000-2010, MMWR Morb Mortal Wkly Rep 61:73–78, 2012.
Centers for Disease Control and Prevention: Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013 summary: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep 62(RR–04):1–34, 2013.
Defay F, De Serres G, Skowronski DM, et al: Measles in children vaccinated. with 2 doses of MMR, Pediatrics 132:e1126–e1133, 2013.
Demicheli V, Rivetti A, Debalini MG, et al: Vaccines for measles, mumps, and rubella in children, Cochrane Database Syst Rev (2):CD004407, 2012.
Fraser B: Measles outbreak in the Americas, Lancet 392:373, 2018.
Gastauaduy PA, Budd J, Fisher N, et al: A measles outbreak in an underimmunized. Amish community in Ohio, N Engl J Med. 375(14):1343–1354, 2016.
Gastauaduy PA, Redd SB, Fiebelkorn AP, Division of Viral Disease, National Center for Immunization and Respiratory Diseases, CDC, et al: Measles—United. States, January 1-May 23, 2014, MMWR Morb Mortal Wkly Rep 63:496–498, 2014.
Halsey NA: Measles in developing countries, BMJ 333:1234, 2006.
Holt E: 41,000 measels cases in Europe since the beginning of 2018, Lancet 392:724, 2018.
Holt RL, Kann D, Rassbach CE, et al: Subacute sclerosing panencephalitis: the foothold in undervaccination, J Pediatr 179:259–262, 2016.
Maltezou H, Wicker S: Measles in health-care settings, Am J Infect Control 30:1–3, 2013.
McLean HQ, Fiebelkorn AP, Temte JL, et al: Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep 62:1–34, 2013.
Michel Y, Saloume K, Tournier C, et al: Rapid molecular diagnosis of measles virus infection in an epidemic setting, J Med. Virol 85:723–730, 2013.
Moss WJ: Measles, Lancet 390:2490–2502, 2017.
Moss WJ, Griffin DE: Measles, Lancet 379:153–162, 2012.
National Center for Health Statistics: Measles. health, United. States, 2016: with chartbook on long-term trends in health, Hyattsville, MD, 2017.
Noyce RS, Bondre DG, Ha MN, et al: Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus, PLoS Pathog 7:e1002240, 2011.
Nyangoma EN, Olson CK, Benoit SR, et al: Measles outbreak associated. with adopted. children from China—Missouri, Minnesota, and Washington, July 2013, MMWR Morb Mortal Wkly Rep 63:301–304, 2014.
Ravikumar S, Crawford JR: Role of carbamazepine in the symptomatic treatment of subacute sclerosing panencephalitis: a case report and review of the literature, Case Rep Neurol Med. 2013:327647, 2013.
Rima BK, Duprex WP: New concepts in measles virus replication: getting in and out in vivo and modulating the host cell environment, Virus Res 162:47–62, 2011.
Sudfeld CR, Navar AM, Halsey NA: Effectiveness of measles vaccination and vitamin A treatment, Int J Epidemiol 39:i48–i55, 2010.
Sugerman DE, Barskey AE, Delea MG, et al: Measles outbreak in a highly vaccinated. population, San Diego, 2008: role of the intentionally under vaccinated, Pediatrics 125:747–755, 2010.
Tatli B, Ekici B, Ozmen M: Current therapies and future perspectives in subacute sclerosing panencephalitis, Expert Rev Neurother 12:485–492, 2012.
Venkat H, Kassem AM, Su CP, et al: Measles outbreak at a United. States immigration and customs enforcement facility—Arizona, May-June 2016, MMWR Morb Mortal Wkly Rep 66(20):543–544, 2017.
Banatvala JE, Brown DWG: Rubella, Lancet 363:1127–1137, 2004.
Bloom S, Rguig A, Berraho A, et al: Congenital rubella syndrome burden in Morocco: a rapid retrospective assessment, Lancet 365:135–140, 2005.
Grant GB, Reef SE, Patel M, et al: Rubella and congenital rubella syndrome control and elimination—2000-2016, MMWR 66(45):1256–1260, 2018.
Hahne S, Macey J, van Binnendijk R, et al: Rubella outbreak in the Netherlands, 2004–2005, Pediatr Infect Dis J 28:795–800, 2009.
Lambert N, Strebel P, Orenstein W, et al: Rubella, Lancet 385:2297–2306, 2015.
McIntosh ED, Menser MA: A fifty-year follow-up of congenital rubella, Lancet 340:414–415, 1992.
McLean HQ, Fiebelkorn AP, Temte JL, et al: Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013, MMWR Recomm Rep 62(RR–04):1–34, 2013.
Miller E, Cradock-Watson JE, Pollock TM: Consequences of confirmed. maternal rubella at successive stages of pregnancy, Lancet 2:781–784, 1982.
Murhekar M, Bavdekar A, Benakappa A, et al: Sentinel surveillance for congenital rubella syndrome—India, 2016-2017, MMWR 67(36):1012–1016, 2018.
Plotkin SA, Reef SE, et al: Rubella. In Remington JS, Klein JO, Wilson CB, et al, editors: Infectious diseases of the fetus and newborn infant, 7th ed, Philadelphia, 2011, Elsevier Saunders, p 861.
WHO vaccine-preventable diseases: monitoring system 2017 global summary.
Albertson JP, Clegg WJ, Reid HD, et al: Mumps outbreak at a university and recommendation for a third dose of measles-mumos-rubella vaccine—Illinois, 2015-2016, MMWR Morb Mortal Wkly Rep 65(29):731–734, 2016.
Barskey AE, Schulte C, Rosen JB, et al: Mumps outbreak in orthodox Jewish communities in the United. States, N Engl J Med. 367:1704–1713, 2012.
Bonwitt J, Kawakami V, Wharton A, et al: Absence of asymptomatic mumps virus shedding among vaccinated. college students during a mumps outbreal—Washington, February-June 2017, MMWR Morb Mortal Wkly Rep 66(47):1307–1308, 2017.
Brady M.T., Bernstein HH, Byington CL: Policy statement–Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children, Pediatrics 128:630–632, 2011.
Cardemil CV, Dahl RM, James L, et al: Effectiveness of a third dose of MMR vaccine for mumps outbreak control, N Engl J Med. 377:947–956, 2017.
Centers for Disease Control and Prevention (CDC): Manual for the surveillance of vaccine-preventable diseases. “Mumps.” Amy Parker Fiebelkorn, MSN, MPH; Albert Barskey, MPH; Carole Hickman, PhD; William Bellini, PhD, Atlanta, GA, 2014, Centers for Disease Control and Prevention.
Centers for Disease Control and Prevention (CDC): Mumps outbreak on a university campus—California, 2011, MMWR Morb Mortal Wkly Rep 61:986–989, 2012.
Centers for Disease Control and Prevention (CDC): Update: multistate outbreak of mumps—United. States, January 1–May 2, 2006, MMWR Morb Mortal Wkly Rep 55:559–564, 2006.
Centers for Disease Control and Prevention (CDC): Update: mumps outbreak—New York and New Jersey, June 2009–January 2010, MMWR Morb Mortal Wkly Rep 59:125–128, 2010.
Centers for Disease Control and Prevention (CDC): Updated. recommendations for isolation of patients with mumps, MMWR Morb Mortal Wkly Rep 57:1103–1105, 2008.
Centers for Disease Control and Prevention: Hamborsky J, Kroger A, Wolfe S, editors:
Epidemiology and prevention of vaccine-preventable diseases, mumps, 13th ed, Washington D.C., 2015, Public Health Foundation.
Cervantes D, Honza H, Lynch D, et al: Mumps outbreak associated. with cheerleading competitions — North Texas, December 2016-February 2017, MMWR Morb Mortal Wkly Rep 67(36):1019–1020, 2018.
Dayan GH, Quinlisk MP, Parker AA, et al: Recent resurgence of mumps in the United. States, N Engl J Med. 358:1580–1589, 2008.
Donahue M, Schneider A, Ukegbu U, et al: Complications of mumps during a university outbreak among students who had received. 2 doses of measles-mumps-rubella vaccine—Iowa, July 2015-May 2016, MMWR Morb Mortal Wkly Rep 66(14):390–391, 2017.
Endo A, Izuni H, Miyashita M, et al: Facial palsy associated. with mumps parotitis, Pediatr Infect Dis J 20:815–816, 2001.
Hamami D, Cameron R, Pollock KG, Shankland C: Waning immunity is associated. with periodic large outbreaks of mumps: a mathematical modeling study of Scottish data, Front Physiol 8:233, 2017.
Horel L, Amir J, Reish O, et al: Mumps arthritis in children, Pediatr Infect Dis J 9:928–929, 1990.
Jin L, ?rvell C, Myers R, et al: Genomic diversity of mumps virus and global distribution of the 12 genotypes, Rev Med. Virol 25:85–101, 2015.
Kanra G, Kara A, Cengiz AB, et al: Mumps meningoencephalitis effect on hearing, Pediatr Infect Dis J 21:1167–1169, 2002.
Kupers TA, Petrich JM, Holloway AW, et al: Depression of tuberculin hypersensitivity by live attenuated. mumps virus, J Pediatr 76:716–721, 1970.
Marin M, Marlow M, Moore KL, Patel M: Recommendations of the advisory committee on immunization practices for use of a third dose of mumps virus –containing vaccine in persons at increased. risk for mumps during an outbreak, MMWR Morb Mortal Wkly Rep 67(1):33–38, 2018.
McLean HQ, Fiebelkorn AP, Temte JL, et al: Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013, MMWR Recomm Rep 62(RR–04):1–34, 2013.
Rubin SA, Li Q, Audet SA, et al: Antibody induced. by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated. with a large outbreak, J Infect Dis 198:508–515, 2008.
Ternavasio-de la Vega HG, Boronat M, Ojeda A, et al: Mumps orchitis in the postvaccine era (1967–2009), Medicine (Baltimore) 89:96–116, 2010.
Zamir CS, Schroeder H, Shoob H, et al: Clinical severity, complications and association with vaccination status of mumps outbreak cases, Hum Vaccin Immunother 11:1413–1417, 2015.
Ali D, Banda R, Mohammed. A, et al: Strengthening routine immunization in areas of Northern Nigeria at high risk for polio transmission during 2012-2014, J Infect Dis 213(Suppl 3):S147–S150, 2016
Anand A, Zaman K, Estivariz CF, et al: Early priming with inactivated. poliovirus vaccine (IPV) and intradermal fractional dose IPV administered. by a microneedle device: a randomized. controlled. trial, Vaccine 33(48):6816–6822, 2015
Asturias EJ, Bandyopadhyay AS, Self S, et al: Humoral and intestinal immunity induced. by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated. poliovirus vaccine in Latin American infants: an open-label randomized. controlled. trial, Lancet 388(10040):158–169, 2016
Blake IM, Pons-Salort M, Molodecky NA, et al: Type 2 poliovirus detection after global withdrawal of trivalent oral vaccine, N Engl J Med. 379:834–845, 2018
CDC: Introduction of inactivated. poliovirus vaccine and switch from trivalent to bivalent oral poliovirus vaccine — Worldwide, 2013-2016, MMWR Morb Mortal Wkly Rep 64(25):699–702, 2015
Gardner TJ, Diop OM, Jorba J, et al: Surveillance to track progress toward polio eradication—worldwide, 2016-2017, MMWR Morb Mortal Wkly Rep 67(14):418–423, 2018
Greninger AL, Naccache SM, Messacar K, et al: A novel outbreak enterovirus D68 strain associated. with acute flaccid myelitis cases in the USA (2012-14): a retrospective study, Lancet 15(6):671–682, 2015
Jorba J, Diop OM, Iber J, et al: Update on vaccine-derived. polioviruses—worldwide, January 2016-June 2017, MMWR Morb Mortal Wkly Rep 66(43):1185–1190, 2017
Kaliner E, Kopel E, Anis E, et al: The Israeli public health response to wild poliovirus importation, Lancet Infect Dis 15(10):1236–1242, 2015
Maes EF, Diop OM, Jorba J, et al: Surveillance systems to track progress toward polio eradication—Worldwide, 2015-2016, MMWR Morb Mortal Wkly Rep 66(13): 359–365, 2017
Marin M, Patel M, Oberste S, Pallansch MA: Guidance for assessment of poliovirus vaccination status and vaccination of children who have received. poliovirus vaccine outside the United. States, MMWR Morb Mortal Wkly Rep 66(1):23–25, 2017
Mbaeyi C, Wadood ZM, Moran T, et al: Strategic response to an outbreak of circulating vaccine-derived. poliovirus type 2—Syria, 2017-2018, MMWR Morb Mortal Wkly Rep 67(24):690–694, 2018
O’Ryan M, Bandyopadhyay AS, Villena R, et al: Inactivated. poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study, Lancet Infect Dis 15(11):1273–1282, 2015
Patel M, Orenstein W: A world free of polio—the final steps, N Engl J Med. 374(6):501–503, 2016
Previsani N, Singh H, St Pierre J, et al: Progress toward containment of poliovirus type 2—worldwide, 2017, MMWR Morb Mortal Wkly Rep 66(24):649–652, 2017
World Health Organization (WHO): Meeting of the Strategic Advisory Group of Experts on Immunization, October 2016—conclusions and recommendations, Wkly Epidemiol Rec 91(48):561–582, 2016
World Health Organization (WHO): Polio vaccines: WHO position paper—March, 2016, Wkly Epidemiol Rec 91(12):145–168, 2016
Abedi GR, Watson JT, Nix A, et al: Enterovirus and parechovirus surveillance—United. States, 2014-2016, MMWR 67(18):515–518, 2018.
Abzug MJ, Michaels M.G., Wald E, et al: A randomized, double-blind, placebo-controlled. trial of pleconaril for the treatment of neonates with enterovirus sepsis, J Pediatr Infect Dis Soc 5:53–62, 2016.
Banta J, Lenz B, Pawlak M, et al: Outbreak of hand, foot, and mouth disease caused. by coxsackievirus A6 among basic military trainees—Texas, 2015, MMWR 65(26):678–680, 2016.
Buttery VW, Kenyon C, Grunewald S, et al: Atypical presentations of hand, foot, and mouth disease caused. by coxsackievirus A6—Minnesota, 2014, MMWR 64(29):805, 2015.
Chi CY, Khanh TH, Thoa LPK, et al: Milrinone therapy for enterovirus 71-induced. pulmonary edema and/or neurogenic shock in children: a randomized. controlled. trial, Crit Care Med. 41:1754–1760, 2013.
Chong P, Liu CC, Chow YH, et al: Review of enterovirus 71 vaccines, Clin Infect Dis 60:797–803, 2015.
Holm-Hansen CC, Midgley SE, Fischer TK: Global emergence of enterovirus D68: a systematic review, Lancet Infect Dis 16:e64–e75, 2016.
Hu Y, Jiang L, Peng HL: Clinical analysis of 134 children with nervous system damage caused. by enterovirus 71 infection, Pediatr Infect Dis J 34:718–723, 2015.
Mathes EF, Oza V, Frieden IJ, et al: “Eczema coxsackium” and unusual cutaneous findings in an enterovirus outbreak, Pediatrics 132:e149–e157, 2013.
Messacar K, Burakoff A, Nix WA, et al: Enterovirus A71 neurologic disease in children—Colorado, 2018, MMWR 67(36):1017–1018, 2018.
Messacar K, Schreiner TL, Maloney JA, et al: A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated. with an outbreak of enterovirus D68 in children in Colorado, USA, Lancet 385:1662–1671, 2015.
Messacar K, Schreiner TL, Van Haren K, et al: Acute flaccid myelitis: a clinical review of US cases 2012-2015, Ann Neurol 80:326–338, 2016.
Midgley C, Watson JT, Nix WA, et al: Severe respiratory illness associated. with a nationwide outbreak of enterovirus D68 in the USA (2014): a descriptive epidemiological evaluation, Lancet Resp Dis 3:879–887, 2015.
Renaud C, Harrison CJ: Human parechovirus 3: the most common viral cause of meningoencephalitis in young infants, Infect Dis Clin North Am 29:415–428, 2015.
Sejvar JJ, Lopez AS, Cortese MM, et al: Acute flaccid myelitis in the United. States, August-December 2014: results of nationwide surveillance, Clin Infect Dis 63:737–745, 2016.
Waldman A, Thomas L, Thacker S, Evans D: Vesiculobullous eruption as an atypical hand, foot, and mouth presentation, J Pediatr 179:273, 2016.
Adler SP, Koch WC: In Remington JS, Klein JO, Wilson CB, et al, editors: Infectious diseases of the fetus and newborn infant, ed. 8, Philadelphia, 2016, Elsevier Saunders, pp . 866–893.
American Academy of Pediatrics: Parvovirus B19. In Kimberlin D.W., Brady M.T., Jackson M.A., Long S.S., editors: Red. book: 2015 report of the Committee on Infectious Diseases, ed. 30, Elk Grove Village, IL, 2015, American Academy of Pediatrics, pp . 593–596.
Christensen A, Nordbo SA, Krokstad S, et al: Human bocavirus in children: monodetection, high viral load and viraemia are associated. with respiratory tract infection, J Clin Virol 49:158–162, 2010.
Douvoyiannis M, Litman N, Goldman DL: Neurologic manifestations associated. with parvovirus B19 infection, Clin Infect Dis 48:1713–1723, 2009.
Kerr JR: A review of blood diseases and cytopenias associated. with human parvovirus B19 infection, Rev Med. Virol 25:224–240, 2015.
Lackner H, Sovinz P, Benesch M, et al: The spectrum of parvovirus B19 infection in a pediatric hemato-oncologic ward, Pediatr Infect Dis J 30:440–442, 2011.
Parez N, Dehee A, Michel Y, et al: Papular-purpuric gloves and socks syndrome associated. with B19V infection in a 6-year-old child, J Clin Virol 44:167–169, 2009.
Peltola V, S?derlund-Venermo M, Jartti T: Human bocavirus infections, Pediatr Infect Dis J 32:178–179, 2013.
Phan TG, Vo NP, Bonkoungnou IJ, et al: Acute diarrhea in West African children: diverse enteric viruses and a novel parvovirus genus, J Virol 86(20):11024–11030, 2012.
Qiu J, S?derlund-Venermo M, Young NS: Human parvoviruses, Clin Microbiol Rev 30:43–113, 2017.
Vigneswaran TV, Brown JR, Breuer J, Burch M: Parvovirus B19 myocarditis in children: an observational study, Arch Dis Child 101(2):177–180, 2016.
Aronson PL, Yan AC, Mittal MK, et al: Delayed. acyclovir and outcomes of children hospitalized. with eczema herpeticum, Pediatrics 128:1161–1167, 2011.
Bajaj M, Mody S, Natarajan G: Clinical and neuroimaging findings in neonatal herpes simplex virus infection, J Pediatr 165:404–407, 2014.
Cantey JB, Mejias A, Wallihan R, et al: Use of blood polymerase chain reaction testing for diagnosis of herpes simplex virus infection, J Pediatr 161:357–361, 2012.
Caviness AC, Demmler GJ, Almendarez Y, et al: The prevalence of neonatal herpes simplex virus infection compared. with serious bacterial illness in hospitalized. neonates, J Pediatr 153:164–169, 2008.
Cernik C, Gallina K, Brodell RT: The treatment of herpes simplex infections: an evidence-based. review, Arch Intern Med. 168:1137–1144, 2008.
Curfman AL, Glissmeyer EW, Ahmad FA, et al: Initial presentation of neonatal herpes simplex virus infection, J Pediatr 172:121–126, 2016.
Cruz AT, Freedman SB, Kulik DM, et al: Herpes simplex virus infection in infants undergoing meningitis evaluation, Pediatrics 141(2):e20171688, 2018.
Fanfair RN, Zaidi A, Taylor LD, et al: Trends in seroprevalence of herpes simplex virus type 2 among non-Hispanic blacks and non-Hispanic whites aged. 14 to 49 years—United. States, 1988 to 2010, Sex Transm Dis 40:860–864, 2013.
Elbers JM, Bitnum A, Richardson SE, et al: A 12-year prospective study of childhood herpes simplex encephalitis: is there a broader spectrum of disease?, Pediatrics 119:e399–e407, 2007.
Hanssfield HH, Waldo AB, Brown ZA, et al: Neonatal herpes should be a reportable disease, Sex Transm Dis 32:521–525, 2005.
Kimberlin D.W., Baley J, Committee on Infectious Diseases; Committee on Fetus and Newborn: Guidance on management of asymptomatic neonates born to women with active genital herpes lesions, Pediatrics 131:e635–e646, 2013.
Kimberlin D.W., Whitley RJ, Wan W, et al: Oral acyclovir suppression and neurodevelopment after neonatal herpes, N Engl J Med. 365:1284–1292, 2011.
Long S.S., Pool TE, Vodzak J, et al: Herpes simplex virus infection in young infants during 2 decades of empiric acyclovir therapy, Pediatr Infect Dis J 30:556–560, 2011.
Madan R, Herold B, Ratner A, et al: Neonatal herpes infection associated. with direct orogenital suction during ritual Jewish circumcision, J Pediatr Infect Dis Soc 4:283–284, 2015.
O’Riordan DP, Golden C, Aucott SW: Herpes simplex virus infections in preterm infants, Pediatrics 118:e1612–e1620, 2006.
Pinninti SG, Angara R, Feja KN, et al: Neonatal herpes disease following maternal antenatal antiviral suppressive therapy: a multicenter case series, J Pediatr 161:134–138, 2012.
Pinninti SG, Kimberlin D.W.: Neonatal herpes simplex virus infections, Pediatr Clin North Am 60:351–365, 2013.
Rao S, Abzug MJ, Carosone-Link P, et al: Intravenous acyclovir and renal dysfunction in children: a matched. case control study, J Pediatr 166:1462–1468, 2015.
Shah SS, Aronson PL, Mohamad Z, et al: Delayed. acyclovir therapy and death among neonates with herpes simplex virus infection, Pediatrics 128:1153–1160, 2011.
Spiegel R, Miron D, Yodko H, et al: Late relapse of herpes simplex virus encephalitis in a child due to reactivation of latent virus: clinicopathological report and review, J Child Neurol 23:344–348, 2008.
Tobian AA, Serwadda D, Quinn TC, et al: Male circumcision for the prevention of HSV-2 and HPV infections and syphilis, N Engl J Med. 360:1298–1309, 2009.
Bialek SR, Perella D, Zhang J, et al: Impact of a routine two-dose varicella vaccination program on varicella epidemiology, Pediatrics 132(5):e1134–e1140, 2013.
Centers for Disease Control and Prevention (CDC): Updated. recommendations for use of VariZIG—United. States, 2013, MMWR Morb Mortal Wkly Rep 62:574–576, 2013.
Chaves SS, Zhang J, Civen R, et al: Varicella disease among vaccinated. persons: clinical and epidemiological characteristics, 1997–2005, J Infect Dis 197:S127–S131, 2008.
Choo PW, Donahue JG, Manson JE, et al: The epidemiology of varicella and its complications, J Infect Dis 172:706–712, 1995.
Civen R, Chaves SS, Jumaan A, et al: The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination, Pediatr Infect Dis J 28:954–959, 2009.
Civen R, Marin M, Zhang JQ, et al: Update on incidence of herpes zoster among children and adolescents following implementation of varicella vaccination, Antelope Valley, CA, 2000 - 2010, Pediatr Infect Dis J 35:1132–1136, 2016.
Enders G, Miller E, Cradock-Watson J, et al: Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases, Lancet 343:1548–1551, 1994.
Gershon AA, Mervish N, LaRussa P, et al: Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection, J Infect Dis 176:1496–1500, 1997.
Guess HA, Broughton DD, Melton LJ 3rd, et al: Epidemiology of herpes zoster in children and adolescents: a population-based. study, Pediatrics 76(4):512–517, 1985.
Guess HA, Broughton DD, Melton LJ II, et al: Population-based. studies of varicella complications, Pediatrics 78:723–727, 1986.
Guris D, Jumaan AO, Mascola L, et al: Changing varicella epidemiology in active surveillance sites—United. States, 1995–2005, J Infect Dis 197:S71–S75, 2008.
Hardy I, Gershon AA, Steinberg S, et al: The incidence of zoster after immunization with live attenuated. varicella vaccine: a study in children with leukemia, N Engl J Med. 325:1545–1550, 1991.
Harris D, Redhead J: Should acyclovir be prescribed. for immunocompetent children presenting with chickenpox?, Arch Dis Child 90:648–650, 2005.
Heininger U, Seward JF: Varicella, Lancet 368:1365–1376, 2006.
Ji G, Niu J, Shi Y, et al: The effectiveness of repetitive paravertebral injections with local anesthetics and steroids for the prevention of postherpetic neuralgia in patients with acute herpes zoster, Anesth Analg 109:1651–1655, 2009.
Kriner P, Lopez K, Leung J, et al; Centers for Disease Control and Prevention (CDC): Varicella-associated. death of a vaccinated. child with leukemia–California, 2012, MMWR Morb Mortal Wkly Rep 63:161, 2014.
Kurlan JG, Connelly BL, Lucky AW: Herpes zoster in the first year of life following postnatal exposure to varicella-zoster virus, Arch Dermatol 140:1268–1272, 2004.
Kustermann A, Zoppini C, Tassis B, et al: Prenatal diagnosis of congenital varicella infection, Prenat Diagn 16:71–74, 1996.
Leung J, Harpaz R, Baughman AL, et al: Evaluation of laboratory methods for diagnosis of varicella, Clin Infect Dis 51(1):23–32, 2010.
Leung J, Lopez AS, et al: Impact of the United. States two-dose varicella vaccination program on the epidemiology of varicella outbreaks: data from 9 states, 2005-2012, Pediatr Infect Dis J 34:1105–1109, 2015.
Leung J, Harpaz R: Impact of the maturing varicella vaccination program on varicella and related. outcomes in the United. States: 1994-2012, J Pediatric Infect Dis Soc 1-8:2015.
Leung J, Bialek SR, Marin M: Trends in varicella mortality in the U.S.: data from vital statistics and national surveillance, Hum Vaccin Immunother 11(3):662–668, 2015.
Leung J, Siegel S, Schulte C, et al: Fatal varicella due to the vaccine strain varicella-zoster virus, Hum Vaccin Immunother 10(1):2822–2825, 2014.
Leung J, Broder KR, Marin M: Severe complications of varicella in persons vaccinated. with varicella vaccine (breakthrough varicella): a systematic review, 2017. Expert Reviews of Vaccines.
Lal H, et al: Efficacy of an adjuvanted. herpes zoster subunit vaccine in older adults, N Engl J Med. 2087–2096, 2137–2121, 2015.
Lopez AS, Zhang J, Brown C, et al: Varicella-related. hospitalizations in the United. States, 2000-2006: the 1-dose varicella vaccination era, Pediatrics 127:238–245, 2011.
Lopez AS, Zhang J, Marin M: Epidemiology of varicella during the 2-dose varicella vaccination program—United. States, 2005-2014, MMWR Morb Mortal Wkly Rep 65:902–905, 2016.
Marin M, Guris D, Chaves S, et al; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC): Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep 56(RR–04):1–40, 2007.
Marin M, Meissner HC, Seward JF: A decade of varicella prevention in the United. States—successes and challenges: a systematic review, Pediatrics 122(3):e744–e751, 2008.
Marin M, Zhang JX, Seward JF: Near elimination of varicella deaths in the US following implementation of the childhood vaccination, Pediatrics 128:214–220, 2011.
Marin M, Marti M, Kambhampati A, et al: Varicella vaccine effectiveness worldwide: a systematic review and meta-analysis, Pediatrics 137(3):1–10, 2016.
Oxman MN, Levin MJ, Johnson GR, et al: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults, N Engl J Med. 352:2271–2284, 2005.
Patel RA, Binns HJ, Shulman ST: Reduction in pediatric hospitalizations for varicellarelated. invasive group A streptococcal infections in the varicella vaccine era, J Pediatr 144:68–74, 2004.
Science M, MacGregor D, Richardson SE, et al: Central nervous system complications of varicella-zoster virus, J Pediatr 165:779–785, 2014.
Smith CK, Arvin AM: Varicella in the fetus and newborn, Semin Fetal Neonatal Med. 14:209–217, 2009.
Son M, Shapiro ED, LaRussa P, et al: Effectiveness of varicella vaccine in children infected. with HIV, J Infect Dis 201(12):1806–1810, 2010.
Weinmann S, Chun C, Schmid DS, et al: Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009, J Infect Dis 208:1859–1868, 2013
Balfour HH Jr, Odumade OA, Schmeling DO, et al: Behavioral, virologic, and immunologic factors associated. with acquisition and severity of primary Epstein-Barr virus infection in university students, J Infect Dis 207:80–88, 2013.
Balfour HH Jr, Sifakis F, Sliman JA, et al: Age-specific prevalence of Epstein-Barr virus infection among individuals aged. 6-19 years in the United. States and factorsaffecting its acquisition, J Infect Dis 208:1286–1293, 2013.
Chovel-Sella A, Tov AB, Lahav E, et al: Incidence of rash after amoxicillin treatmentin children with infectious mononucleosis, Pediatrics 131:e1424–e1427, 2013.
Dasari V, Bhatt KH, Smith C, Khanna R: Designing an effective vaccine to prevent Epstein-Barr virus-associated. diseases: challenges and opportunities, Expert Rev Vaccines 16:377–390, 2017.
Dunmire SK, Grimm JM, Schmeling DO, et al: The incubation period of primary Epstein-Barr virus infection: viral dynamics and immunologic events, PLoS Pathog 11:e1005286, 2015.
Ebell MH, Call M, Shinholser J, Gardner J: Doe this patient have infectious mononucleosis? The rational clinical examination systematic review, JAMA 315(14):1502–1509, 2016.
Johnson KH, Webb C, Schmeling DO, et al: Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study, Clin Transl Immunol 5:e81, 2016.
Khan G, Hashim M: Global burden of deaths from Epstein-Barr virus: attributable malignancies 1990-2010, Infect Agent Cancer 9:38, 2014.
Kimura H, Ito Y, Kawabe S, et al: EBV-associated. T/NK-cell lymphoproliferative diseases in nonimmunocompromised. hosts: prospective analysis of 108 cases, Blood 119(3):673–686, 2012.
Norman SD, Murray IA, Shetty D, et al: Jaundice, abdominal pain, and fever in a young woman, Lancet 390:1713–1714, 2017.
Tangye SG, Palendira U, Edwards ESJ: Human immunity against EBV—lessons from the clinic, J Exp Med. 214:269–283, 2017.
Tashiro H, Brenner MK: Immunotherapy against cancer-related. viruses, Cell Res 27:59–73, 2017.
Young LS, Yap LF, Murray PG: Epstein-Barr virus: more than 50 years old and still providing surprises, Nat Rev Cancer 16:789–802, 2016.
Bilavsky E, Pardo J, Attias J, et al: Clinical implications for children born withcongenital cytomegalovirus infection following a negative amniocentesis, ClinInfect Dis 63:33–38, 2016.
Boppana SB, et al: Intrauterine transmission of cytomegalovirus to infants of womenwith preconceptional immunity, N Engl J Med. 344(18):1366–1371, 2001.
Boppana SB, et al: Saliva polymerase-chain-reaction assay for cytomegalovirus screeningin newborns, N Engl J Med. 364(22):2111–2118, 2011.
Boppana SB, Ross SA, Fowler KB: Congenital cytomegalovirus infection: clinicaloutcome, Clin Infect Dis 57(Suppl 4):S178–S181, 2013.
Boppana S, Britt WJ: Synopsis of clinical aspects of human cytomegalovirus disease. In Reddehase M, editor: Cytomegaloviruses: from molecular pathogenesis to intervention, Casister Academic Press: Norfolk, UK, 2013, pp . 1–25.
Britt WJ: Congenital HCMV infection and the enigma of maternal immunity, J Virol 2017.
de Vries JJ, et al: The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a population-based. prediction model, Rev Med. Virol 23(4):241–249, 2013.
Ellington SR, Clarke REN, Kourtis AP: Cytomegalovirus infection in human immunodeficiency virus (HIV)-exposed. and HIV-infected. infants: a systematic review, J Infect Dis 213(6):891–900, 2016.
Enders G, et al: Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age, J Clin Virol 52(3):244–246, 2011.
Feng P, Moses A, Fruh K: Evasion of adaptive and innate immune response mechanisms by gamma-herpesviruses, Curr Opin Virol 3(3):285–295, 2013.
Forner G, Abate D, Mengoli C, et al: High cytomegalovirus (CMV) DNAemia predicts CMV sequwlae in asymptomatic congenitally infected. newborns born to women with primary infection during pregnancy, J Infect Dis 212:67–71, 2015.
Gooderis J, Keymeulen A, Smets K, et al: Hearing in children with enital cytomegalovirus infection: results of a longitudunal study, J Pediatr 172:110–115, 2016.
Guo H, Kaiser WJ, Mocarski ES: Manipulation of apoptosis and necroptosis signaling by herpesviruses, Med. Microbiol Immunol 204(3):439–448, 2015.
Hamprecht K, et al: Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding, Lancet 357(9255):513–518, 2001.
Hamprecht K, Goelz R: Postnatal cytomegalovirus infection through human milk in preterm infants: transmission, clinical presentation, and prevention, Clin Perinatol 44(1):121–130, 2017.
Hodson EM, et al: Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients, Cochrane Database Syst Rev (2):CD003774, 2013.
Inagaki K, Blackshear C, Palmer A, Hobbs CV: Risk factors, geographic distribution, and healthcare burden of symptomatic congenital cytomegalovirus infection in the United. States: analysis of a nationally representative database, 200-2012, J Pediatr 199:118–123, 2018.
Kenneson A, Cannon MJ: Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection, Rev Med. Virol 17(4):253–276, 2007.
Kimberlin D.W., et al: Valganciclovir for symptomatic congenital cytomegalovirus disease, N Engl J Med. 372(10):933–943, 2015.
Lisnic B, Lisnic VJ, Jonjic S: NK cell interplay with cytomegaloviruses, Curr Opin Virol 15:9–18, 2015.
Ljungman P, et al: Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials, Clin Infect Dis 64(1):87–91, 2017.
Lopez AS, Lanzieri TM, Claussen AH, et al: Intelligence and academic achievement with asymptomatic congenital cytomegalovirus infection, Pediatrics 140(4):e2017517, 2017.
Manicklal S, et al: The “silent” global burden of congenital cytomegalovirus, Clin Microbiol Rev 26(1):86–102, 2013.
Pasternak Y, Ziv L, Attias J, et al: Valganciclovir is beneficial in children with congenital cytomegalovirus and isolated. hearing loss, J Pediatr 199:166–170, 2018.
Rawlinson WD, Boppana SB, Fowler KB, et al: Congenital cytomegalovirus infection in pregnancy and the neonate: concensus recommendations for prevention, diagnosis, and therapy, Lancet 17:e177–e188, 2017.
Renzette N, et al: Limits and patterns of cytomegalovirus genomic diversity in humans, Proc Natl Acad Sci USA 112(30):E4120–E4128, 2015.
Revello MG, et al: A randomized. trial of hyperimmune globulin to prevent congenital cytomegalovirus, N Engl J Med. 370(14):1316–1326, 2014.
Revello MG, et al: Prevention of primary cytomegalovirus infection in pregnancy, EBioMedicine 2(9):1205–1210, 2015.
Ross SA, et al: Detection of congenital cytomegalovirus infection by real-time polymerase chain reaction analysis of saliva or urine specimens, J Infect Dis 210(9):1415–1418, 2014.
Ross S, Long S.S., Kimberlain DW: Closer to universal newborn screening for congenital cytomegalovirus infection but far away from antiviral therapy in all infected. infants, J Pediatr 199:7–9, 2018.
Agut H, Bonnafous P, Gautheret-Dejean A: Update on infections with human herpesviruses 6A, 6B, and 7, Med. Mal Infect 2016. doi:10.1016/j.medmal.2016.09.004.
Aoki J, Numata A, Yamamoto E, et al: Impact of Human Herpesvirus-6 Reactivation on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation, Biol Blood Marrow Transplant 21:2017–2022, 2015.
Caserta MT, Hall CB, Schnabel K, et al: Diagnostic assays for active infection with human herpesvirus 6 (HHV-6), J Clin Virol 48:55–57, 2010.
Epstein LG, Shinnar S, Hesdorffer DC, et al: Human herpesvirus 6 and 7 in febrile status epilepticus: the FEBSTAT study, Epilepsia 53:1481–1488, 2012.
Hall CB, Long CE, Schnabel KC, et al: Human herpesvirus-6 infection in children. A prospective study of complications and reactivation, N Engl J Med. 331:432–438, 1994.
Hill JA, Koo S, Guzman Suarez BB, et al: Cord-blood hematopoietic stem cell transplant confers an increased. risk for human herpesvirus-6-associated. acute limbic encephalitis: a cohort analysis, Biol Blood Marrow Transplant 18:1638–1648, 2012.
Millichap JJ, Millichap JG: Role of HHV-6B Infection in Mesial Temporal Lobe Epilepsy, Pediatr Neurol Briefs 29:40, 2015.
Pellett PE, Ablashi DV, Ambros PF, et al: Chromosomally integrated. human herpesvirus 6: questions and answers, Rev Med. Virol 22:144–155, 2012.
Quintela A, Escuret V, Roux S, et al: HHV-6 infection after allogeneic hematopoietic stem cell transplantation: from chromosomal integration to viral co-infections and T-cell reconstitution patterns, J Infect 72:214–222, 2016.
Tang H, Serada S, Kawabata A, et al: CD134 is a cellular receptor specific for human herpesvirus-6B entry, Proc Natl Acad Sci USA 110:9096–9099, 2013.
Tembo J, Kabwe M, Chilukutu L, et al: Prevalence and risk factors for betaherpesvirus DNAemia in children ?3 weeks and <2 years of age admitted. to a large referral hospital in sub-Saharan Africa, Clin Infect Dis 60:423–431, 2015.
Zerr DM, Meier AS, Selke SS, et al: A population-based. study of primary human herpesvirus 6 infection, N Engl J Med. 352:768–776, 2005.
Andreoni M, Sarmati L, Nicastri E, et al: Primary human herpesvirus 8 infection in immunocompetent children, JAMA 287:1295–1300, 2002.
Anglemyer A, Agrawal AK, Rutherford GW: Treatment of Kaposi sarcoma in children with HIV-1 infection, Cochrane Database Syst Rev (1):Cd009826, 2014. doi:10.1002/14651858.CD009826.pub2.
Dalla Pria A, Pinato D, Roe J, et al: Relapse of multicentric Castleman’s disease following based. therapy in HIV-positive patients, Blood 2017. doi:10.1182/ blood-2016-10-747477.
Dow DE, Cunningham CK, Buchanan AM: A review of human herpesvirus 8, the Kaposi’s sarcoma-associated. herpesvirus, in the pediatric population, J Pediatric Infect Dis Soc 3:66–76, 2014.
Feiterna-Sperling C, Konigs C, Notheis G, et al: High seroprevalence of antibodies against Kaposi’s sarcoma-associated. herpesvirus (KSHV) among HIV-1-infected. children and adolescents in a non-endemic population, Med. Microbiol Immunol 205:425–434, 2016.
Goncalves PH, Ziegelbauer J, Uldrick TS, Yarchoan R: Kaposi sarcoma herpesvirus associated. cancers and related. diseases, Curr Opin HIV AIDS 12:47–56, 2017.
Kahn JA, Rudy BJ, Xu J, et al: Prevalence and risk factors for oral DNA tumor viruses in HIV-infected. youth, J Med. Virol 88:1944–1952, 2016.
Murphy C, Hawkes E, Chionh F, Chong G: Durable remission of both multicentric Castleman’s disease and Kaposi’s sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patient, J Clin Pharm Ther 42:111–114, 2017.
Olp LN, Minhas V, Gondwe C, et al: Longitudinal analysis of the humoral response to Kaposi’s sarcoma-associated. herpesvirus after primary infection in children, J Med. Virol 88:1973–1981, 2016.
Chartrand C, Leeflang MMG, Minion J, et al: Accuracy of rapid influenza diagnostic tests, Ann Intern Med. 156: 500-511, 2012.
Chung JR, Flannery B, Thompson MG, et al: Seasonal effectiveness of live attenuated. and inactivated. influenza vaccine, Pediatrics 137(2): e20153279, 2016.
Committee on Infectious Diseases: Recommendations for prevention and control of influenza in children, 2016-2017, Pediatrics 138(4): e20162527, 2016.
Fiore AE, Fry A, Shay D, et al: Antiviral agents for the treatment and chemoprophylaxis of influenza — recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep 60(1): 1-24, 2011.
Fowlkes A, Steffens A, Temte J, et al: Incidence of medically attended. influenza during pandemic and post-pandemic seasons through the Influenza Incidence Surveillance Project, 2009-13, Lancet Respir Med. 3(9): 709-718, 2015.
Fry AM, Goswami D, Nahar K, et al: Efficacy of oseltamivir treatment started. within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised. placebo-controlled. trial, Lancet Infect Dis 14(2): 109-118, 2014.
Gaglani M, Pruszynski J, Murthy K, et al: Influenza vaccine effectiveness against 2009 pandemic influenza A(H1N1) virus differed. by vaccine type during 2013-2014 in the United. States, J Infect Dis 213(10): 1546-1556, 2016.
Grohskopf LA, Sokolow LZ, Fry AM, et al: Update: ACIP recommendations for the use of quadrivalent live attenuated. influenza vaccine (LAIV4) — United. States, 2018-19 influenza season, MMWR 67(22): 643-644, 2018.
Grohskopf LA, Sokolow LZ, Broder KR, et al: Prevention and control of seasonal influenza with vaccines, MMWR Recomm Rep 65(RR-5): 1-54, 2016. Available at: http://dx.doi.org/10.15585/mmwr.rr6505a1.
Hayden F, Sugaya N, Hirotsu N, et al; Baloxavir Marboxil Investigators Group: Baloxavir marboxil for uncomplicated. influenza in adults and adolescents, N Engl J Med. 379(10): 913-923, 2018. [Epub 2018/09/06].
Maldonado YA, Zaoutis TE, Banerjee, et al: AAP Policy Statement from the Committee on Infectious Diseases: recommendations for prevention and control of influenza in children 2018-2019, Pediatrics 142(4): e20182367, 2018.
Malosh RE, Martin ET, Heikkinen T, et al: Efficacy and safety of oseltamivir in children: systematic review and individual patient data meta-analysis of randomized. controlled. trials, Clin Infect Dis 2017. doi:10.1093/cid/cix1040. [Epub 2017/12/01]. The Medical Letter: Antiviral drugs for seasonal influenza 2016-2017, Med. Lett Drugs Ther 59(1511): 1-3, 2017.
Muthuri SG, Venkatesan S, Myles PR, et al: Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted. to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data, Lancet Respir Med. 2(5): 395-404, 2014.
Pebody R, Sile B, Warburton F, et al: Live attenuated. influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed. influenza in children two to six years of age in England in the 2015/16 season, Euro Surveill 22(4): 2017.
Poehling KA, Edwards KM, Griffin MR, et al: The burden of influenza in young children, 2004-2009, Pediatrics 131(2): 207-216, 2013.
Rolfes MA, Foppa IM, Garg S, et al: Annual estimates of the burden of seasonal influenza in the United. States: a tool for strengthening influenza surveillance and preparedness, Influenza Other Respir Viruses 12(1): 132-137, 2018.
Schulert GS, Zhang M, Fall N, et al: Whole-exome sequencing reveals mutations in genes linked. to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza, J Infect Dis 231: 1180-1188, 2016.
Uyeki TM, Katz JM, Jernigan DB: Novel influenza A viruses and pandemic threats, Lancet 389: 2172-2174, 2017.
Uyeki T, Bernstein H, Bradley J, et al: Clinical practice guidelines by the Infectious Diseases Society of America: 2018 Update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza, Clin Infect Dis 2018. doi:10.1093/cid/ciy866. [Epub 2018/12/19].
Venkatesan S, Myles PR, Leonardi-Bee J, et al: Impact of outpatient neuraminidase inhibitor treatment in patients infected. with influenza A(H1N1) pdm09 at high risk of hospitalization: an individual participant data metaanalysis, Clin Infect Dis 64: 1328-1334, 2017.
Wong KK, Jain S, Blanton L, et al: Influenza-associated. pediatric deaths in the United. States, 2004-2012, Pediatrics 132: 796-804, 2013.
Abedi GR, Prill MM, Langley GE, et al: Estimates of parainfluenza virus-associated. hospitalizations and cost among children aged. less than 5 years in the United. States, 1998-2010, J Pediatr Infect Dis Soc 5:7-13, 2016.
American Academy of Pediatrics: Parainfluenza viral infections. In Kimberlin D.W., Brady M.T., Jackson M.A., Long S.S., editors: Red. Book: 2015 report of the committee on infectious diseases, Elk Grove Village, IL., 2015, American Academy of Pediatrics, pp . 586-588.
Bjornson C, Russell KF, Vandermeer B, et al: Nebulized. epinephrine for croup in children, Cochrane Database Syst Rev (10):CD006619, 2013.
Fraser CS, Jha A, Openshaw PJ: Vaccines in the prevention of viral pneumonia, Clin Chest Med. 38:155-169, 2017.
Frost HM, Robinson CC, Dominguez SR: Epidemiology and clinical presentation of parainfluenza type 4 in children: a 3-year comparative study to parainfluenza types 1-3, J Infect Dis 209:695-702, 2014.
Liu WK, Liu Q, Chen DH, et al: Epidemiology and clinical presentation of the four human parainfluenza virus types, BMC Infect Dis 13:28, 2013.
Russell KF, Liang Y, O’Gorman K, et al: Glucocorticoids for croup, Cochrane Database Syst Rev (1):CD001955, 2011.
Shah DP, Shah PK, Azzi JM, Chemaly Hb: Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: a systematic review, Cancer Lett 370:358-364, 2016.
Waghmare A, Wagner T, Andrews R, et al: Successful treatment of parainfluenza virus respiratory tract infection with DAS181 in 4 immunocompromised. children, J Pediatr Infect Dis Soc. 4:114-118, 2015.
Blanken MO, Rovers MM, Molenaar JM, et al: Respiratory syncytial virus and recurrent wheeze in healthy preterm infants, N Engl J Med 368: 1791-1799, 2013.
Boyce TG, Mellen BG, Mitchel EF Jr, et al: Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid, J Pediatr 137: 865-870, 2000.
Committee on Infectious Diseases and Bronchiolitis Guidelines Committee: Updated guidelines for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection, Pediatrics 134: 415-420, 2014.
Farley R, Gkp S, Eriksson L, et al: Antibiotics for bronchiolitis in children under two years of age, Cochrane Database Syst Rev (10): CD005189, 2014.
Forster J, Ihorst G, Rieger CHL, et al: Prospective population-based study of viral lower respiratory tract infections in children under 3 years of age (the PRI.DE study), Eur J Pediatr 163: 709-716, 2004.
Glenn GM, Fries LF, Thomas DN, et al: A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age, J Infect Dis 213: 411-422, 2016.
Glezen WP, Paredes A, Allison JE, et al: Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group and maternal antibody level, J Pediatr 98: 708-715, 1981.
Hall CB, Douglas RG Jr, Geiman JM, et al: Nosocomial respiratory syncytial virus infections, N Engl J Med 293: 1343-1346, 1975.
Hall CB, Weinberg GA, Iwane MK, et al: The burden of respiratory syncytial virus infection in young children, N Engl J Med 360: 588-598, 2009.
Hall CB: Respiratory syncytial virus in young children, Lancet 375: 1500-1502, 2010.
Henderson FW, Collier AM, Clyde WA Jr, et al: Respiratory-syncytial-virus infections, reinfections and immunity: a prospective, longitudinal study in young children, N Engl J Med 300: 530–534, 1979.
Hsu C-H, Lin C-Y, Chi H, et al: (2014) Prolonged seasonality of respiratory syncytial virus infection among preterm infants in a subtropical climate, PLoS ONE 9: e110166, 2014.
Iwane MK, Weinberg GA, Blunkin MK, et al: The burden of respiratory syncytial virus infection in young children, N Engl J Med 360: 588-598, 2009.
Johnson JE, Gonzales RA, Olson SJ, et al: The histopathology of fatal untreated human respiratory syncytial virus infection, Mod Pathol 20: 108-119, 2007.
Kern S, Uhl M, Berner R, et al: Respiratory syncytial virus infection of the lower respiratory tract: radiological findings in 108 children, Eur Radiol 11: 2581-2584, 2001.
Klein MI, Bergel E, Gibbons L, et al: Differential gender response to respiratory infections and to the protective effect of breast milk in preterm infants, Pediatrics 121: e1510-e1516, 2008.
Madhi SA, Klugman KP, Vaccine Trialist Group: A role for Streptococcus pneumonia in virus-associated pneumonia, Nat Med 10: 811-813, 2004.
Melendi GA, Laham FR, Monsalvo AC, et al: Cytokine profiles in the respiratory tract during primary infection with human metapneumovirus, respiratory syncytial virus, or influenza virus in infants, Pediatrics 120: e410-e415, 2007.
Nair H, Nokes DJ, Gessner BD, et al: Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis, Lancet 375: 1173-1181, 2010.
Shi T, McAllister DA, O’Brien KL, et al: Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study, Lancet 390: 946-958, 2017.
Stein R, Sherrill D, Morgan W, et al: Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years, Lancet 354: 541-545, 1999.
The IMpact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants, Pediatrics 102: 531-537, 1998.
Wright PF, Karron RA, Belshe RB, et al: The absence of enhanced disease with wild-type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines, Vaccine 25: 7372-7378, 2007.
Arnold JC, Singh KK, Milder E, et al: Human metapneumovirus associated. with central nervous system infection in children, Pediatr Infect Dis J 28: 1057-1060, 2009.
Bao X, Liu T, Shan Y, et al: Human meta-pneumovirus glycoprotein G inhibits innate immune responses, PLoS Pathog 4: e1000077, 2008.
Crowe JE Jr: Human metapneumovirus as a major cause of human respiratory tract disease, Pediatr Infect Dis J 23(Suppl): S215-S221, 2004.
Edwards KM, Zhu Y, Griffin MR, et al: Burden of human metapneumovirus infection in young children, N Engl J Med. 368: 633-643, 2013.
Erickson JJ, Gilchuk P, Hastings AK, et al: Viral acute lower respiratory infections impair CD8+ T cells through PD-1, J Clin Invest 122: 2967-2982, 2012.
Foulongne V, Buyon G, Rodiere M, et al: Human metapneumovirus infection in young children hospitalized. with respiratory tract disease, Pediatr Infect Dis J 25: 34-39, 2006.
Hilmes MA, Daniel Dunnavant F, Singh SP, et al: Chest radiographic features of human metapneumovirus infection in pediatric patients, Pediatr Radiol 47(13): 1745-1750, 2017.
Klein MI, Coviello S, Bauer G, et al: The impact of infection with human metapneumovirus and other respiratory viruses in young infants and children at high risk for severe pulmonary disease, J Infect Dis 193: 1544-1551, 2006.
Midgley CM, Baber JK, Biggs HM, et al: Severe human metapneumovirus infections — North Dakota, 2016, MMWR Morb Mortal Wkly Rep 66(18): 486-488, 2017.
Semple MG, Cowell A, Dove W, et al: Dual infection of infants by human metapneumovirus and human respiratory syncytial virus is strongly associated. with severe bronchiolitis, J Infect Dis 191: 382-386, 2005.
Williams JV, Crowe JE Jr, Enriquez R, et al: Human metapneumovirus infection plays an etiologic role in acute asthma exacerbations requiring hospitalization in adults, J Infect Dis 192: 1149-1153, 2005.
Williams JV, Tollefson SJ, Heymann PW, et al: Human metapneumovirus infection in children hospitalized. for wheezing, J Allergy Clin Immunol 115: 1311-1312, 2005.
Williams JV, Wang CK, Yang CF, et al: The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience, J Infect Dis 193: 387-395, 2006.
Castro-Rodriguez JA, Giebergia V, Fischer GB, et al: Postinfectious bronchiolitis obliterans in children: the South American contribution, Acta Paediatr 103:913-921, 2014.
Clemmons NS, McCormic ZD, Gaydos JC, et al: Acute respiratory disease in US Army trainees 3 years after reintroduction of adenovirus vaccine, Emerg Infect Dis 23:95-98, 2017.
Feucht J, Opherk K, Kayser S, et al: Adoptive T cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT, Blood 125:1986-1994, 2015.
Grimley MS, Chemaly Hb, Englund JA, et al: Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult hematopoietic cell transplant recipients: a randomized. placebo-controlled. phase II trial, Biol Blood Marrow Transplant 23:512-521, 2017.
Lion T: Adenovirus infections in immunocompetent and immunocompromised. patients, Clin Microbiol Rev 27:441-462, 2014.
Lynch JP, Kajon AE: Adenovirus: epidemiology, global spread of novel serotypes, and advance in treatment and prevention, Semin Respir Crit Care Med. 37:586-602, 2016.
McCarthy MK, Malitz DH, Procario MC, et al: Interferon-dependent immunoproteasome activity during mouse adenovirus type 1 infection, Virology 498:57-68, 2016.
Rodriguez E, Ip WH, Kolbe V, et al: Humanized. mice reproduce acute and persistent human adenovirus infection, J Infect Dis 215:70-79, 2017.
Wold WSM, Ison MG: Adenoviruses. In Knipe DM, Howley PM, editors: Fields’ virology, ed. 6, Philadelphia, 2013, Lippincott Williams & Wilkins, pp . 1732-1767
Arden KE, Mackay IM: Newly identified. human rhinoviruses: molecular methods heat up the cold viruses, Rev Med. Virol 20:156-176, 2010.
Bochkov YA, Watters K, Ashraf S, et al: Cadherin-related. family member 3, a childhood asthma susceptibility gene product, mediates rhinovirus C binding and replication, Proc Natl Acad Sci USA 112:5485-5490, 2015.
Caluakan M, Bochkov YA, Kreiner-M?ller E, et al: Rhinovirus wheezing illness and genetic risk of childhood-onset asthma, N Engl J Med. 368:1398-1407, 2013.
Gern JE: The ABCs of rhinoviruses, wheezing, and asthma, J Virol 84:7418-7426, 2010.
Heinonen S, Jartti T, Garcia C, et al: Rhinovirus detection in symptomatic and asymptomatic children: value of host transcriptome analysis, Am J Respir Crit Care Med. 193:772-782, 2016.
Iwane MK, Prill MM, Lu X, et al: Human rhinovirus species associated. with hospitalizations for acute respiratory illness in young US children, J Infect Dis 204:1702-1710, 2011.
Jackson DJ, Lemanske Hb Jr: The role of respiratory virus infections in childhood asthma inception, Immunol Allergy Clin North Am 30:513-522, 2010.
Kieninger E, Fuchs O, Latzin P, et al: Rhinovirus infections in infancy and early childhood, Eur Respir J 41:443-452, 2013.
Kim WK, Gern JE: Updates in the relationship between human rhinoviruses and asthma, Allergy Asthma Immunol Res 4:116-121, 2012.
Lee S, Nguyen MT, Currier MG, et al: A polyvalent inactivated. rhinovirus vaccine is broadly immunogenic in rhesus macaques, Nat Commun 7:12838, 2016.
Linder JE, Kraft DC, Mohamed. Y, et al: Human rhinovirus C: age, season, and lower respiratory illness over the past 3 decades, J Allergy Clin Immunol 131:69-77, 2013.
Miller EK, Edwards KM, Weinberg GA, et al: A novel group of rhinoviruses is associated. with asthma hospitalizations, J Allergy Clin Immunol 123:98-104, 2009.
Simmonds P, McIntyre C, Savolainen-Kopra C, et al: Proposals for the classification of human rhinovirus species C into genotypically assigned. types, J Gen Virol 91:2409-2419, 2010.
Alper CM, Winther B, Mandel EM, et al: Rate of concurrent otitis media in upper respiratory tract infections with specific viruses, Arch Otolaryngol Head Neck Surg 135: 17-21, 2009.
Arabi YM, Balkhy HH, Hayden FG, et al: Middle East respiratory syndrome, N Engl J Med. 376: 584-594, 2017.
Assiri A, McGeer A, Perl TM, et al: Hospital outbreak of Middle East respiratory syndrome coronavirus, N Engl J Med. 369: 407-416, 2013.
Bialek SR, Allen D, Alvaredo-Ramy R, et al: First confirmed. cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in the United. States, updated. information on the epidemiology of MERS-CoV infection, and guidance for the public, clinicians, and public health authorities–May 2014, MMWR Morb Mortal Wkly Rep 63: 431-436, 2014.
Bitnun A, Read S, Tellier R, et al: Severe acute respiratory syndrome-associated. coronavirus infection in Toronto children: a second look, Pediatrics 123: 97-101, 2009.
Breban R, Riou J, Fontanet A: Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk, Lancet 382: 694-699, 2013.
Centers for Disease Control and Prevention (CDC): Update on the epidemiology of middle east respiratory syndrome coronavirus (MERS-CoV) infection, and guidance for the public, clinicians, and public health authorities, MMWR Morb Mortal Wkly Rep 64(03): 61-62, 2015.
Cho SY, Kang JM, Ha YE, et al: MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study, Lancet 388: 994-1001, 2016.
Choi J, Kim M-G, Oh Y-K, Kim YB: Progress of Middle east respiratory syndrome coronavirus vaccines: a patent review, Expert Opin Therapeutic Patents 0(0): 1-11, 2017.
Dominguez SR, Robinson CC, Holmes KV: Detection of four human coronaviruses in respiratory infections in children: a one-year study in Colorado, J Med. Virol 81: 1597-1604, 2009.
Gomersall CD, Joynt GM: Middle East respiratory syndrome: new disease, old lessons, Lancet 381: 2229-2230, 2013.
Graham RL, Becker MM, Eckerle LD, et al: A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised. model of lethal disease, Nat Med. 18: 1820-1826, 2012.
Gralinksi LE, Baric RS: Molecular pathology of coronavirus infections, J Pathol 235: 185-195, 2015.
Guery B, Poissy J, el Mansouf L, et al: Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus: a report of nosocomial transmission, Lancet 381: 2265-2272, 2013.
Hui DS: Tracking the transmission and evolution of MERS-CoV, Lancet 382: 1962-1964, 2013.
Lessler J, Reich NG, Brookmeyer R, et al: Incubation periods of acute respiratory viral infections: a systematic review, Lancet Infect Dis 9: 291-300, 2009.
Memish ZA, Zumla AI, Al-Hakeem Hb, et al: Family cluster of Middle East respiratory syndrome coronavirus infections, N Engl J Med. 368: 2487-2494, 2013.
Memish ZA, Cotten M, Meyer B, et al: Human infection with MERS coronavirus after exposure to infected. camels, Saudi Arabia, 2013, Emerg Infect Dis 20: 1012-1015, 2014.
Perlman S, Zhao J: Human coronavirus EMC is not the same as severe acute respiratory syndrome coronavirus, MBio 4(1): e2-e13, 2013.
Smith EC, Sexton NR, Denison MD: Thinking outside the triangle: replication fidelity of the largest RNA viruses, Ann Rev Virol 1: 111-132, 2014.
Stempel HE, Martin ET, Kuypers J, et al: Multiple viral respiratory pathogens in children with bronchiolitis, Acta Paediatr 98: 123-126, 2009.
Talbot HK, Crowe JE Jr, Edwards KM, et al: Coronavirus infection and hospitalizations for acute respiratory illness in young children, J Med. Virol 81: 853-856, 2009.
van Boheemen S, de Graaf M, Lauber C, et al: Genomic characterization of a newly discovered. coronavirus associated. with acute respiratory distress syndrome in humans, MBio 3(6): e473-e512, 2012.
World Health Organization: Middle East respiratory syndrome coronavirus (MERSCoV)
Burke RM, Tate JE, Barin N, et al: Three rotavirus outbreaks in the postvaccine era—California, 2017, MMWR Morb Mortal Wkly Rep 67(16):470–472, 2018.
Chhabra P, Gregoricus N, Weinberg G: Comparison of three commercial multiplex gastrointestinal platforms for the detection of gastroenteritis viruses, J Clin Virol 95:66–71, 2017.
Chhabra P, Payne DC, Szilagyi PG, et al: Etiology of viral gastroenteritis in children <5 years of age in the United. States, 2008–2009, J Infect Dis 208(5):790–800, 2013.
Costantini VP, Cooper EM, Hardaker HL, et al: Epidemiologic, virologic, and host genetic factors of norovirus outbreaks in long-term care facilities, Clin Infect Dis 62(1):1–10, 2016.
Gruber JF, Gruber LF, Palmieri R, et al: Rotavirus vaccine schedules and vaccine response among infants in low- and middle-income countries: a systematic review, Open Forum Infect Dis 4(2):ofx066, 2017.
Guarino A, Ashkenazi S, Gendrel D, et al: European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based. guidelines for the management of acute gastroenteritis in children in Europe: update 2014, J Pediatr Gastroenterol Nutr 59:132, 2014.
Lanata CF, Fischer-Walker CL, Olascoaga AC, et al: Global causes of diarrheal disease mortality in children <5 years of age: a systematic review, PLoS ONE 8(9):e72788, 2013.
Matsuoka T, Yodoshi T, Sugai M, et al: A case of mild encephalopathy with a reversible splenial lesion associated. with G5P[6] rotavirus infection, Case Rep Pediatr 2013:197163, 2013.
Mwenda JM, Burke RM, Shaba K, et al: Implementation of rotavirus surveillance and vaccine introduction: World Health Organization African region, 2007-2016, MMWR Morb Mortal Wkly Rep 66(43):1192–1196, 2017.
Olortegui MP, Rouhani S, Yori PP, et al: Astrovirus infection and diarrhea in 8 countries, Pediatrics 141(1):e20171326, 2018.
Soares-Weiser K, Goldberg E, Tamimi G, et al: Rotavirus vaccine for preventing diarrhea, Cochrane Database Syst Rev (1):CD002848, 2004.
Svensson L, Desselberger U, Estes MK, Greenberg HB, editors: Viral gastroenteritis: molecular epidemiology and pathogenesis, St. Louis, 2016, Elsevier.
Tate JE, Panozzo CA, Payne DC, et al: Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine, Pediatrics 124:465–471, 2009.
Yokoyama T, Yamada S, Doichi N, Kato E: Rotavirus-infected. children with clinically mild encephalopathy with a reversible splenial lesion (MERS), BMJ Case Rep 2013:bcr2013008644, 2013.1
Bruggink SC, de Koning MN, Gussekloo J, et al: Cutaneous wart-associated. HPV types: prevalence and relation with patient characteristics, J Clin Virol 55(3):250–255, 2012.
Centers for Disease Control and Prevention: FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP), MMWR Morb Mortal Wkly Rep 59:630–631, 2010.
Darragh TM, Colgan TJ, Cox JT, et al: The lower anogenital squamous terminology standardization project for HPV-associated. lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology, J Low Genit Tract Dis 16(3):205–242, 2012.
Dobson SR, McNeil S, Dionne M, et al: Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized. clinical trial, JAMA 309(17):1793–1802, 2013.
Doorbar J, Quint W, Banks L, et al: The biology and life-cycle of human papillomaviruses, Vaccine 30(Suppl 5):F55–F70, 2012.
Drolet M, B?nard E, Boily MC, et al: Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis, Lancet Infect Dis 15(5):565–580, 2015.
Food and Drug Administration: FDA approves expanded. use of Gardasil 9 to include individuals 27 through 45 years old.
Gillison ML, Alemany L, Snijders PJ, et al: Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis, Vaccine 30(Suppl 5):F34–F54, 2012.
Leval A, Herweijer E, Ploner A, et al: Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study, J Natl Cancer Inst 105(7):469–474, 2013.
Markowitz LE, Liu G, Hariri S, et al: Prevalence of HPV after introduction of the vaccination program in the United. States, Pediatrics 137(3):e20151968, 2016.
Massad LS, Einstein MH, Huh WK, et al: 2012 updated. consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors, Obstet Gynecol 121(4):829–846, 2013.
Meites E, Kempe A, Markowitz LE: Use of a 2-dose schedule for human papillomavirus vaccination—updated. recommendations of the advisory committee on immunization practices, MMWR Morb Mortal Wkly Rep 65(49):1405–1408, 2016.
Moscicki AB, Ma Y, Farhat S, et al: Redetection of cervical HPV16 in women with a previous history of HPV16, J Infect Dis 208(3):403–412, 2013.
Moscicki AB, Ma Y, Wibbelsman C, et al: Rate of and risks for regression of CIN-2 in adolescents and young women, Obstet Gynecol 116(6):1373–1380, 2010.
Moscicki AB, Schiffman M, Burchell A, et al: Updating the natural history of human papillomavirus and anogenital cancers, Vaccine 30(Suppl 5):F24–F33, 2012.
Moyer VA, U.S. Preventive Services Task Force: Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med. 156(12):880–891, W312, 2012.
Petrosky E, Bocchini JA, Hariri S, et al: Use of 9-valent human papillomavirus (HPC) vaccine: updated. HPV vaccination recommendations of the advisory committee on immunization practices, MMWR Morb Mortal Wkly Rep 64(11):300–304, 2015.
Quint W, Jenkins D, Molijn A, et al: One virus, one lesion—individual components of CIN lesions contain a specific HPV type, J Pathol 227(1):62–71, 2012.
Reagan-Steiner S, Yanke D, Jeyarajah J, et al: National, regional, state and selected. local-area vaccination coverage among adolescents aged. 13-17 years—United. States, MMWR Morb Mortal Wkly Rep 65(33):850–858, 2016, 2015.
Saslow D, Solomon D, Lawson HW, et al; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer, CA Cancer J Clin 62(3):147–172, 2012.
Unger ER, Fajman NN, Maloney EM, et al: Anogenital human papillomavirus in sexually abused. and nonabused. children: a multicenter study, Pediatrics 128(3):e658–e665, 2011.
Waxman AG, Chelmow D, Darragh TM, et al: Revised. terminology for cervical histopathology and its implications for management of high-grade squamous intraepithelial lesions of the cervix, Obstet Gynecol 120(6):1465–1471, 2012.
Widdice L, Ma Y, Jonte J, et al: Concordance and transmission of human papillomavirus within heterosexual couples observed. over short intervals, J Infect Dis 207(8):1286–1294, 2013.
Charlier C, Beaudoin MC, Couderc T, et al: Arboviruses and pregnancy: maternal, fetal, and neonatal effects, Lancet Child Adolesc Health 1:134–146, 2017.
Gaensbauer JT, Lindsey NP, Messacar K, et al: Neuroinvasive arboviral disease in the United. States: 2003 to 2012, Pediatrics 134(3):e642–e650, 2014.
Go YY, Balasuriya UB, Lee CK: Zoonotic encephalitides caused. by arboviruses: transmission and epidemiology of alphaviruses and flaviviruses, Clin Exp Vaccine Res 3(1):58–77, 2014.
Rebaza A, Lee PJ: “One more shot for the road: a review and update of vaccinations for pediatric international travelers.”, Pediatr Ann 44(4):e89–e96, 2015.
Ronca SE, Dineley KT, Paessler S: Neurological sequelae resulting from encephalitic alphavirus infection, Front Microbiol 7:959, 2016.
Wilson AL, Dhiman RC, Kitron U, et al: Benefit of insecticide-treated. nets, curtains and screening on vector borne diseases, excluding malaria: a systematic review and meta-analysis, PLoS Negl Trop Dis 8(10):e3228, 2014.
Barzon L, Pacenti M, Sinigaglia A, et al: West Nile virus infection in children, Expert Rev Anti Infect Ther 13(11):1373–1386, 2015.
Burakoff A, Lehman J, Fischer M, et al: West Nile virus and other nationally notifiable arboviral diseases—United. States, 2016, MMWR Morb Mortal Wkly Rep 67(1):13–17, 2018.
David S, Abraham AM: Epidemiological and clinical aspects on West Nile virus, a globally emerging pathogen, Infect Dis (Lond) 48(8):571–586, 2016.
Piantadosi A, Rubin DB, McQuillen DP, et al: Emerging cases of Powassan virus encephalitis in New England: clinical presentation, imaging, and review of the literature, Clin Infect Dis 62(6):707–713, 2016.
Weaver SC, Lecuit M: Chikungunya virus and the global spread of a mosquito-borne disease, N Engl J Med. 372(13):1231–1238, 2015.
Pavli A, Maltezou HC: Travel-acquired. Japanese encephalitis and vaccination considerations, J Infect Dev Ctries 9(9):917–924, 2015.
Sathiamoorthi S, Smith WM: The eye and tick-borne disease in the United. States, Curr Opin Ophthalmol 27(6):530–537, 2016.
Steffen R: Epidemiology of tick-borne encephalitis (TBE) in international travellers to Western/Central Europe and conclusions on vaccination recommendations, J Travel Med. 23(4):2016.
Adebanjo T, Godfred-Cato S, Viens L, et al: Update: interim guidance for the diagnois, evaluation, and management of infants with possible congenital Zika virus infection—United. States, October 2017, MMWR Morb Mortal Wkly Rep 66(41):1089–1098, 2017.
Baud D, Gubler DJ, Schaub B, et al: An update on Zika virus infection, Lancet 390:2099–2109, 2017.
Brasil P, Sequeria PC, Freitas AD, et al: Guillain-Barre syndrome associated. with Zika virus infection, Lancet 387:1482, 2016.
Brooks RB, Carlos MP, Myers RA, et al: Likely sexual transmission of Zika virus from a man with no symptoms of infection—Maryland, 2016, MMWR Morb Mortal Wkly Rep 65(34):915–916, 2016.
Chan JF, Choi GK, Yip CC, et al: Zika fever and congenital Zika syndrome: an unexpected. emerging arboviral disease, J Infect 72(5):507–524, 2016.
Falcao MB, Cimerman S, Luz KG, et al: Management of infection by the Zika virus, Ann Clin Microbiol Antimicrob 15(1):57, 2016.
Hoen B, Schaub B, Funk AL, et al: Pregnancy outcomes after ZIKV infection in French territories in the Americas, N Engl J Med. 378(11):985–994, 2018.
Klase ZA, Khakhina S, Schneider Ade B, et al: Zika fetal neuropathogenesis: etiology of a viral syndrome, PLoS Negl Trop Dis 10(8):e0004877, 2016.
Kleber de Oliveira W, de Franca GVA, Carmo EH, et al: Infection-related. microcephaly after the 2015 and 2016 Zika virus outbreaks in Brazil: a surveillance-based. analysis, Lancet 390:861–870, 2017.
Landry ML, St George K: Laboratory diagnosis of Zika virus infection, Arch Pathol Lab Med. 141(1):60–67, 2017.
Leal MC, Muniz LF, Ferreira TSA, et al: Hearing loss in infants with microcephaly and evidence of congenital Zika virus infection—Brazil, November 2015-May 2016, MMWR Morb Mortal Wkly Rep 65(34):917–919, 2016.
Likos A, Griffin I, Bingham AM, et al: Local mosquito-borne transmission of Zika virus—Miami-Dade and Broward counties, Florida, June-August 2016, MMWR Morb Mortal Wkly Rep 65(38):1032–1038, 2016.
Mead PS, Duggal NK, Hook SA, et al: Zika virus shedding in semen of symptomatic infected. men, N Engl J Med. 378(15):1377–1384, 2018.
Mecharles S, Herrmann C, Poullain P, et al: Acute myelitis due to Zika virus infection, Lancet 387:1481, 2016.
Medin CL, Rothman AL: Zika virus: the agent and its biology, with relevance to pathology, Arch Pathol Lab Med. 141(1):33–42, 2017.
Moore CA, Staples JE, Dobyns WB, et al: Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians, JAMA Pediatr 171(3):288–295, 2017.
Polen KD, Gilboa SM, Hills S, et al: Update: interim guidance for preconception counseling and prevention of sexual transmission of Zika virus for men with possible Zika virus exposure—United. States, August 2018, MMWR Morb Mortal Wkly Rep 67(31):868–870, 2018.
Rice ME, Galang RR, Roth NM, et al: Vital Signs: Zika-associated. birth defects and neurodevelopmental abnormalities possibly associated. with congenital Zika virus infection—US territories and freely associated. sataes, 2018, MMWR Morb Mortal Wkly Rep 67(31):858–866, 2018.
Satterfield-Nash A, Kotzky K, Allen J, et al: Health and development at age 19-24 months of 19 children who were born with microcephaly and laboratory evidence of congenital Zika virus infection during the 2015 Zika virus outbreal—Brazil, 2017, MMWR Morb Mortal Wkly Rep 66(49):1347–1350, 2017.
Ventura CV, Maia M, Dias N, et al: Zika: neurological and ocular findings in infant without microcephaly, Lancet 387:2502, 2016.
Ventura CV, Maia M, Travassos SB, et al: Risk factors associated. with the ophthalmoscopic findings identified. in infants with presumed. Zika virus congenital infection, JAMA Ophthalmol 134(8):912–918, 2016.
Weaver SC, Costa F, Garcia-Blanco MA, et al: Zika virus: history, emergence, biology, and prospects for control, Antiviral Res 130:69–80, 2016.
Bhatt S, Gething PW, Brady OJ, et al: The global distribution and burden of dengue, Nature 496(7446): 504-507, 2013.
Brady OJ, Gething PW, Bhatt S, et al: Refining the global spatial limits of dengue virus transmission by evidence-based. consensus, PLoS Negl Trop Dis 6(8): e1760, 2012.
Furuya-Kanamori L, Liang S, Milinovich G, et al: Co-distribution and co-infection of chikungunya and dengue viruses, BMC Infect Dis 16: 84, 2016.
Glasner DR, Puerta-Guardo H, Beatty PR, et al: The good, the bad, and the shocking: the multiple roles of dengue virus nonstructural protein 1 in protection and pathogenesis, Annu Rev Virol 5(1): 227-253, 2018.
Guzman MG, Gubler DJ, Izquierdo A, et al: Dengue infection, Nat Rev Dis Primers 2: 16055, 2016.
Halstead SB: Pathogenesis of dengue: dawn of a new era, F1000Res 4(F1000 FacultyRev):1315, 2015.
Halstead SB: Safety issues from a Phase 3 clinical trial of a live-attenuated. chimeric yellow fever tetravalent dengue vaccine, Hum Vaccin Immunother 14(9): 2158-2162, 2018.
Halstead SB: Which dengue vaccine approach is the most promising, and should we be concerned. about enhanced. disease after vaccination? there is only one true winner, Cold Spring Harb Perspect Biol 10(6): 2018.
Johnstom D, Viray M, Ushiroda J, et al: Outbreak of locally acquired. cases of dengue fever—Hawaii, 2015, MMWR Morb Mortal Wkly Rep 65(2): 34, 2016.
Jones JM, Lopez B, Adams L, et al: Binational dengue outbreak along the United. States-Mexico border–Yuma county, Arizona, and Sonora, Mexico, 2014, MMWR Morb Mortal Wkly Rep 65(19): 495-499, 2016.
Katzelnick LC, Coloma J, Harris E: Dengue: knowledge gaps, unmet needs, and research priorities, Lancet Infect Dis 17(3): ee100, 2017.
Lee TH, Lee LK, Lye DC, et al: Current management of severe dengue infection, Expert Rev Anti Infect Ther 15(1): 67-78, 2017.
Lye DC, Archuleta S, Syed-Omar SF, et al: Prophylactic platelet transfusion plus supportive care versus supportive care alone in adults with dengue and thrombocytopenia: a mulricentre, open-label, randomised, superiority trial, Lancet 389: 1611-1618, 2017.
Martina BE, Barzon L, Pijlman GP, et al: Human to human transmission of arthropodborne pathogens, Curr Opin Virol 22: 13-21, 2017.
Medeiros DN, Ferranti JF, Delgado AF, et al: Colloids for the Initial Management of Severe Sepsis and Septic Shock in Pediatric Patients: a Systematic Review, Pediatr Emerg Care 31: e11, 2015.
Sharp TM, Tomashek KM, Read JS, et al: A new look at an old disease: recent insights into the global epidemiology of Dengue, Curr Epidemiol Rep 4(1): 11-21, 2017.
Simmons CP, McPherson K, Van Vinh Chau N, et al: Recent advances in dengue pathogenesis and clinical management, Vaccine 33(50): 7061-7068, 2015.
Sierra B, Triska P, Soares P, et al: OSBPL10, RXRA and lipid metabolism confer African-ancestry protection against Dengue haemorrhagic fever in admixed. Cubans, PLoS Pathog 13(2): e1006220, 2017.
Stanaway JD, Shepard DS, Undurraga EA, et al: The global burden of dengue: an analysis from the Global Burden of Disease Study 2013, Lancet Infect Dis 16(6): 71223, 2016.
Wakimoto MD, Camacho LA, Guaraldo L, et al: Dengue in children: a systematic review of clinical and laboratory factors associated. with severity, Expert Rev Anti Infect Ther 13 (12): 1441-1456, 2015.
World Health Organization: Dengue: guidelines for diagnosis, treatment, prevention and control, Geneva, Switzerland, 2009, WHO.
Barrett AD: Yellow fever in Angola and Beyond — The problem of vaccine supply and demand, N Engl J Med. 375: 301-303, 2016.
Boyd AT, Dombaxe D, Moreira R, et al: Investigation of patients testing positive for yellow fever viral RNA after vaccination during a mass yellow fever vaccination campaign—Angola, 2016, MMWR Morb Mortal Wkly Rep 66(10): 282-283, 2017.
Calisher CH, Woodall JP: Yellow fever-more a policy and planning problem than a biological one, Emerg Infect Dis 22: 1859-1860, 2016.
Collins ND, Barrett AD: Live attenuated. yellow fever 17D vaccine: a legacy vaccine still controlling outbreaks in modern day, Curr Infect Dis Rep 19: 14, 2017.
Grobbelaar AA, Weyer J, Moolla N, et al: Resurgence of yellow fever in Angola, 2015-2016, Emerg Infect Dis 22: 1854-1855, 2016.
Hamer DH, Angelo K, Caumes E, et al: Fatal yellow fever in travelers to Brazil, 2018, MMWR Morb Mortal Wkly Rep 67(11): 340-341, 2018.
Lindsey NP, Rabe IB, Miller ER, et al: Adverse event reports following yellow fever vaccination, 2007-13, J Travel Med. 23(5): 2016.
Otshudiema JO, Ndakala NG, Mawanda EK, et al: Yellow fever outbreak — Kongo Central Province, Democratic Republic, MMWR Morb Mortal Wkly Rep 66(12): 335-338, 2017.
Paules CI, Fauci AS: Yellow fever — once again on the radar screen in the Americas, N Engl J Med. 376(15): 1397-1400, 2017.
Seligman SJ: Risk groups for yellow fever vaccine-associated. viscerotropic disease (YEL-AVD), Vaccine 32: 5769-5775, 2014.
Thomas RE: Yellow fever vaccine-associated. viscerotropic disease: current perspectives, Drug Des Devel Ther 10: 3345-3353, 2016.
Wieten RW, Jonker EF, van Leeuwen EM, et al: A single 17D yellow fever vaccination provides lifelong immunity; characterization of yellow-fever-specific neutralizing antibody and T-cell responses after vaccination, PLoS ONE 11: e0149871, 2016.
Al-Abri SS, Al Abaidani I, Fazlalipour M, et al: Current status of Crimean-Congo hemorrhagic fever in WHO Eastern Mediterranean Region: issues, challenges and future directions, Int J Infect Dis 58:82–89, 2017.
Bausch DG: One step closer to an Ebola virus vaccine, N Engl J Med. 376(10):984–985, 2017.
Biava M, Caglioti C, Bordi L, et al: Detection of viral RNA in tissues following plasma clearance from an Ebola virus infected. patient, PLoS Pathog 13(1):e1006065, 2017.
Damkjaer M, Rudolf F, Mishra S, et al: Clinical features and outcome of Ebola virus disease in pediatric patients: a retrospective case series, J Pediatr 182:378–381. e371, 2017.
Deen GF, Broutet N, Xu W, et al: Ebola RNA persistence in semen of Ebola virus disease survivors: final report, N Engl J Med. 377(15):1428–1436, 2017.
Delamou A, Camara BS, Kolie JP, et al: Profile and reintegration experience of Ebola survivors in Guinea: a cross-sectional study, Trop Med. Int Health 22(3):254–260, 2017.
Dokubo EK, Wendland A, Mate SE, et al: Persistence of ebola virus after the end of widespread transmission in Liberia: an outbreak report, Lancet 18(9):1015–1024, 2018.
Dornemann J, Burzio C, Ronsse A, et al: First newborn baby to receive experimental therapies survives Ebola virus disease, J Infect Dis 215(2):171–174, 2017.
The Ebola Outbreak Epidemiology Team: Outbreak of Ebola virus disease in the Democratic Republic of the Congo, April-May, 2018: an epidemiological study, Lancet 392:213–220, 2018.
Fitzgerald F, Naveed. A, Wing K, et al: Ebola virus disease in children, Sierra Leone, 2014-2015, Emerg Infect Dis 22(10):1769–1777, 2016.
Grant A, Seregin A, Huang C, et al: Junin virus pathogenesis and virus replication, Viruses 4(10):2317–2339, 2012.
Henao-Restrepo AM, Camacho A, Longini IM, et al: Efficacy and effectiveness of an rVSV-vectored. vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised. trial (Ebola Ca Suffit!), Lancet 389(10068):505–518, 2017.
Long S.S.: Ebola virus disease in children presents special challenges, J Pediatr 182:1, 2017.
Jacobs M, Rodger A, Bell DJ, et al: Late Ebola virus relapse causing meningoencephalitis: a case report, Lancet 388:498–502, 2016.
Jiang H, Du H, Wang LM, et al: Hemorrhagic fever with renal syndrome: pathogenesis and clinical picture, Front Cell Infect Microbiol 6:1, 2016.
Kennedy SB, Bolay F, Kieh M, et al: Phase 2 placebo-controlled. trial of two vaccines to prevent Ebola in Liberia, N Engl J Med. 377(15):1438–1446, 2017.
Lamontagne F, Fowler RA, Adhikari NK, et al: Evidence-based. guidelines for supportive care of patients with Ebola virus disease, Lancet 391:700–708, 2018.
Linthicum KJ, Britch SC, Anyamba A: Rift Valley fever: an emerging mosquito-borne disease, Annu Rev Entomol 61:395–415, 2016.
Mansfield KL, Banyard AC, McElhinney L, et al: Rift Valley fever virus: a review of diagnosis and vaccination, and implications for emergence in Europe, Vaccine 33(42):5520–5531, 2015.
Patterson M, Grant A, Paessler S: Epidemiology and pathogenesis of Bolivian hemorrhagic fever, Curr Opin Virol 5:82–20, 2014.
Regules JA, Beigel JH, Paolino KN, et al: A recombinant vesicular stomatitis virus Ebola vaccine, N Engl J Med. 376(4):330–340, 2017.
Sahr F, Ansumana R, Massaquoi TA, et al: Evaluation of convalescent whole blood for treating Ebola virus disease in Freetown, Sierra Leone, J Infect 74(3):302–309, 2017.
Shao J, Liang Y, Ly H: Human hemorrhagic fever causing arenaviruses: molecular mechanisms contributing to virus virulence and disease pathogenesis, Pathogens 4(2):283–306, 2015.
Trad MA, Naughton W, Yeung A, et al: Ebola virus disease: an update on current prevention and management strategies, J Clin Virol 86:5–13, 2017.
Trehan I, Kelly T, Marsh RH, et al: Moving towards a more aggressive and comprehensive model of care for children with ebola, J Pediatr 170(28):33, 2016.
Uyeki TM, Mehta AK, Davey RT Jr, et al: Clinical management of Ebola virus disease in the United. States and Europe, N Engl J Med. 374(7):636–646, 2016.
WHO Guidelines Approved. by the Guidelines Review Committee: Guidelines on core components of infection prevention and control programmes at the national and acute health care facility level, Geneva, 2016, World Health Organization.
WHO Guidelines Approved. by the Guidelines Review Committee: Personal protective equipment for use in a filovirus disease outbreak: rapid advice guideline, Geneva, 2016, World Health Organization.
Zou LX, Chen MJ, Sun L: Haemorrhagic fever with renal syndrome: literature review and distribution analysis in China, Int J Infect Dis 43:95–100, 2016.
Bonthius DJ: Lymphocytic choriomeningitis virus: an underrecognised. cause of neurologic disease in the fetus, child, and adult, Semin Pediatr Neurol 19: 89-95, 2012.
Bonthius DJ, Nichols B, Harb H, et al: Lymphocytic choriomeningitis virus infection in brain: critical role of host age, Ann Neurol 62: 356-374, 2007.
Bonthius DJ, Perlman S: Congenital viral infections of the brain: lessons learned. from lymphocytic choriomeningitis virus in the neonatal rat, PLoS Pathog 3(11): e149, 2007.
Bonthius DJ, Wright R, Tseng B, et al: Congenital lymphocytic choriomeningitis virus infection: spectrum of disease, Ann Neurol 62: 347-355, 2007.
Centers for Disease Control and Prevention (CDC): Update: interim guidance for minimizing risk for human lymphocytic choriomeningitis virus infection associated. with pet rodents, MMWR Morb Mortal Wkly Rep 54: 799-801, 2005.
Childs J, Glass G, Korch G, et al: Lymphocytic choriomeningitis virus infection and house mouse (Mus musculus) distribution in urban baltimore, Am J Trop Med. Hyg 47: 27-34, 1992.
Farmer M, Sebire G: Genetic mimics of congenital lymphocytic choriomeningitis virus encephalitis, Ann Neurol 64: 353-355, 2008.
Fischer SA, Graham MB, Kuehnert MJ, et al: Transmission of lymphocytic choriomeningitis virus by organ transplantation, N Engl J Med. 34: 2235-2249, 2006.
Macneil A, Stroher U, Farnon E, et al: Solid organ transplant-associated. lymphocytic choriomeningitis, United. States, 2011, Emerg Infect Dis 18: 1256-1262, 2012.
Mathur G, Yadav K, Ford B, et al: High clinical suspicion of donor-derived. disease leads to timely recognition and early intervention to treat solid organ transplanttransmitted. lymphocytic choriomeningitis virus, Transpl Infect Dis 19(4): 2017. doi:10.1111/tid.12707.
Wright R, Johnson D, Neumann M, et al: Congenital lymphocytic choriomeningitis virus syndrome. A disease that mimics congenital toxoplasmosis or cytomegalovirus infection, Pediatrics 100: E9, 1997.
Centers for Disease Control and Prevention: Hantavirus pulmonary syndrome (HPS)
Diaz JH: Rodent-borne infectious disease outbreaks after flooding disasters: epidemiology, management, and prevention, J Emerg Manag 13: 459, 2015.
Figueiredo LT, Souza WM, Ferres M, et al: Hantaviruses and cardiopulmonary syndrome in South America, Virus Res 187: 43, 2014.
Hartline J, Mierek C, Knutson T, et al: Hantavirus infection North America: a clinical review, Am J Emerg Med. 31: 978-982, 2013.
MacNeil A, Ksiazek TG, Rollin PE: Hantavirus pulmonary syndrome, United. States, 1993-2009, Emerg Infect Dis 17(7): 1195-1201, 2011.
Mattar S, Guzman C, Figueiredo LT: Diagnosis of hantavirus infection in humans, Expert Rev Anti Infect Ther 13: 939, 2015.
Rhee DK, Clark RP, Blair RJ, et al: Clinical problem-solving. Breathtaking journey, N Engl J Med. 367(5): 452-457, 2012.
Sargianou M, Watson DC, Chra P, et al: Hantavirus infections for the clinician: from case presentation to diagnosis and treatment, Crit Rev Microbiol 38(4):317–329, 2012.
Schmaljohn CS: Vaccines for hantaviruses: progress and issues, Expert Rev Vaccines 11(5): 511-513, 2012.
Srikiatkhachorn A, Spiropoulou CF: Vascular events in viral hemorrhagic fevers: a comparative study of dengue and hantaviruses, Cell Tissue Res 355: 621-633, 2014.
Watson DC, Sargianou M, Papa A, et al: Epidemiology of Hantavirus infections in humans: a comprehensive, global overview, Crit Rev Microbiol 40: 261, 2014.
Caicedo Y, Paez A, Kuzmin I, et al: Virology, immunology and pathology of human rabies during treatment, Pediatr Infect Dis J 34:520–528, 2015.
Christiansen AH, Rodriguez AB, Nielsen J, Cowan SA: Should travellers to rabiesendemic ountries be pre-exposure vaccinated? An assessment of post-exposure prophylaxis and pre-exposure prophylaxis given to Danes travelling to rabies-endemic countries 2000-12, J Travel Med. 23(4):2016. doi:10.1093/jtm/taw022.
Cote A, Guagliardo AJ, Tran CH, et al: Assessing rabies risk after a mass bat exposure at a research facility in a national park, Wyoming, 2017, MMWR Morb Mortal Wkly Rep 67(10):313–314, 2018.
Dato VM, Campagnolo ER, Long J, Rupprecht CE: A systematic review of human bat rabies virus variant cases: evaluating unprotected. physical contact with claws and teeth in support of accurate risk assessments, PLoS ONE 11(7):e0159443, 2016.
Fitzpatrick JL, Dyer JL, Blanton JD, et al: Rabies in rodents and lagomorphs in the United. States, 1995-2010, J Am Vet Med. Assoc 245(3):333–337, 2014.
Hampson K, Coudeville L, Lembo T, et al: Estimating the global burden of endemic canine rabies, PLoS Negl Trop Dis 9(4):e0003709, 2015.
Hemachudha T, Ugolini G, Wacharapluesadee S, et al: Human rabies: neuropathogenesis, diagnosis, and management, Lancet Neurol 12:498–513, 2013.
Mani RS: Human rabies survivors in India: an emerging paradox? PLoS Negl Trop Dis 10:e0004774, 2016.
Schroeder B, Boland A, Pieracci EG, et al: Assessment of rabies exposure risk among residents of a university sorority house—Indiana, February 2017, MMWR Morb Mortal Wkly Rep 67(5):166, 2018.
Styczynski A, Tran C, Dirlikov E, et al: Human rabies—Puerto Rico, 2015, MMWR Morb Mortal Wkly Rep 65(52):1474–1476, 2017.
Vashishtha VM, Choudhury P, Kalra A, et al: Indian Academy of Pediatrics (IAP) recommended. immunization schedule for children aged. 0 through 18 years–India, 2014 and updates on immunization, Indian Pediatr 51:785–800, 2014.
Vora NM, Orciari LA, Bertumen JB, et al: Potential confounding of diagnosis of rabies in patients with recent receipt of intravenous immune globulin, MMWR Morb Mortal Wkly Rep 67(5):161–164, 2018.
Wallace RM, Gilbert A, Slate D, et al: Right place, wrong species: a 20-year review of rabies virus cross species transmission among terrestrial mammals in the United. States, PLoS ONE 9(10):e107539, 2014.
World Health Organ Tech Rep Ser (982):1–139, 2013, back cover.
Allander T, Andreasson K, Gupta S, et al: Identification of a third human polyomavirus, J Virol 81: 4130-4136, 2007.
Dalianis T, Hirsch HH: Human polyomaviruses in disease and cancer, Virology 437: 63-72, 2013.
DeCaprio JA, Garcea RL: A cornucopia of human polyomaviruses, Nat Rev Microbiol 11: 264-276, 2013.
Egli A, Infanti L, Dumoulin A, et al: Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors, J Infect Dis 199: 837-846, 2009.
Feng H, Shuda M, Chang Y, et al: Clonal integration of a polyomavirus in human Merkel cell carcinoma, Science 319: 1096-1100, 2008.
Gaynor AM, Nissen MD, Whiley DM, et al: Identification of a novel polyomavirus from patients with acute respiratory tract infections, PLoS Pathog 3: e64, 2007.
Hirsch HH, Knowles S, Dickenmann M, et al: Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients, N Engl J Med. 347: 488-496, 2002.
Lam WY, Leung BW, Chu IM, et al: Survey for the presence of BK, JC, KI, WU and Merkel cell polyomaviruses in human brain tissues, J Clin Virol 48: 11-14, 2010.
Major EO: Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies, Annu Rev Med. 61: 35-47, 2010.
Muftuoglu M, Olson A, Marin D, et al: Allogenic BK virus-specific T cells for progressive multifocal leukoencephalopathy, N Engl J Med. 379(15): 1443-1450, 2018.
Nguyen KD, Lee EE, Yue Y, et al: Human polyomaviruses 6 and 7 are associated. with pruritic and dyskeratotic dermatoses, J Am Acad Dermatol 76(5): 932-940, 2017.
van der Meijda E, Janssens RWA, Lauber C, et al: Discovery of a new human polyomavirus associated. with Trichodysplasia spinulosa in an immunocompromised. patient, PLoS Pathog 6: e1001024, 2010.
Wunderink HF, van der Meijden E, ban der Blij-de Brouwer CS, et al: Pretransplantation donor-recipient pair seroreactivity against BK polyomavirus predicts viremia and nephropathy after renal transplantation, Am J Transplant 17: 161-172, 2017.
Angelmyer A, Horvath T, Rutherford G: Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples, JAMA 310:1619–1620, 2013.
The Antiviral Therapy Cohort Collaboration: Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies, Lancet 4(8):e349–e356, 2017.
Braun DL, Kouyos RD, Balmer B, et al: Frequency and spectrum of unexpected. clinical manifestations of primary HIV-1 infection, Clin Infect Dis 61:1013–1021, 2015.
Brooks JT, Kawwass JF, Smith DK, et al: Effects of antiretroviral therapy to prevent HIV transmission to women in couples attempting conception when the man has HIV infection—United. States, 2017, MMWR 66(32):859–860, 2017.
Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, et al: A randomized. trial of prolonged. co-trimoxazole in HIV-infected. children in Africa, N Engl J Med. 370:41–53, 2014.
Centers for Disease Control and Prevention and Association of Public Health Laboratories: Laboratory Testing for the Diagnosis of HIV Infection: Updated. Recommendations. Published. June 27, 2014
Centers for Disease Control and Prevention (CDC): Revised. surveillance case definition for HIV infection—United. States, MMWR Recomm Rep 63(RR–03):1–10, 2014.
Centers for Disease Control and Prevention (CDC): Update to interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection: PrEP for injecting drug users, MMWR Morb Mortal Wkly Rep 62:463–465, 2013.
Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United. States—2017 Update: a clinical practice guideline, Published. March 2018.
Cohen MS, Chen YQ, McCauley M, et al: Antiretroviral therapy for the prevention of HIV-1 transmission, N Engl J Med. 375:830–839, 2016.
Cohen MS, Shaw GM, McMichael AJ, et al: Acute HIV-1 infection, N Engl J Med. 364:1943–1952, 2011.
Cotton MF, Violari A, Otwombe K, et al: Early time-limited. antiretroviral therapy versus deferred. therapy in South African infants infected. with HIV: results from the children with HIV early antiretroviral (CHER) randomized. trial, Lancet 382:1555–1562, 2013.
DiNenno EA, Prejean J, Irwin K, et al: Recommendations for HIV screening of gay, bisexual, and other men who have sex with men—United. States, 2017, MMWR 66(31):830–832, 2017.
Druand CM, Blankson JN, Siliciano Hb: Developing strategies for HIV-1 eradication, Trends Immunol 33:554–562, 2012.
Evans ME, Labuda SM, Hogan V, et al: HIV infection investigation in a rural area—West Virginia, 2017, MMWR 67(8):257–258, 2018.
Fowler MG, Gable AL, Lamp MA, et al: Perinatal HIV and its prevention: progress toward an HIV-free generation, Clin Perinatol 37:699–719, 2010.
Guidelines for the prevention and treatment of opportunistic infections in HIV Infected. adults and adolescents.
Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed. and HIV-infected. children.
Guidelines for the use of antiretroviral agents in HIV-1 infected. adults and adolescents.
Guidelines for the use of antiretroviral agents in pediatric HIV infection.
Hakim J, Musiime V, Szubert AJ, et al: Enhanced. prophylaxis plus antiretroviral therapy for advanced. HIV infection in Africa, N Engl J Med. 377(3):233–245, 2017.
Hazra R, Siberry GK, Mofenson LM: Growing up with HIV: children, adolescents, and young adults with perinatally acquired. HIV infection, Annu Rev Med. 61:169–185, 2010.
Hellmuth J, Fletcher JLK, Valcour V, et al: Neurologic signs and symptoms frequently manifest in acute HIV infection, Neurology 87:1–7, 2016.
The INSIGHT START Study Group: Initiation of antiretroviral therapy in early asymptomatic HIV infection, N Engl J Med. 373:795–807, 2015.
Jamison DJ, Chasela CS, Hudgens MG, et al: Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomized. controlled. trial, Lancet 379:2449–2458, 2012.
LeDoara K, Bland R, Newell ML: Neurodevelopment in children born to HIV-infected. mothers by infection and treatment status, Pediatrics 130:e1326–e1344, 2012.
Lowenthal ED, Ellenberg JH, Machine E, et al: Association between efavirenz-based. compared. with nevirapine-based. antiretroviral regimens and virological failure in HIV-infected. children, JAMA 309:180–31808, 2013.
Maartens G, Celum C, Lewin SR: HIV infection: epidemiology, pathogenesis, treatment, and prevention, Lancet 384:258–268, 2014.
Marrazzo JM, del Rio C, Holtgrave DR, et al: HIV prevention in clinical care settings. 2014 recommendations of the international antiviral society—USA panel, JAMA 312:390–402, 2014.
Motswere-Chirwa C, Voetsch A, Lu L, et al, Centers for Disease Control and Prevention (CDC): Follow-up of infants diagnosed. with HIV—early infant diagnosis program, Francistown, Botswana, 2005-2012, MMWR Morb Mortal Wkly Rep 63:158–160, 2014.
Moyer VA, U.S. Preventive Services Task Force: Screening for HIV: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med. 159:51–60, 2013.
Natukunda E, Gaur AH, Kosalaraska P, et al: Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected. children: a single-arm, open-label trial, Lancet 1:27–34, 2017.
Nielsen-Saines K, Watts H, Veloso VG, et al: Three postpartum antiretroviral regimens to prevent intrapartum HIV infection, N Engl J Med. 366:2368–2378, 2012.
Novak RM, Richardson JT, Buchacz K, et al: Immune reconstitution inflammatory syndrome (IRIS) in the HIV outpatient study (HOPS): incidence and implications for mortality, AIDS 26:721–730, 2012.
Ocfemia MCB, Dunvulle R, Zhang T, et al: HIV diagnoses among persons aged. 13-29 years—United. States, 2010-2014, MMWR 67(7):212–215, 2018.
Recommendations for use of antiretroviral drugs in pregnant HIV-1–infected. women for maternal health and interventions to reduce perinatal HIV transmission in the United. States.
Rough K, Seage IIIGR, Williams PL, et al: Birth outcomes for pregnant women with HIV using tenofovir-emtricitabine, N Engl J Med. 378(17):1593–1602, 2018.
Schomaker M, Leroy V, Wolfs T, et al: Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe, Int J Epidemiol 46(2):453–465, 2017.
Siemieniuk RAC, Lytvyn L, Ming JM, et al: Antiretroviral therapy in pregnant women living with HIV: a clinical practice guideline, BMJ 358:j3961, 2017.
Singh S, Mitsch A, Wu B: HIV care outcomes among men who have sex with men with diagnosed. HIV infection—United. States, MMWR 66(37):969–974, 2017, 2015.
Tobin NH, Aldrovandi GM: Immunology of pediatric HIV infection, Immunol Rev 254:143–169, 2013.
World Health Organization HIV/AIDS Programme: Consolidated. guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, recommendations for a public health approach. 2013
Yarchoan R, Uldrick TS: HIV-associated. cancers and related. diseases, N Engl J Med. 378(11):1029–1040, 2018.
Bangham CR, Araujo A, Yamano Y, Taylor GP: HTLV-1-associated. myelopathy/tropical spastic paraparesis, Nat Rev Dis Primers 1:15012, 2015.
Bangham CR, Ratner L: How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)? Curr Opin Virol 14:93–100, 2015.
Cook LB, Elemans M, Rowan AG, Asquith B: HTLV-1: persistence and pathogenesis, Virology 435(1):131–140, 2013.
de Oliveira Mde F, Fatal PL, Primo JR, et al: Infective dermatitis associated. with human T-cell lymphotropic virus type 1: evaluation of 42 cases observed. in Bahia, Brazil, Clin Infect Dis 54(12):1714–1719, 2012.
Fuzii HT, da Silva Dias GA, de Barros RJ, et al: Immunopathogenesis of HTLV1-assoaciated. myelopathy/tropical spastic paraparesis (HAM/TSP), Life Sci 104(1–2):9–14, 2014.
Hlela C, Bittencourt A: Infective dermatitis associated. with HTLV-1 mimics common eczemas in children and may be a prelude to severe systemic diseases, Dermatol Clin 32(2):237–248, 2014.
Martin JL, Maldonado JO, Mueller JD, et al: Molecular studies of HTLV-1 replication: an update, Viruses 8(2):2016.
Matsuoka M, Yasunaga J: Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor, Curr Opin Virol 3(6):684–691, 2013.
Murphy EL: Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): implications for blood transfusion safety, Transfus Clin Biol 23(1):13–19, 2016.
Percher F, Jeannin P, Martin-Latil S, et al: Mother-to-Child transmission of HTLV-1 epidemiological aspects, mechanisms and determinants of Mother-to-Child transmission, Viruses 8(2):2016.
Asher DM, with AAMI TSE Elimination Working Group (AAMI Tissue Product Safety Committee): Medical devices utilizing animal tissues and their derivatives—Part 4: Principles for elimination and/or inactivation of transmissible spongiform encephalopathy (TSE) agents and validation assays for those processes (ISO Technical Information Report/American National Standards Institute Technical Report). In ANSI/AAMI ISO (Association for the Advancement of Medical Instrumentation), Arlington, VA, pp . 1-10, and i-xi, introduction, 2011.
Belay ED, Schonberger LB, Brown P, et al: Disinfection and sterilization of prioncontaminated. medical instruments, Infect Control Hosp Epidemiol 31:1304–1306, 2010, and author reply, 31:1306-1308, 2010.
Blase J, Cracco L, Schonberger L, et al: Sporadic fatal insomnia in an adolescent, Pediatrics 133(3):e766–e770, 2014.
Botsios S, Manuelidis L: CJD and scrapie require agent-associated. nucleic acids for infection, J Cell Biochem 117(8):1947–1958, 2016.
Coulthart MB, Geschwind MD, Qureshi S, et al: A case cluster of variant CreutzfeldtJakob disease linked. to the Kingdom of Saudi Arabia, Brain 139:2609–2616, 2016.
Crowder LA, Schonberger LB, Dodd RY, Steele WR: Creutzfeldt-Jakob disease lookback study: 21 years of surveillance for transfusion transmission risk, Transfusion 57(8):1875–1878, 2017.
Czub S, et al: Prion, 2017. Edinburgh, Conference Abstracts.
Douet JY, Zafar S, Perret-Liaudet A, et al: Detection of infectivity in blood of persons with variant and sporadic Creutzfeldt-Jakob disease, Emerg Infect Dis 20:114–117, 2014.
Maheshwari A, Fischer M, Gambetti P, et al: Recent US case of variant Creutzfeldt-Jakob disease-global implications, Emerg Infect Dis 21:750–759, 2015.
Occupational Safety and Health Administration, US Department of Labor: Occupational exposure to bloodborne pathogens; final rule: bloodborne pathogens (29 CFR Part 1910.1030), Fed. Regist 56:64175–64182, 1991.
Prusiner SB: Madness and memory. In The discovery of prions: a new biological principle of disease, New Haven and London, 2014, Yale University Press.
Urwin P, Thanigaikumar K, Ironside JW, et al: Sporadic Creutzfeldt-Jakob disease in 2 plasma product recipients, United. Kingdom, Emerg Infect Dis 23:893–897, 2017.
Aichelburg AC, Walochnik J, Assadian O, et al: Successful treatment of disseminated Acanthamoeba sp. infection with miltefosine, Emerg Infect Dis 14:1743–1746, 2008.
Bennett WM, Nespral JF, Rosson MW, et al: Use of organs for transplantation from a donor with primary meningoencephalitis due to Naegleria fowleri, Am J Transplant 8:1334–1335, 2008.
Centers for Disease Control and Prevention (CDC): Balamuthia amebic encephalitis—California, 1999-2007, MMWR Morb Mortal Wkly Rep 57:768–771, 2008.
Centers for Disease Control and Prevention (CDC): Investigational drug therapy directly from CDC for the treatment of infections with free-living amebae, MMWR Morb Mortal Wkly Rep 62:666, 2013.
Centers for Disease Control and Prevention (CDC): Notes from the field: primary amebic meningoencephalitis associated with ritual nasal rinsing—St. Thomas, U.S. Virgin Islands, 2012, MMWR Morb Mortal Wkly Rep 62:903, 2013.
Centers for Disease Control and Prevention (CDC): Primary amebic meningoencephalitis— Arizona, Florida, and Texas, 2007, MMWR Morb Mortal Wkly Rep 57:573–577, 2008.
Cope JR, Ratard RC, Hill VR, et al: The first association of a primary amebic meningoencephalitis death with culturable Naegleria fowleri in tap water from a US treated public drinking water system, Clin Infect Dis 60:e36–e42, 2015.
Debnath A, Tunac JB, Galindo-Gomez S, et al: Corifungin, a new drug lead against Naegleria, identified from a high-throughput screen, Antimicrob Agents Chemother 56:5450–5457, 2012.
Deetz TR, Sawyer MH, Billman G, et al: Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases, Clin Infect Dis 37:1304–1312, 2003.
Gelman BB, Popov V, Chaljub G, et al: Neuropathological and ultrastructural features of amebic encephalitis caused by Sappinia diploidea, J Neuropathol Exp Neurol 62:990–998, 2003.
Johnson RO, Cope JR, Moskowitz M, et al: Primary amebic meningoencephalitis associated with exposure to swimming pool water supplied by an overland pipe—Inyo County, California, 2015, MMWR Morb Mortal Wkly Rep 65(16):424, 2016.
Linam WM, Ahmed M, Cope JR, et al: Successful treatment of an adolescent with Naegleris fowleri primary amebic meningoencephalitis, Pediatrics 135(3):e744–e748, 2015.
Martinez DY, Seas C, Bravo F, et al: Successful treatment of Balamuthia mandrillaris amoebic infection with extensive neurological and cutaneous involvement, Clin Infect Dis 51:e7–e11, 2010.
Radford CF, Minassian DC, Dart J: Acanthamoeba keratitis in England and Wales: incidence, outcome, and risk factors, Br J Ophthalmol 86:536–542, 2002.
Schuster FL, Visvesvara GS: Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals, Int J Parasitol 34:1001–1027, 2004.
Schuster FL, Visvesvara GS: Opportunistic amoebae: challenges in prophylaxis and treatment, Drug Resist Updat 7:41–51, 2004.
Vargas-Zepeda J, Gomez-Alcala AV, Vasquez-Morales JA, et al: Successful treatment of Naegleria fowleri meningoencephalitis by using intravenous amphotericin B, fluconazole and rifampicin, Arch Med Res 36:83–86, 2005.
Yoder JS, Straif-Bourgeois S, Roy SL, et al: Primary amebic meningoencephalitis deaths associated with sinus irrigation using contaminated tap water, Clin Infect Dis 55:e79–e85, 2012.
Andrade RM, Reed. SL: New drug target in protozoan parasites: the role of thioredoxin reductase, Front Microbiol 6:975, 2015.
Gilchrist CA, Petri SE, Schneider BN, et al: Role of the gut microbiota of children in diarrhea due to the protozoan parasite Entamoeba histolytica, J Infect Dis 213:1579–1585, 2016.
Kato K, Yahata K, Gopal Dhoubhadel B, et al: Novel hemagglutinating, hemolytic and cytotoxic activities of the intermediate subunit of Entamoeba histolytica lectin, Sci Rep 5:13901, 2015.
Lopez MC, Leon CM, Fonseca J, et al: Molecular epidemiology of Entamoeba: first description of Entamoeba moshkovskii in a rural area from central Colombia, PLoS ONE 10:2015. e0140302.
Min X, Feng M, Guan Y, et al: Evaluation of the C-terminal fragment of Entamoeba histolytica Gal/GalNAc lectin intermediate subunit as a vaccine candidate against amebic liver abscess, PLoS Negl Trop Dis 10:e0004419, 2016.
Torgerson PR, Devleesschauwer B, Praet N, et al: World Health Organization estimates of the global and regional disease burden of 11 foodborne parasitic diseases, 2010: a data synthesis, PLoS Med. 12:e1001920, 2015.
Watanabe K, Petri WA Jr: Molecular biology research to benefit patients with Entamoeba histolytica infection, Mol Microbiol 98(2):208–217, 2015.
Berkman DS, Lescano AG, Gilman RH, et al: Effects of stunting, diarrhoeal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study, Lancet 359:564–571, 2002.
Drugs for parasitic infections, ed. 3, New Rochelle, NY, 2013, The Medical Letter, Inc. Fuglestad AJ, Lehmann AE, Kroupina MG, et al: Iron deficiency in international adoptees from Eastern Europe, J Pediatr 153:272–277, 2008.
Escobedo AA, Ballesteros J, Gonz?lez-Fraile E, Almirall P: A meta-analysis of the efficacy of albendazole compared. with tinidazole as treatments for Giardia infections in children, Acta Trop 153:120–127, 2016.
Escobedo AA, Lalle M, Hrastnik NI, et al: Combination therapy in the management of giardiasis: what laboratory and clinical studies tell us, so far, Acta Trop 162:196–205, 2016.
Escobedo AA, Hanevik K, Almirall P, et al: Management of chronic Giardia infection, Expert Rev Anti Infect Ther 12:1143–1157, 2014.
Granados CE, Reveiz L, Uribe LG, et al: Drugs for treating giardiasis, Cochrane Database Syst Rev (12):CD007787, 2012.
Halliez MC, Buret AG: Extra-intestinal and long term consequences of Giardia duodenalis infections, World J Gastroenterol 19:8974–8985, 2013.
Mank TG, Zaat JO, Deelder AM, et al: Sensitivity of microscopy versus enzyme immunoassay in the laboratory diagnosis of giardiasis, Eur J Clin Microbiol Infect Dis 16:615–619, 1997.
Aten Hove RJ, van Esbroeck M, Vervoort T, et al: Molecular diagnostics of intestinal parasites in returning travellers, Eur J Clin Microbiol Infect Dis 28:1045–1053, 2009.
Roberts DM, Craft JC, Mather FJ, et al: Prevalence of giardiasis in patients with cystic fibrosis, J Pediatr 112(4):555–559, 1988.
Dhawan S, Jain D, Mehta VS: Balantidium coli: an unrecognized. cause of vertebral osteomyelitis and myelopathy, J Neurosurg Spine 18:310–313, 2013.
Schuster FL, Ramirez-Avila L: Current world status of Balantidium coli, Clin Microbiol Rev 21:626–638, 2008.
Vasilakopoulou A, Dimarongona K, Samakovli A, et al: Balantidium coli pneumonia in an immunocompromised. patient, Scand J Infect Dis 35:144–146, 2003.
Abubakar I, Aliyu SH, Arumugam C, et al: Prevention and treatment of cryptosporidiosis in immunocompromised. patients, Cochrane Database Syst Rev (1):CD004932, 2007.
Barry MA, Weatherhead JE, Hotez PJ, et al: Childhood parasitic infections endemic to the United. States, Pediatr Clin North Am 60:471–485, 2013.
Cabada MM, White AC Jr: Treatment of cryptosporidiosis: do we know what we think we know? Curr Opin Infect Dis 23:494–499, 2010.
Cama VA, Ross JM, Crawford S, et al: Differences in clinical manifestations among Cryptosporidium species and subtypes in HIV-infected. persons, J Infect Dis 196:684–691, 2007.
Chen X-M, Keithly JS, Paya CV, et al: Cryptosporidiosis, N Engl J Med. 346:1723–1731, 2002.
Fletcher SM, Stark D, Harkness J, et al: Enteric protozoa in the developed. world: a public health perspective, Clin Microbiol Rev 25:420–449, 2012.
Hlavsa MC, Roellig DM, Seabolt MH, et al: Using molecular characterization to support investigations of aquatic facility-associated. outbreaks of cryptosporidiosis—Alabama, Arizona, ad Ohio, 2016, MMWR Morb Mortal Wkly Rep 66(19):493–497, 2017.
Huang DB, White AC: An updated. review on Cryptosporidium and Giardia, Gastroenterol Clin North Am 35:291–314, 2006.
Ortega YR, Sanchez R: Update on Cyclospora cayetanensis, a food-borne and waterborne parasite, Clin Microbiol Rev 23:218–234, 2010.
Pierce KK, Kirkpatrick BD: Update on human infections caused. by intestinal protozoa, Curr Opin Gastroenterol 25:12–17, 2008.
Rosenthal M, Pedersen R, Leibsle S, et al: Cryptosporidiosis associated. with consumption of unpasteurized. goat milk—Idaho, MMWR Morb Mortal Wkly Rep 64(7):194–2015, 2014.
Rossignol JF: Cryptosporidium and Giardia: treatment options and prospects for new drugs, Exp Parasitol 124:45–53, 2010.
Su C, Stover DT, Buss BE, et al: Occupational animal exposure among persons with campylobacteriosis and cryptosporidiosis—Nebraska, 2005-2015, MMWR Morb Mortal Wkly Rep 66(36):955–958, 2017.
Verdier RI, Fitzgerald DW, et al: Trimethoprim-sulfamethoxazole compared. with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected. patients. A randomized, controlled. trial, Ann Intern Med. 132:885–888, 2000.
Yoder JS, Beach MJ: Cryptosporidium surveillance and risk factors in the United. States, Exp Parasitol 124:31–39, 2010.
Figueroa-Angulo EE, Calla-Choque JS, Mancilla-Olea MI, et al: RNA-binding proteins in Trichomonas vaginalis: atypical multifunctional proteins, Biomolecules 26:3354–3395, 2015.
Leitsch D: Recent advances in the Trichomonas vaginalis field, F1000Res 11:F1000 Faculty Rev-162, 2016.
Meites E, Gaydos CA, Hobbs MM: A review of evidence-based. care of symptomatic trichomoniasis and asymptomatic Trichomonas vaginalis infections, Clin Infect Dis 15:S837–S848, 2015.
Menezes CB, Tasca T: Trichomoniasis immunity and the involvement of the purinergic signaling, Biomed. J 39:234–243, 2016.
Satterwhite CL, Torrone E, Meites E: Sexually transmitted. infections among US women and men: prevalence and incidence estimates, 2008, Sex Transm Dis 40:187–193, 2013.
Tsevat DG, Wiesenfeld HC, Parks C, et al: Sexually transmitted. diseases and infertility, Am J Obstet Gynecol 216:1–9, 2017.
Alvar J, Velez ID, Bern C, et al: Leishmaniasis worldwide and global estimates of its incidence, PLoS ONE 7:e35671, 2012.
Aronson N, Herwaldt BL, Libman M, et al: Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH), Am J Trop Med. Hyg 96(1):24–45, 2017.
Ben Salah A, Ben Messaoud N, Guedri E, et al: Topical paromomycin with or without gentamicin for cutaneous leishmaniasis, N Engl J Med. 368:524–532, 2013.
Du R, Hotez PJ, Al-Salem WS, Acosta-Serrano A: Old World cutaneous leishmaniasis and refugee crises in the Middle East and North Africa, PLoS Negl Trop Dis 10(5):e0004545, 2016.
Khalil EA, Weldegebreal T, Younis BM, et al: Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised. trial, PLoS Negl Trop Dis 8(1):e2613, 2014.
Machado PR, Rosa ME, Guimar?es LH, et al: Treatment of disseminated. leishmaniasis with liposomal amphotericin B, Clin Infect Dis 61(6):945–949, 2015.
Picado A, Ostyn B, Singh SP, et al: Risk factors for visceral leishmaniasis and asymptomatic Leishmania donovani infection in India and Nepal, PLoS ONE 9(1):e87641, 2014.
Scott P, Novais FO: Cutaneous leishmaniasis: immune responses in protection and pathogenesis, Nat Rev Immunol 16(9):581–592, 2016.
Singh OP, Hasker E, Boelaert M, et al: Elimination of visceral leishmaniasis on the Indian subcontinent, Lancet Infect Dis 16(12):e304–e309, 2016.
Sundar S, Singh A: Recent developments and future prospects in the treatment of visceral leishmaniasis, Ther Adv Infect Dis 3(3/4):98–109, 2016.
Wasunna M, Njenga S, Balasegaram M, et al: Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: phase ii randomized. trial, PLoS Negl Trop Dis 10(9):e0004880, 2016.
Bonnet J, Boudot C: Courtioux B: overview of the diagnostic methods used. in the field for human African trypanosomiasis: what could change in the next years?, Biomed. Res Int 2015:583262, 2015.
Chappuis F: Oral fexinidazole for human African trypanosomiasis, Lancet 391:100–102, 2018.
Franco JR, Simarro PP, Diarra A, Jannin JG: Epidemiology of human African trypanosomiasis, Clin Epidemiol 6:257–275, 2014.
Gilbert JA, Medlock J, Townsend JP, et al: Determinants of human African trypanosomiasis elimination via paratransgenesis, PLoS Negl Trop Dis 10:e0004465, 2016.
Hamill L, Picozzi K, Fyfe J, et al: Evaluating the impact of targeting livestock for the prevention of human and animal trypanosomiasis, at village level, in districts newly affected. with T. b. rhodesiense in Uganda, Infect Dis Poverty 6:16, 2017.
Ponte-Sucre A: An overview of Trypanosoma brucei infections: an intense host-parasite interaction, Front Microbiol 7:2126, 2016.
Stijlemans B, Caljon G, Van Den Abbeele J, et al: Immune evasion strategies of Trypanosoma brucei within the mammalian host: progression to pathogenicity, Front Immunol 24:233, 2016.
Vincent IM, Daly R, Courtioux B, et al: Metabolomics identifies multiple candidate biomarkers to diagnose and stage human African trypanosomiasis, PLoS Negl Trop Dis 10:e0005140, 2016.
Borges BC, Uehara IA, Dias LO, et al: Mechanisms of infectivity and evasion derived. from microvesicles cargo produced. by Trypanosoma cruzi, Front Cell Infect Microbiol 6:161, 2016.
Brum-Soares L, Cubides JC, Burgos I, et al: High seroconversion rates in Trypanosoma cruzi chronic infection treated. with benznidazole in people under 16 years in Guatemala, Rev Soc Bras Med. Trop 49:721–727, 2016.
De Oliveira AP, Ayo CM, Bestetti RB, et al: The role of CCR5 in Chagas disease: a systematic review, Infect Genet Evol 45:132–137, 2016.
Garcia MN, Burroughs H, Gorchakov R, et al: Molecular identification and genotyping of Trypanosoma cruzi DNA in autochthonous Chagas disease patients from Texas, USA, Infect Genet Evol 49:151–156, 2017.
Lewis MD, Kelly JM: Putting infection dynamics at the heart of Chagas disease, Trends Parasitol 32:899–911, 2016.
Manne-Goehler J: Chagas disease in the United. States: out of the shadows, Clin Infect Dis 64(9):1189–1190, 2017.
Paucar R, Moreno-Viguri E, P?rez-Silanes S: Challenges in Chagas disease drug discovery: a review, Curr Med. Chem 23:3154–3170, 2016.
Trochine A, Creek DJ, Faral-Tello P, et al: Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed. by metabolomics, PLoS Negl Trop Dis 8:e2844, 2014.
Ashley EA, Dhorda M, Fairhurst RM, et al: Spread of artemisinin resistance in Plasmodium falciparum malaria, N Engl J Med. 371:411–422, 2014.
Bangirana P, Opoka RO, Boivin MJ, et al: Severe malarial anemia is associated. with long-term neurocognitive impairment, Clin Infect Dis 59(3):336–344, 2014.
Cullen KA, Mace KE, Arguin PM: Centers for Disease Control and Prevention: malaria surveillance—United. States, 2013, MMWR Surveill Summ 65(2):1–22, 2016.
Dondorp AM, Fanello CI, Hendriksen IC, et al: Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised. trial, Lancet 376(9753):1647–1657, 2010.
Mordmuller B, Surat G, Lagler H, et al: Sterile protection against human malaria by chemoattenuated. PfSPZ vaccine, Nature 542(7642):445–449, 2017.
Olotu A, Fegan G, Wambua J, et al: Seven-year efficacy of RTS,S/AS01 malaria vaccine among young African children, N Engl J Med. 374(26):2519–2529, 2016.
Protopopoff N, Mosha JF, Lukole E, et al: Effectiveness of a long-lasting piperonyl butoxide–treated. insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted. by pyrethroid-resistant mosquitoes: a cluster, randomized. controlled, two-by-two factorial design trial, Lancet 391:1577–1588, 2018.
Schwartz KR, Vinci R: Imported. pediatric malaria presenting to an urban pediatric emergency department: a case series, Pediatr Emerg Care 28(12):1385–1388, 2012.
Seydel KB, Kampondeni SD, Valim C, et al: Brain swelling and death in children with cerebral malaria, N Engl J Med. 372(12):1126–1136, 2015.
Tiono AB, Ouedraogo A, Ouattara D, et al: Efficacy of Olyset Duo, a bednet containing pyripoxyfen and permethrin, versus a permethrin-only net against clinical malaria in an area with highly pyrethroid-resistant vectors in rural Burkina Faso: a cluster-randomised. controlled. trial, Lancet 392:569–580, 2018.
Von Seidlein L, Olaosebikan R, Hendriksen IC, et al: Predicting the clinical outcome of severe falciparum malaria in African children: findings from a large randomized. trial, Clin Infect Dis 54(8):1080–1090, 2012.
White NJ, Pukrittayakamee S, Hien TT, et al: Malaria, Lancet 383:723–732, 2014.
World Health Organization: Management of severe malaria: a practical handbook, Geneva, 2012, WHO.
Centers for Disease Control and Prevention: Babesiosis surveillance—18 states, 2011, MMWR Morb Mortal Wkly Rep 61:505–509, 2012.
Fox L, Wingerter S, Ahmed. A, et al: Neonatal babesiosis: case report and review of the literature, Pediatr Infect Dis J 25:169–173, 2006.
Hatcher JC, Greenberg PD, Antique J, et al: Severe babesiosis in Long Island: review of 34 cases and their complications, Clin Infect Dis 32:1117–1125, 2001.
Herwaldt BL, Linden JV, Bosserman E, et al: Transfusion-associated. babesiosis in the United. States: a description of cases, Ann Intern Med. 155:509–519, 2011.
Kletsova EA, Spitzer ED, Fries BC, Marcos LA: Babesiosis in Long Island: review of 62 cases focusing on treatment with azithromycin and atovaquone, Ann Clin Microbiol Antimicrob 16:26, 2017.
Krause PJ, Gewurz BE, Hill D, et al: Persistent and relapsing babesiosis in immunocompromised. patients, Clin Infect Dis 46:370–376, 2008.
Krause PJ, Lepore T, Sikand VK, et al: Atovaquone and azithromycin for the treatment of babesiosis, N Engl J Med. 343:1454–1458, 2000.
Krause PJ, Telford SR III, Pollack RJ, et al: Babesiosis: an underdiagnosed. disease of children, Pediatrics 89:1045–1048, 1992.
Moritz ED, Winton CS, Tonnetti L, et al: Screening for Babesia microti in the U.S. blood supply, N Engl J Med. 375(23):2236–2245, 2016.
Stein E, Elbadawi LI, Kazmierczak J, Davis JP: Babesiosis surveillance—Wisconsin, 2001–2015, MMWR Morb Mortal Wkly Rep 66(26):687–690, 2017.
Vannier E, Krause PJ: Human babesiosis, N Engl J Med. 366:2397–2407, 2012.
Arun V, Noble AG, Latkany P, et al; Toxoplasmosis Study Group: Cataracts in congenital toxoplasmosis, J AAPOS 11:551–554, 2007.
Begeman IJ, Lykins J, Zhou Y, et al: Point-of-care testing for Toxoplasma gondii IgG/IgM using Toxoplasma ICT IgG-IgM test with sera from the United. States and implications for developing countries, PLoS Negl Trop Dis 11(6):e0005670, 2017.
Benevento JD, Jager RD, Noble AG, et al; Toxoplasmosis Study Group: Toxoplasmosisassociated. neovascular lesions treated. successfully with ranibizumab and antiparasitic therapy, Arch Ophthalmol 126:1152–1156, 2008.
Berrebi A, Bardou M, Bessieres MH, et al: Outcome for children infected. with congenital toxoplasmosis in the first trimester and with normal ultrasound findings: a study of 36 cases, Eur J Obstet Gynecol Reprod Biol 135:53–57, 2007.
Boyer K, Hill D, Mui E, et al; Toxoplasmosis Study Group: Unrecognized. ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America, Clin Infect Dis 53:1081–1089, 2011.
Caselli D, Andreoli E, Paolicchi O, et al: Acute encephalopathy in the immunecompromised. child: never forget toxoplasmosis, J Pediatr Hematol Oncol 34:383–386, 2012.
Chapey E, Wallon M, Peyron F: Evaluation of the LDBIO point of care test for the combined. detection of toxoplasmic IgG and IgM, Clin Chim Acta 464:200–201, 2017.
Contopoulos-Ioannidis D, Wheeler KM, Ramirez R, et al: Clustering of Toxoplasma gondii infections within families of congenitally infected. infants, Clin Infect Dis 61:1815–1824, 2015.
Cortina-Borja M, Tan HK, Wallon M, European Multicentre Study on Congenital Toxoplasmosis, et al: Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study, PLoS Med. 7(10):2010.
Dard C, Fricker-Hidalgo H, Brenier-Pinchart MP, Pelloux H: Relevance of and new developments in serology for toxoplasmosis, Trends Parasitol 32(6):492–506, 2016.
Delair E, Latkany P, Noble AG, et al: Clinical manifestations of ocular toxoplasmosis, Ocul Immunol Inflamm 19:91–102, 2011.
Demar M, Hommel D, Djossou F, et al: Acute toxoplasmoses in immunocompetent patients hospitalized. in an intensive care unit in French Guiana, Clin Microbiol Infect 18:E221–E231, 2012.
Dos Santos TR, Nunes CM, Luvizotto MC, et al: Detection of Toxoplasma gondii oocysts in environmental samples from public schools, Vet Parasitol 171:53–57, 2010.
Dubey JP: Schizogony and gametogony of oocsyst-deficient T-263 strain of Toxoplasma gondii, Vet Parasitol 245:160–162, 2017.
Dubey JP, Lago EG, Gennari SM, et al: Toxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiology, Parasitology 139:1375–1424, 2012.
El Bissati K, Chentoufi AA, Krishack PA, et al: Adjuvanted. multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii, JCI Insight 1(15):e85955, 2016.
El Bissati K, Zhou Y, Paulillo SM, et al: Protein nanovaccine confers robust immunity against Toxoplasma, npj Vaccines Sept 2017.
Elbez-Rubinstein A, Ajzenberg D, Darde ML, et al: Congenital toxoplasmosis and reinfection during pregnancy: case report, strain characterization, experimental model of reinfection, and review, J Infect Dis 199:280–285, 2009.
Felix JP, Lira RP, Zacchia RS, et al: Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of Toxoplasma gondii retinochoroiditis: randomized. controlled. clinical trial, Am J Ophthalmol 157(4):762–766, e1, 2014.
Ferguson DJ, Bowker C, Jeffery KJ, et al: Congenital toxoplasmosis: continued. parasite roliferation in the fetal brain despite maternal immunological control in other tissues, Clin Infect Dis 56(2):204–208, 2013.
Foulon W, Villena I, Stray-Pedersen B, et al; European multicentre study on congenital toxoplasmosis: ocular sequelae of congenital toxoplasmosis in Brazil compared. with Europe, PLoSNegl Trop Dis 2(8):e277, 2008.
Hill D, Coss C, Dubey JP, et al: Identification of a sporozoite-specific antigen from Toxoplasma gondii, J Parasitol 97:328–337, 2011.
Hotop A, Hlobil H, Gross U: Efficacy of rapid treatment initiation following primary Toxoplasma gondii infection during pregnancy, Clin Infect Dis 54(11):1545–1552, 2012.
Hutson SL, Wheeler KM, McLone D, et al: Patterns of hydrocephalus caused. by congenital Toxoplasma gondii infection associated. with parasite genetics, Clin Infect Dis 61:1831–1834, 2015.
Jamieson SE, de Roubaix LA, Cortina-Borja M, et al: Genetic and epigenetic factors at COL2a1 and ABCA4 influence clinical outcome in congenital toxoplasmosis, PLoS ONE 3(6):e2285, 2008.
Kieffer F, Wallon M, Garcia P, et al: Risk factors for retinochoroiditis during the first 2 years of life in infants with treated. congenital toxoplasmosis, Pediatr Infect Dis J 27:27–32, 2008.
Li X, Pomares C, Gonfrier G, et al: Multiplexed. anti-Toxoplasma IgG, IgM, and IgA assay on plasmonic gold chips: towards making mass screening possible with dye test precision, J Clin Microbiol 54:1726–1733, 2016.
Lorenzi H, Khan A, Behnke MS, et al: Local admixture of amplified. and diversified. secreted. pathogenesis determinants shapes mosaic Toxoplasma gondii genomes, Nat Commun 7:10147, 2016.
Lykins J, Wang K, Wheeler K, et al: Understanding toxoplasmosis in the United. States through “Large Data” analyses, Clin Infect Dis 63:468–475, 2016.
Lykins JD, Filippova EV, Halavaty AS, et al: CSGID solves structures and identifies phenotypes for five Enzymes in Toxoplasma gondii, Front Cell Infect Microbiol 8:352, 2018.
Lykins J, Li X, Levigne P, et al: Rapid, inexpensive, fingerstick, whole-blood, sensitive, specific, point-of-care test for anti-Toxoplasma antibodies, PLoS Negl Trop Dis 12(8), 2018.
Maldonado YA, Read JS: Diagnosis, treatment, and prevention of congenital toxoplasmosis in the United. States, Pediatrics 139(2):e20163860, 2017.
Mandelbrot L, Kieffer F, Sitta R, et al: Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized. trial, Am J Obstet Gynecol 219(4):386, 2018.
McLeod R, Boyer K, Karrison T, et al; Toxoplasmosis Study Group: Outcome of treatment for congenital toxoplasmosis, 1981–2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study, Clin Infect Dis 42:1383–1394, 2006.
McLeod R, Boyer KM, Lee D, et al; Toxoplasmosis Study Group: Prematurity and severity are associated. with Toxoplasma gondii alleles (NCCCTS, 1981–2009), Clin Infect Dis 54:1595–1605, 2012.
McLeod R, Kieffer F, Sautter M, et al: Why prevent, diagnose and treat congenital toxoplasmosis?, Mem Inst Oswaldo Cruz 104(2):320–344, 2009.
McLeod R, Wheeler KM, Boyer K: Reply to Wallon and Peyron, Clin Infect Dis 62:812–814, 2016.
McPhillie M, Zhou Y, El Bissati K, et al: New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections, Sci Rep 6:29179, 2016.
Nge HM, Zhou Y, Lorenzi H, et al: Toxoplasma modulates signature pathways of human epilepsy, neurodegeneration, and, cancer, Sci Rep 7(1):11496, 2017.
Olariu TR, Remington JS, McLeod R, et al: Severe congenital toxoplasmosis in the United. States: clinical and serologic findings in untreated. infants, Pediatr Infect Dis J 30:1056–1061, 2011.
Peyron F, Garweg JG, Wallon M, et al: Long-term impact of treated. congenital toxoplasmosis on quality of life and visual performance, Pediatr Infect Dis J 30:597–600, 2011.
Peyron F, McLeod R, Ajzenberg D, et al: Congenital toxoplasmosis in France and the United. States: one parasite, two diverging approaches, PLoS Negl Trop Dis 11:e0005222, 2017.
Peyron F, Wallon M, Kieffer F, Garweg J: Toxoplasmosis. In Wilson CB, Nizet V, Maldonado YA, et al, editors: Remington and Klein’s infectious diseases of the fetus and newborn infant, ed. 8, Philadelphia, 2016, Saunders Elsevier, pp . 949–1042.
Phan L, Kasza K, Jalbrzikowski J, et al; Toxoplasmosis Study Group: Longitudinal study of new eye lesions in treated. congenital toxoplasmosis, Ophthalmology 115:553–559, e8, 2008.
Phan L, Kasza K, Jalbrzikowski J, et al; Toxoplasmosis Study Group: Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated. during the first year of life, Am J Ophthalmol 146:375–384, 2008.
Pomares C, Zhang B, Arulkumar S, et al: Validation of IgG, IgM multiplex plasmonic gold platform in French clinical cohorts for the serodiagnosis and follow-up of Toxoplasma gondii infection, Diagn Microbiol Infect Dis 87:213–218, 2017.
Prusa AR, Kasper DC, Sawers L, et al: Congenital toxoplasmosis in Austria: prenatal screening for prevention is cost-saving, PLoS Negl Trop Dis 11(7):e0005648, 2017.
Remington JS, McLeod R, Wilson CB, et al: Infectious diseases of the fetus and newborn, ed. 7, Philadelphia, 2011, Saunders Elsevier, pp . 918–1041.
Roizen N, Kasza K, Karrison T, et al: Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies, Pediatrics 118:e379–e390, 2006.
Siberry GK, Abzug MJ, Nachman S, et al: Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed. and HIV-infected. children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics, Pediatr Infect Dis J 32(Suppl 2):i-KK4, 2013.
Sidik SM, Huet D, Ganesan SM, et al: A genome-wide CRISPR screen in Toxoplasma identifies essential apicomplexan genes, Cell 166(6):1423–1435, 2016.
Stillwaggon E, Carrier CS, Sautter M, McLeod R: Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model, PLoS Negl Trop Dis 5(9):e1333, 2011.
Vasconcelos-Santos DV, Machado Azevedo DO, Campos WR, et al: Congenital toxoplasmosis in southeastern Brazil: results of early ophthalmologic examination of a large cohort of neonates, Ophthalmology 116:2199–2205, e1, 2009.
Vidadala RS, Rivas KL, Ojo KK, et al: Development of an orally available and central nervous system (CNS) penetrant Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitor with minimal human ether-a-go-go-related. gene (hERG) activity for the treatment of toxoplasmosis, J Med. Chem 59:6531–6546, 2016.
Wallon M, Franck J, Thulliez P, et al: Accuracy of real-time polymerase chain reaction for Toxoplasma gondii in amniotic fluid, Obstet Gynecol 115:727–733, 2010.
Wallon M, Peyron F, Cornu C, et al: Congenital Toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years, Clin Infect Dis 56(9):1223–1231, 2013.
Zhang NZ, Chen J, Wang M, et al: Vaccines against Toxoplasma gondii: new developments and perspectives, Expert Rev Vaccines 12:1287–1299, 2013.
Bieri FA, Gray DJ, Williams GM, et al: Health-education package to prevent worm infections in Chinese schoolchildren, N Engl J Med. 368:1603–1612, 2015.
Clarke NE, Clements ACA, Doi SA, et al: Differential effect of mass deworming and targeted. deworming for soil-transmitted. helminth control in children: a systematic review and meta-analysis, Lancet 389:287–297, 2017.
Jia TW, Melville S, Utzinger J, et al: Soil-transmitted. helminth reinfection after drug treatment: a systematic review and meta-analysis, PLoS Negl Trop Dis 6:e1621, 2012.
Khuroo MS, Rather AA, Khuroo NS, Khuroo MS: Hepatobiliary and pancreatic ascariasis, World J Gastroenterol 22:7507–7517, 2016.
The Medical Letter: Drugs for parasitic infections, Med. Lett Drugs Ther 11(Suppl):e1–e31, 2013.
Miller LA, Colby K, Manning SE, et al: Ascariasis in humans and pigs on small-scale farms, Maine, USA, 2010–2013, Emerg Infect Dis 21:332–334, 2015.
Papier K, Williams GM, Luceres-Catubig R, et al: Childhood malnutrition and parasitic helminth interactions, Clin Infect Dis 5:234–243, 2014.
Awasthi S, Peto R, Read S, et al: Population deworming every 6 months with albendazole in 1 million pre-school children in north India: DEVTA, a cluster-randomised. trial, Lancet 381:1478–1486, 2013.
Bartsch SM, Hotez PJ, Asti L, et al: The global economic and health burden of human hookworm infection, PLoS Negl Trop Dis 10(9):e0004922, 2016.
Budhatohoki S, Shah D, Bhurtyal KK, et al: Hookworm causing melaena and severe anaemia in early infancy, Ann Trop Paediatr 28:293–296, 2008.
Global Burden of Disease Study: Disease and Injury Incidence and Prevalence Collaborators: Global, regional, and national incidence, prevalence, and years lived. with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015, Lancet 388:1545–1602, 2016.
Hotez PJ, Brooker S, Bethony JM, et al: Hookworm infection, N Engl J Med. 351:799–807, 2004.
Hotez PJ, Strych U, Lustigman S, Bottazzi ME: Human anthelminthic vaccines: rationale and challenges, Vaccine 34(30):3549–3555, 2016.
Keiser J, Utzinger J: Efficacy of current drugs against soil-transmitted. helminth infections: systematic review and meta-analysis, JAMA 299:1937–1948, 2008.
Koukounari A, Hollingsworth TD: A strengthening evidence-base for mass deworming, but questions remain, Lancet 389:231–233, 2017.
Navarro S, Pickering DA, Ferreira IB, et al: Hookworm recombinant protein promotes regulatory T cell responses that suppress experimental asthma, Sci Transl Med. 8(362):362ra143, 2016.
Smith JL, Brooker S: Impact of hookworm infection and deworming on anaemia in non-pregnant populations: a systematic review, Trop Med. Int Health 15:776–795, 2010.
Bowman DD, Montgomery SP, Zajac AM, et al: Hookworms of dogs and cats as agents of cutaneous larva migrans, Trends Parasitol 26:162–167, 2010.
Speich B, Ali SM, Ame SM, et al: Efficacy and safety of albendazole plus ivermectin, albendazole plus mebendazole, albendazole plus oxantel pamoate, and mebendazole alone against Trichuris trichiura and concomitant soil-transmitted. helminth infections: a four-arm, randomised. controlled. trial, Lancet Infect Dis 15:277–284, 2015.
Weatherhead JE, Hotez PJ: Worm infections in children, Pediatr Rev 36:341–352, 2015.
The Medical Letter: Drugs for parasitic infections, Med. Lett Drugs Ther 11(Suppl):e1–e31, 2013.
Weatherhead JE, Hotez PJ: Worm infections in children, Pediatr Rev 36:341–352, 2015.
Beknazarova M, Whiley H, Ross K: Advocating for both environmental and clinical approaches to control human strongyloidiasis, Pathogens 5:59, 2016.
Beknazarova M, Whiley H, Ross K: Strongyloidiasis: a disease of socioeconomic disadvantage, Int J Environ Res Public Health 13:517, 2016.
Centers for Disease Control and Prevention: Notes from the field. Strongyloidiasis in a rural setting—southeastern Kentucky, 2013, MMWR Morb Mortal Wkly Rep 62(42):843, 2013.
Centers for Disease Control and Prevention: Transmission of Strongyloides stercoralis through transplantation of solid organs—Pennsylvania, 2012, MMWR Morb Mortal Wkly Rep 62:264–266, 2013.
Croker C, She R: Increase in reports of Stronglyloides infection—Los Angeles, County, 2013–2014, MMWR Morb Mortal Wkly Rep 64(33):922, 2015.
Jones JM, Hill C, Briggs G, et al: Strongyloidiasis at a long-term care facility for the developmentally disabled—Arizona, 2015, MMWR Morb Mortal Wkly Rep 65(23):608–609, 2016.
The Medical Letter: Drugs for parasitic infections, Med. Lett Drugs Ther 11(Suppl): e1–e31, 2013.
Mejia R, Nutman TB: Screening, prevention, and treatment for hyperinfection syndrome and disseminated. infections caused. by Strongyloides stercoralis, Curr Opin Infect Dis 25:458–463, 2012.
Elimination of lymphatic filariasis, Wkly Epidemiol Rec 77:177–179, 2002.
Koroma JB, Sesay S, Sonnie M, et al: Impact of three rounds of mass drug administration on lymphatic filariasis in areas previously treated. for onchocerciasis in Sierra Leone, PLoS Negl Trop Dis 7:e2273, 2013.
Rebollo MP, Bockarie MJ: Can lymphatic filariasis be eliminated. by 2020?, Trends Parasitol 33:83–92, 2017.
Weil GJ, Curtis KC, Fakoli L, et al: Laboratory and field evaluation of a new rapid test for detecting Wuchereria bancrofti antigen in human blood, Am J Trop Med. Hyg 89:11–15, 2013.
Edge C, Waight P, Ribeiro S, et al: Clinical diagnoses and outcomes of 4619 hospitalised cases of laboratory-confirmed. invasive meningococcal disease in England: linkage analysis of multiple national databases, J Infect 73:427–436, 2016.
MacNeil J.R., Rubin L, McNamara L, et al: Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC: use of MenACWY-CRM vaccine in children aged. 2 through 23 months at increased. risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013, MMWR Morb Mortal Wkly Rep 63:527–530, 2014.
MacNeil J.R., Rubin L, Patton M, et al: Recommendations for use of meningococcal conjugate vaccines—HIV infected. persons—Advisory Committee on Immunization Practices, MMWR Morb Mortal Wkly Rep 65(4):1189–1194, 2016.
The Medical Letter: Meningococcal vaccine for infants, Med. Lett Drugs Ther 55:92, 2013.
The Medical Letter: Prevention of meningococcal B disease, Med. Lett Drugs Ther 55:97, 2013.
Moore AE, MacNeil J.R., Wang X, et al: Emergence of localized. serogroup W meningococcal disease in the United. States—Gerogia, 2006–2016, MMWR Morb Mortal Wkly Rep 67(32):894–897, 2018.
Nanduri S, Foo C, Ngo V, et al: Outbreak of serogroup C meningococcal disease primarily affecting men who have sex with men—Southern California, 2016, MMWR Morb Mortal Wkly Rep 65(35):939–940, 2016.
Nnadi C, Oladejo J, Yennan S, et al: Large outbreak of Neisseria meningitidis serogroup C—Nigeria, December 2016–June 2017, MMWR Morb Mortal Wkly Rep 66(49):1352–1356, 2017.
Ostergaard L, Vesikari T, Absalon J, et al: A bivalent meningococcal B vaccine in adolescents and young adults, N Engl J Med. 377(24):2349–2362, 2017.
Parikh SR, Andrews NJ, Beebeejaun K, et al: Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study, Lancet 388:2775–2782, 2016.
Patton ME, Stephens D, Moore K, MacNeil J.R.: Updated. recommendations for use of MenB-FHbp serogroup B meningococcal vaccine: Advisory Committee on Immunization Practices, 2016, MMWR Morb Mortal Wkly Rep 66(19):509–513, 2017.
Persa OD, Jazmati N, Robinson N, et al: A pregnant woman with chronic meningococcaemia from Neisseria meningitidis with lpxL1-mutations, Lancet 384:1900, 2014.
World Health Organization: Meningococcal disease in countries of the African meningitis belt, 2012: emerging needs and future perspectives, Wkly Epidemiol Rec 88(12):129–136, 2013.
Barbee LA, Khosropour CM, Dombrowski JC, et al: An estimate of the proportion of symptomatic gonococcal, chlamydial, and non-gonococcal non-chlamydial urethritis attributable to oral sex among men who have sex with men: a case-control study, Sex Transm Infect 92(2):155–160, 2016.
Belkacem A, Caumes E, Ouanich J, et al: Changing patterns of disseminated. gonococcal infection in France: cross-sectional data 2009–2011, Sex Transm Infect 89(8):613–615, 2013.
Black CM, Driebe EM, Howard LA, et al: Muticenter study of nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in children being evaluated. for sexual abuse, Pediatr Infect Dis J 28(7):608–613, 2009.
Centers for Disease Control and Prevention: Sexually transmitted. disease surveillance, 2015, Atlanta, 2016, US Department of Health and Human Services.
Centers for Disease Control and Prevention (CDC): Sexually transmitted. diseases treatment guidelines, 2015, MMWR Recomm Rep 64(RR–03):1–138, 2015.
Cohen MS, Sparling PF: Mucosal infection with Neisseria gonorrhoeae, bacterial adaptation and mucosal defenses, J Clin Invest 89:1699–1705, 1992.
Jenny C, Crawford-Jakubiak JE, Committee on Child Abuse and Neglect, et al: The evaluation of children in the primary care setting when sexual abuse is suspected, Pediatrics 132(2):e558–e567, 2013.
Klein EJ, Fisher LS, Chow AW, et al: Anorectal gonococcal infection, Ann Intern Med. 86(3):340–346, 1977.
Mathews C, Coetzee D: Partner notification for the control of STIs, BMJ 334:323, 2007.
Papp . JR, Schachter J, Gaydos CA, Van Der Pol B: Recommendations for the laboratorybased. detection of Chlamydia trachomatis and Neisseria gonorrhoeae—2014, MMWR Recomm Rep 63(2):1–19, 2014.
Plummer FA, Chubb H, Simonsen JN, et al: Antibody to Rmp (outer membrane protein 3) increases susceptibility to gonococcal infection, J Clin Invest 91:339–343, 1993.
Rice PA, McQuillen DP, Gulati S, et al: Serum resistance of Neisseria gonorrhoeae: does it thwart the inflammatory response and facilitate the transmission of infection? Ann NY Acad Sci 730:7–14, 1994.
Suzaki A, Hyashi K, Kosuge K, et al: Disseminated. gonococcal infection in Japan: a case report and literature review, Intern Med. 50(18):2039–2043, 2011.
Watson J, Carlile J, Dunn A, et al: Increased. gonorrhea cases—Utah, 2009–2014, MMWR Morb Mortal Wkly Rep 65(34):889–893, 2016.
Wi T, Lahara MM, Ndowa F, et al: Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action, PLoS Med 14(7):e1002344, 2017.
Amit U, Porat N, Basmaci R, et al: Genotyping of invasive Kingella kingae isolates reveals predominant clones and association with specific clinical syndromes, Clin Infect Dis 55:1074–1079, 2012.
Chometon S, Benito Y, Chaker M, et al: Specific real-time polymerase chain reaction places Kingella kingae as the most common cause of osteoarticular infections in young children, Pediatr Infect Dis J 26:377–381, 2007.
Dubnov-Raz G, Ephros M, Garty BZ, et al: Invasive pediatric Kingella kingae infections: a nationwide collaborative study, Pediatr Infect Dis J 29:639–643, 2010.
Foster MA, Walls T: High rates of complications following Kingella kingae infective endocarditis in children: a case series and review of the literature, Pediatr Infect Dis J 33:785–786, 2014.
Kehl-Fie TE, St Geme JW 3rd: Identification and characterization of an RTX toxin in the emerging pathogen Kingella kingae, J Bacteriol 189:430–436, 2007.
Kiang KM, Ogunmodede F, Juni BA, et al: Outbreak of osteomyelitis/septic arthritis caused. by Kingella kingae among child care center attendees, Pediatrics 116:e206–e213, 2005.
Porsch EA, Kehl-Fie TE, St Geme JW 3rd: Modulation of Kingella kingae adherence to human epithelial cells by type IV pili, capsule, and a novel trimeric autotransporter, MBio 3:2012.
Starr KF, Porsch EA, Seed. PC, et al: Kingella kingae expresses four structurally distinct polysaccharide capsules that differ in their correlation with invasive disease, PLoS Pathog 12:e1005944, 2016.
Yagupsky P, Dagan R, Howard CW, et al: High prevalence of Kingella kingae in joint fluid from children with septic arthritis revealed. by the BACTEC blood culture system, J Clin Microbiol 30:1278–1281, 1992.
Yagupsky P, Dubnov-Raz G, Gen? A, Ephros M; Israeli-Spanish Kingella kingae Research Group: Differentiating Kingella kingae septic arthritis of the hip from transient synovitis in young children, J Pediatr 165:985–989, 2014.
Yagupsky P, El Houmami N, Fournier PE: Outbreaks of invasive Kingella kingae in daycare facilities: approach to investigation and management, J Pediatr 182:14–20, 2017.
Yagupsky P, Katz O, Peled. N: Antibiotic susceptibility of Kingella kingae isolates from respiratory carriers and patients with invasive infections, J Antimicrob Chemother 47:191–193, 2001.
Yagupsky P, Porat N, Pinco E: Pharyngeal colonization by Kingella kingae in children with invasive disease, Pediatr Infect Dis J 28:155–157, 2009.
Adderson EE, Byington CL, Spencer L, et al: Invasive serotype a Haemophilus influenza infections with a virulence genotype resembling Haemophilus influenzae type b: emerging pathogen in the vaccine era?, Pediatrics 108:18–24, 2001.
Bamberger EE, Ben-Shimol S, Raya BA, Israeli Pediatric Bacteremia and Meningitis Group, et al: Pediatric invasive Haemophilus influenzae infections in Israel in the era of Haemophilus influenzae type b vaccine: a nationwide prospective study, Pediatr Infect Dis J 33(5):477–481, 2014.
Butler DF, Myers AL: Changing epidemiology of Haemophilus influenzae in children, Infect Dis Clin North Am 32(1):119–128, 2018.
Centers for Disease Control and Prevention: Invasive Haemophilus influenzae type b disease in five young children—Minnesota, 2008, MMWR 58:58–60, 2009.
Gessner BD, Sutanto A, Linehan M, et al: Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised. vaccine-probe trial, Lancet 365:43–52, 2005.
McIntyre PB, Berkey CS, King SM, et al: Dexamethasone as adjunctive therapy in bacterial meningitis: a meta-analysis of randomized. clinical trials since 1988, JAMA 278:925–931, 1997.
Perrett KP, John TM, Jin C, et al: Long-term persistence of immunity and B-cell memory following Haemophilus influenzae type b conjugate vaccine in early childhood and response to booster, Clin Infect Dis 58(7):949–959, 2014.
Prymula P, Peeters P, Chrobok V, et al: Pneumococcal capsular polysaccharides conjugated. to protein D for prevention of acute otitis media caused. by both Streptococcus pneumoniae and non-typeable Haemophilus influenzae: a randomized. double-blind efficacy study, Lancet 367:740–748, 2006.
Saha SK, Baqui AH, Darmstadt GL, et al: Invasive Haemophilus influenzae type b diseases in Bangladesh, with increased. resistance to antibiotics, J Pediatr 146:227–233, 2005.
Triden L, Glennen A, Juni B, et al: Invasive Haemophilus influenzae disease and antibiotic susceptibility of invasive isolates in Minnesota, 2002–2005, Infect Dis Clin Pract (Baltim Md) 15:373–376, 2007.
Watt JP, Wolfson LJ, O’Brien KL, et al: Burden of disease caused. by Haemophilus influenzae type b in children younger than 5 years: global estimates, Lancet 374: 903–910, 2009.
World Health Organization: Haemophilus influenzae type b (Hib) vaccination, WHO position paper: July 2013—Recommendations, Vaccine 31:6168–6169, 2013.
Belda W Jr, Di Chiacchio NG, Di Chiacchio N, et al: A comparative study of single-dose treatment of chancroid using thiamphenicol versus azithromycin, Braz J Infect Dis 13:218–220, 2009.
Gangaiah D, Spinola SM: Haemophilus ducreyi cutaneous ulcer strains diverged. from both class I and class II genital ulcer strains: implications for epidemiological studies, PLoS Negl Trop Dis 10(12):e0005259, 2016.
Gonzolez-Beiras C, Marks M, Chen CY, et al: Epidemiology of Haemophilus ducreyi infections, Emerg Infect Dis 22:1–8, 2016.
Hope-Rapp . E, Anyfantakis V, Fou?r? S, et al: Etiology of genital ulcer disease: a prospective study of 278 cases seen in an STD clinic in Paris, Sex Transm Dis 37(3):153–158, 2010.
Johnson LF, Lewis DA: The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis, Sex Transm Dis 11:946–959, 2008.
Kemp M, Christensen JJ, Lautenschlager S, et al: European guideline for the management of chancroid, 2011, Int J STD AIDS 22:241–244, 2011.
Lemonovich TI, Salata RA: Chancroid and lymphogranuloma venereum. In Beigi RH, editor: Sexually transmitted. diseases, New York, 2012, Wiley & Sons, pp . 45–53.
Workowski KA, Berman S: Centers for Disease Control and Prevention: sexually transmitted. diseases treatment guidelines, 2010, MMWR Recomm Rep 59(RR–12):1–110, 119, 2010.
Earl JP, de Vries SP, Ahmed. A, et al: Comparative genomic analyses of the Moraxella catarrhalis serosensitive and seroresistant lineages demonstrate their independent evolution, Genome Biol Evol 8:955–974, 2016.
Murphy TF, Brauer AL, Johnson A, et al: ATP-binding cassette (ABC) transporters of the human respiratory tract pathogen, Moraxella catarrhalis: role in virulence, PLoS ONE 11:e0158689, 2016.
Ngo CC, Massa HM, Thornton RB, et al: Predominant bacteria detected. from the middle ear fluid of children experiencing otitis media: a systematic review, PLoS ONE 11:e0150949, 2016.
Otsuka T, Kirkham C, Johnson A, et al: Substrate binding protein SBP2 of a putative ABC transporter as a novel vaccine antigen of Moraxella catarrhalis, Infect Immun 82:3503–3512, 2014.
Ren D, Almudevar AL, Murphy TF, et al: Serum antibody response to Moraxella catarrhalis proteins OMP CD, OppA, Msp22, Hag, and PilA2 after nasopharyngeal colonization and acute otitis media in children, Vaccine 33:5809–5814, 2015.
Ruohola A, Pettigrew MM, Lindholm L, et al: Bacterial and viral interactions within the nasopharynx contribute to the risk of acute otitis media, J Infect 66:247–254, 2013.
Schaar V, Paulsson M, Morgelin M, et al: Outer membrane vesicles shield Moraxella catarrhalis beta-lactamase from neutralization by serum IgG, J Antimicrob Chemother 68:593–600, 2013.
Shaikh SB, Ahmed. Z, Arsalan SA, et al: Prevalence and resistance pattern of Moraxella catarrhalis in community-acquired. lower respiratory tract infections, Infect Drug Resist 8:263–267, 2015.
Smidt M, Battig P, Verhaegh SJ, et al: Comprehensive antigen screening identifies Moraxella catarrhalis proteins that induce protection in a mouse pulmonary clearance model, PLoS ONE 8:e64422, 2013.
Baxter R, Bartlett J, Fireman B, et al: Effectiveness of vaccination during pregnancy to prevent infant pertussis, Pediatrics 139(5):e20164091, 2017.
Breakwell L, Kelso P, Finley C, et al: Pertussis vaccine effectiveness in the setting of pertactin-deficient pertussis, Pediatrics 137:e20153973, 2016.
Centers for Disease Control and Prevention: Updated. recommendations for use of tetanus toxoid, reduced. diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women: Advisory Committee on Immunization Practices, 2012, MMWR Morb Mortal Wkly Rep 62:131–135, 2013.
Clark T.A.: Changing pertussis epidemiology: everything old is new again, J Infect Dis 209:978–981, 2014.
Eberly MD, Eide MB, Thompson JL, et al: Azithromycin in early infancy and pyloric stenosis, Pediatrics 135:483–488, 2015.
Healy CM, Renck MA, Baker CJ: Importance of timing of maternal combined. tetanus, diphtheria and acellular pertussis (Tdap) immunization and protection of young infants, Clin Infect Dis 56:539–544, 2013.
McGirr A, Fisman DN: Duration of pertussis immunity after DTaP immunization: a meta-analysis, Pediatrics 135:331–343, 2015.
McIntyre PB, Sintchenko V: The “how” of polymerase chain reaction testing for Bordetella pertussis depends on the “why”, Clin Infect Dis 56:332–334, 2013.
Munoz FM, Bond NH, Maccato M, et al: Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized. clinical trial, JAMA 311:1760–1768, 2014.
Pawloski LC, Queenan AM, Cassiday PK, et al: Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United. States, Clin Vaccine Immunol 21:119–125, 2014.
Queenan AM, Cassiday PK, Evangelista A: Pertactin-negative variants of Bordetella pertussis in the United. States, N Engl J Med. 368:583–584, 2013.
Rodgers L, Martin SW, Cohn A, et al: Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated. with cocirculating Bordetella holmesii and Bordetella pertussis—Ohio 2010–2011, Clin Infect Dis 56:322–331, 2013.
Skoff TH, Kenyon C, Cocoros N, et al: Sources of infant pertussis infection in the United. States, Pediatrics 136(4):635–641, 2015.
Souder E, Vodzak J, Evangelista A, Long S.S.: Antimicrobial susceptibility and molecular detection of pertactin-producing and pertactin-deficient Bordetella pertussis, Pediatr Infect Dis J 36:119–121, 2017.
Tartof SY, Lewis M, Kenyon C, et al: Waning immunity to pertussis following 5 doses of DTaP, Pediatrics 131:e1047–e1052, 2013.
Vodzak J, Queenan AM, Souder E, et al: Clinical manifestations and molecular characterization of pertactin-deficient and pertactin-producing Bordetella pertussis in children, Philadelphia 2007–2014, Clin Infect Dis 64:60–66, 2017.
Winter K, Nickell S, Powell M, et al: Effectiveness of prenatal versus postpartum tetanus, diphtheria, and acellular pertussis vaccination in preventing infant pertussis, Clin Infect Dis 64:3–8, 2017.
Witt MA, Arias L, Katz PH, et al: Reduced. risk of pertussis among persons ever vaccinated. with whole cell pertussis vaccine compared. to recipients of acellular pertussis vaccines in a large US cohort, Clin Infect Dis 56:1248–1254, 2013.
Bottichio L, Webb LM, Leos G, et al: Salmonella oranienburg infection linked. to consumption of rattlesnake pills—Kansas and Texas, 2017, MMWR Morb Mortal Wkly Rep 67(17):502–503, 2018.
Centers for Disease Control and Prevention: Reptile-associated. salmonellosis—selected. states, 1998–2002, MMWR Morb Mortal Wkly Rep 52:1206–1210, 2003.
Centers for Disease Control and Prevention: Notes from the field: update on human Salmonella typhimurium infections associated. with aquatic frogs—United. States, 2009–2011, MMWR Morb Mortal Wkly Rep 60:628, 2011.
Coburn B, Grassl GA, Finlay BB: Salmonella, the host and disease: a brief review, Immunol Cell Biol 85:112–118, 2007.
Crump JA, Mintz ED: Global trends in typhoid and paratyphoid fever, Clin Infect Dis 50:241–246, 2010.
Feasey N.A., Dougan G., Kingsley R.A., et al: Invasive non-typhoidal salmonella disease: an emerging and neglected. tropical disease in Africa, Lancet 379:2489–2499, 2012.
Gunn JS, Marshall JM, Baker S, et al: Salmonella chronic carriage: epidemiology, diagnosis, and gallbladder persistence, Trends Microbiol 22(11):648–655, 2014.
Hanning IB, Nutt JD, Ricke SC: Salmonellosis outbreaks in the United. States due to fresh produce: sources and potential intervention measures, Foodborne Pathog Dis 6:635–648, 2009.
Haraga A, Ohlson MB, Miller SI: Salmonellae interplay with host cells, Nat Rev Microbiol 6:53–66, 2008.
Jackson BR, Griffin PM, Cole D, et al: Outbreak associated. Salmonella enterica serotypes and food commodities 1998–2008, United. States, Emerg Infect Dis 19:1239–1244, 2013.
Su CP, de Perio MA, Fagan K, et al: Occupational distribution of campylobacteriosis and salmonellosis cases—Maryland, Ohio, and Virginia, 2014, MMWR Morb Mortal Wkly Rep 66(32):850–853, 2017.
Capoor MR, Nair D, Posti J, et al: Minimum inhibitory concentration of carbapenems and tigacycline against Salmonella spp, J Med. Microbiol 58:337–341, 2009.
Crump JA, Mintz ED: Global trends in typhoid and paratyphoid fever, Clin Infect Dis 50:241–246, 2010.
Effa EE, Lassi ZS, Critchley JA, et al: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever), Cochrane Database Syst Rev (10):CD004530, 2011.
Fowler CC, Chang S-J, Goa X, et al: Emerging insights into the biology of typhoid toxin, Curr Opin Microbiol 35:70–77, 2017.
Frenck RW Jr, Mansour A, Nakhla I, et al: Short-course azithromycin for the treatment of uncomplicated. typhoid fever in children and adolescents, Clin Infect Dis 38:951–957, 2004.
Huang DB, DuPont HL: Problem pathogens: extra-intestinal complications of Salmonella enterica serotype Typhi infection, Lancet Infect Dis 5:341–348, 2005.
Kumar Y, Sharma A, Mani KR: Re-emergence of susceptibility to conventionally used. drugs among strains of Salmonella Typhi in central west India, J Infect Dev Ctries 5:227–230, 2011.
Sinha A, Sazawal S, Kumar R, et al: Typhoid fever in children aged. less than 5 years, Lancet 354:734–737, 1999.
Sur D, Ochiai RL, Bhattacharya SK, et al: A cluster-randomized. effectiveness trial of Vi typhoid vaccine in India, N Engl J Med. 361:335–344, 2009.
Ache R, DacCam P, Forsum U, et al: Titres of class-specific antibodies against Shigella and Salmonella lipopolysaccharide antigens in colostrum and breast milk of Costa Rican, Swedish and Vietnamese mothers, J Infect 25:89–105, 1992.
Ashida H, Ogawa M, Kim M, et al: Shigella deploy multiple countermeasures against host innate immune responses, Curr Opin Microbiol 14:16–23, 2011.
Bowen A, Grass J, Bicknese A, et al: Elevated. risk for antimicrobial drug-resistant Shigella infection among men who have sex with men, United. States, 2011–2015, Emerg Infect Dis 22:1613–1616, 2016.
Bowen A, Hurd J, Hoover C, et al: Importation and domestic transmission of Shigella sonnei resistant to ciprofloxacin—United. States, May 2014–February 2015, MMWR 64:318–320, 2015.
Cam PD, Achi R, Lindberg AA, P?l T: Antibodies against invasion plasmid coded. antigens of shigella in human colostrum and milk, Acta Microbiol Hung 39:263–270, 1992.
Centers for Disease Control and Prevention (CDC) Health Alert Network: CDC recommendations for diagnosing and managing Shigella strains with possible reduced. susceptibility to ciprofloxacin.
El-Gendy AM, Mansour A, Weiner MA, et al: Genetic diversity and antibiotic resistance in Shigella dysenteriae and Shigella boydii strains isolated. from children, Epidemiol Infect 140:299–310, 2012.
Gaudio PA, Sethabutr O, Echeverria P, Hoge CW: Utility of a polymerase chain reaction diagnostic system in a study of the epidemiology of shigellosis among dysentery patients, family contacts, and well controls living in a shigellosis-endemic area, J Infect Dis 176:1013–1018, 1997.
Hayani KC, Guerrero ML, Morrow AL, et al: Concentration of milk secretory immunoglobulin A against Shigella virulence plasmid–associated. antigens as a predictor of symptom status in Shigella-infected. breast-fed. infants, J Pediatr 121:852–856, 1992.
Henao OL, Jones TF, Vugia DJ, Griffin PM: Foodborne diseases active surveillance network—2 decades of achievements, 1996–2015, Emerg Infect Dis 1529–1536, 2015.
Hines JZ, Pinsent T, Rees K, et al: Shigellosis outbreak among men who have sex with men and homeless persons—Oregon, 2015–2016, MMWR 65(31):812–813, 2016.
Huang JY, Henao OL, Griffin PM, et al: Infection with pathogens transmitted. commonly through food and the effect of increasing use of culture-independent diagnostic tests on surveillance—Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2012–2015, MMWR 65:368–371, 2016.
Khan WA, Griffiths JK, Bennish ML: Gastrointestinal and extra-intestinal manifestations of childhood shigellosis in a region where all four species of Shigella are endemic, PLoS ONE 8:e64097, 2013.
Lindsay B, Ochieng JB, Ikumapayi UN, et al: Quantitative PCR for detection of Shigella improves ascertainment of Shigella burden in children with moderate-to-severe diarrhea in low-income countries, J Clin Microbiol 51:1740–1746, 2013.
Marteyn B, Gazi A, Sansonetti P: Shigella, Gut Microbes 3:104–120, 2012.
Niesel DW, Hess CB, Cho YJ, et al: Natural and recombinant interferons inhibit epithelial cell invasion by Shigella spp., Infect Immun 52:828–833, 1986.
Porter CK, Thura N, Ranallo RT, Riddle MS: The Shigella human challenge model, Epidemiol Infect 141:223–232, 2013.
Rabbani GH, Ahmed. S, Hossain I, et al: Green banana reduces clinical severity of childhood shigellosis: a double-blind, randomized, controlled. clinical trial, Pediatr Infect Dis J 28:420–425, 2009.
Raqib R, Roy SK, Rahman MJ, et al: Effect of zinc supplementation on immune and inflammatory responses in pediatric patients with shigellosis, Am J Clin Nutr 79:444–450, 2004.
Roy SK, Raqib R, Khatun W, et al: Zinc supplementation in the management of shigellosis in malnourished. children in Bangladesh, Eur J Clin Nutr 62:849–855, 2008.
Ruel MT, Rivera JA, Santizo M-C, et al: Impact of zinc supplementation on morbidity from diarrhea and respiratory infections among rural Guatemalan children, Pediatrics 99:808–813, 1997.
Samandari T, Kotloff KL, Losonsky GA, et al: Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated. with a Shiga toxin–deleted. Shigella dysenteriae type 1 strain, J Immunol 164:2221–2232, 2000.
Scallan E, Mahon BE: Foodborne diseases active surveillance network (FoodNet) in 2012: a foundation for food safety in the United. States, Clin Infect Dis 54(Suppl 5):S381–S384, 2012.
Svob D, Bolint B, Vosorhelyi B, et al: Comparative genomic and phylogenetic analysis of a Shiga toxin producing Shigella sonnei (STSS) strain, Front Cell Infect Microbiol 7:229, 2017.
Vila J: New molecular diagnostic tools in traveller’s diarrhea, J Travel Med. 24:S23–S28,2017.
Wang S-M, Ma J-C, Hao Z-Y, et al: Surveillance of shigellosis by real-time PCR suggests underestimation of shigellosis prevalence by culture-based. methods in a population of rural China, J Infect 61:471–475, 2010.
Zhang H, Morrison S, Tang Y-W: Multiplex polymerase chain reaction tests for detection of pathogens associated. with gastroenteritis, Clin Lab Med. 35:461–486, 2015.
Barletta F, Ochoa TJ, Mercado E, et al: Quantitative real-time polymerase chain reaction for enteropathogenic Escherichia coli: a tool for investigation of asymptomatic versus symptomatic infections, Clin Infect Dis 53:1223–1229, 2011.
Bielaszewska M, Mellmann A, Zhang W, et al: Characterisation of the Escherichia coli strain associated. with an outbreak of haemolytic-uraemic syndrome in Germany, 2011: a microbiological study, Lancet Infect Dis 11:671–676, 2011.
Bugarel M, Martin A, Fach P, et al: Virulence gene profiling of enterohemorrhagic and enteropathogenic Escherichia coli strains: a basis for molecular risk assessment of typical and atypical EPEC strains., BMC Microbiol 11:142, 2011.
Clements A, Young JC, Constantinou N, et al: Infection strategies of enteric pathogenic Escherichia coli, Gut Microbes 3:71–87, 2012.
Colpan A, Johnston B, Porter S, et al: Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans, Clin Infect Dis 57:1256–1265, 2013.
Doi Y, Park YS, Rivera JI, et al: Community-associated. extended-spectrum ?-lactamaseproducing Escherichia coli infection in the United. States, Clin Infect Dis 56:641–648, 2013.
Donnenberg MS, Finlay BB: Combating enteropathogenic Escherichia coli (ÝÏÊÏ) infections: the way forward, Trends Microbiol 21:317–319, 2013.
Frank C, Werber D, Cramer JP, et al: Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany, N Engl J Med. 365:1771–1780, 2011.
Hermos CR, Janineh M, Han LL, et al: Shiga toxin-producing Escherichia coli in children: diagnosis and clinical manifestations of O157:H7 and non-O157:H7 infection, J Clin Microbiol 49:955–959, 2011.
Kotloff KL, Nataro JP, Blackwelder WC, et al: Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study, Lancet 382:209–222, 2013.
Lima IF, Boisen N, QuetzJda S, et al: Prevalence of enteroaggregative Escherichia coli and its virulence-related. genes in a case-control study among children from north-eastern Brazil, J Med. Microbiol 62:683–693, 2013.
Lopez EL, Contrini MM, Glatstein E, et al: An epidemiologic surveillance of Shiga-like toxin-producing Escherichia coli infection in Argentinean children: risk factors and serum Shiga-like toxin 2 values, Pediatr Infect Dis J 31:20–24, 2012.
Mansan-Almeida R, Pereira AL, Giugliano L: Diffusely adherent Escherichia coli strains isolated. from children and adults constitute two different populations, BMC Microbiol 13:22, 2013.
Rohde H, Qin J, Cui Y, et al: E. coli O104:H4 Genome Analysis Crowd-Sourcing Consortium open-source genomic analysis of Shiga-toxin-producing E. coli O104:H4, N Engl J Med. 365:718–724, 2011.
Ruppe E, Lixandru B, Cojocaru R, et al: Relative fecal abundance of extended-spectrum beta-lactamases-producing Escherichia coli and their occurrence in urinary infections in women, Antimicrob Agents Chemother 57:4512–4517, 2013.
Scaletsky IC, Aranda KR, Souza TB, et al: Evidence of pathogenic subgroups among atypical enteropathogenic Escherichia coli strains, J Clin Microbiol 47:3756–3759, 2009.
Ali M, Nelson AR, Lopez AL, Sack DA: Updated. global burden of cholera in endemic countries, PLoS Negl Trop Dis 9(6):e0003832, 2015.
Clemens JD, Nair GB, Ahmed. T, et al: Cholera, Lancet 390:1539–1548, 2017.
Desai SN, Pezzoli L, Martin S, et al: A second affordable oral cholera vaccine: implications for the global vaccine stockpile, Lancet Glob Health 4(4):e223–e224, 2016.
Hall V, Medus C, Wahl G, et al: Vibrio cholerae serogroup O1, serotype Inaba — Minnesota, August 2016, MMWR Morb Mortal Wkly Rep 66(36):961–962, 2017.
Qadri F, Islam T, Clemons JD: Cholera in Yemen: an old foe rearing its ugly head, N Engl J Med. 377(21):2005–2007, 2017.
Sauvageot D, Njanpop-Lafourcade B-M, Akilimali L, et al: Cholera incidence and mortality in sub-Saharan African sites during multi-country surveillance, PLoS Negl Trop Dis 10(5):e0004679, 2016.
UNICEF: Cholera toolkit, New York, 20123, UNICEF.
Williams PCM, Berkley JA: Guidelines for the management of paediatric cholera infection: a systematic review of the evidence, Paediatr Int Child Health 38:S16–S31, 2018.
Ben-Shimol S, Carmi A, Greenberg D: Demographic and clinical characteristics of Campylobacter bacteremia in children with and without predisposing factors, Pediatr Infect Dis J 32:e414–e418, 2013.
Burakoff A, Brown K, Knutsen J, et al: Outbreak of fluoroquinolone-resistant Campylobacter jejuni infections associated. with raw milk consumption from a herdshare dairy—Colorado, 2016, MMWR 67(5):146–148, 2018.
Buss SN, Leber A, Chapin K, et al: Multicenter evaluation of the BioFire FilmArray gastrointestinal panel for etiologic diagnosis of infectious gastroenteritis, J Clin Microbiol 53(3):915–925, 2015.
Centers for Disease Control and Prevention: Multistate outbreak of Campylobacter jejuni infections associated. with undercooked. chicken livers—Northeastern United States, 2012, MMWR 62:874–876, 2013.
Feodoroff B, Lauhio A, Ellstr?m P, et al: A nationwide study of Campylobacter jejuni and Campylobacter coli bacteremia in Finland over a 10-year period, 1998–2007, with special reference to clinical characteristics and antimicrobial susceptibility, Clin Infect Dis 53(8):e99–e106, 2011.
Glashower D, Snyder J, Welch D, McCarthy S: Outbreak of Campylobacter jejuni associated. with consuming undercooked. chicken liver mousse—Clark County, Washington, 2016, MMWR 66(38):1027–1028, 2017.
Kaakoush NO, Castano-Rodriguez N, Mitchel HM, Man SM: Global epidemiology of Campylobacter infection, Clin Microbiol Rev 28(3):687–720, 2015.
Kaira V, Chaudhry R, Dua T, et al: Association of Campylobacter jejuni infection with childhood Guillain-Barr? syndrome: a case-control study, J Child Neurol 24(6):664–668, 2009.
Man SM: The clinical importance of emerging Campylobacter species, Nat Rev Gastroenterol Hepatol 8:669–985, 2011.
Su CP, de Perio MA, Fagan K, et al: Occupational distribution of campylobacteriosis and salmonellosis cases—Maryland, Ohio, and Virginia, 2014, MMWR 66(32):850–853, 2017.
World Health Organization Media Centre: Campylobacter: Factsheet No 255, 2016.
Centers for Disease Control and Prevention: Yersinia and chitlins prevention fact sheet.
Chakraborty A, Komatsu K, Roberts M, et al: The descriptive epidemiology of yersiniosis: a multistate study, 2005–2011, Public Health Rep 130:269–277, 2015.
Hale CR, Scallan E, Cronquist AB, et al: Estimates of enteric illness attributable to contact with animals and their environments in the United. States, Clin Infect Dis 54(Suppl 5):S472–S479, 2012.
Huang JY, Henao OL, Griffin PM, et al: Infection with pathogens transmitted. commonly through food and the effect of increasing use of culture-independent diagnostic tests on surveillance—Foodborne Diseases Active Surveillance Network, 10 U.S. sites, 2012–2015, MMWR Morb Mortal Wkly Rep 65:368–371, 2016.
Scallan E, Mahon BE, Hoekstra RM, et al: Estimates of illnesses, hospitalizations and deaths caused. by major bacterial enteric pathogens in young children in the United. States, Pediatr Infect Dis J 32:217–221, 2013.
Horinouchi T, Nozu K, Hamahira K, et al: Yersinia pseudotuberculosis infection in Kawasaki disease and its clinical characteristics, BMC Pediatr 15:177, 2015.
Long C, Jones TF, Vugia DJ, et al: Yersinia pseudotuberculosis and Y. enterocolitica infections, FoodNet, 1996–2007, Emerg Infect Dis 16:566–567, 2010.
Mischnik A, Dahme T, Bekeredjian R, et al: Haemophilia-associated. Yersinia pseudotuberculosis serotype O:1 septicaemia: the role of iron, J Med. Microbiol 61(Pt1):157–159, 2012.
Vasala M, Hallanvuo S, Ruuska P, et al: High frequency of reactive arthritis in adults after Yersinia pseudotuberculosis O:1 outbreak caused. by contaminated. grated. carrots, Ann Rheum Dis 73:1793–1796, 2014
Centers for Disease Control and Prevention: Fatal laboratory-acquired. infection with an attenuated. Yersinia pestis strain—Chicago, Illinois, 2009, MMWR Morb Mortal Wkly Rep 60:201–205, 2011.
Centers for Disease Control and Prevention: Human plague—United. States, 2015, MMWR Morb Mortal Wkly Rep 64(33):918–919, 2015.
Centers for Disease Control and Prevention/
Centers for Disease Control and Prevention, 2015: Recommended. antibiotic treatment for plague.
Francourt M, Raoult D: Molecular history of plague, Clin Microbiol Infect 22(11):911–915, 2016.
Kassem AM, Tengelsen L, Atkins B, et al: Plague in domestic cats—Idaho, 2016, MMWR Morb Mortal Wkly Rep 65(48):1378–1379, 2016.
Kwit N, Nelson C, Kugeler K, et al: Human plague—United. States, MMWR Morb Mortal Wkly Rep 64(33):918–2015, 2015.
Runfola JK, House J, Miller L, et al: Outbreak of human pneumonic plague with dog-to-human and possible human-to-human transmission—Colorado, June–July 2014, MMWR Morb Mortal Wkly Rep 64(16):429–434, 2015.
Verma SK, Tuteja U: Plague vaccine development: current research and future trends, Front Immunol 6:602, 2016.
Ahmed. D, Hoque A, Elahi MS, et al: Bacterial aetiology of diarrhoeal diseases and antimicrobial resistance in Dhaka, Bangladesh, 2005–2008, Epidemiol Infect 140(9): 1678–1684, 2012.
Aravena-Roman M, Inglis TJ, Henderson B, et al: Antimicrobial susceptibilities of Aeromonas strains isolated. from clinical and environmental sources to 26 antimicrobial agents, Antimicrob Agents Chemother 56:1110–1112, 2012.
Chen P-L, Lamy B, Ko W-C: Aeromonas dhakensis, an increasingly recognized. human pathogen, Front Microbiol 7:793, 2016.
Esteve C, Alcaide E, Gim?nez MJ: Multidrug-resistant (MDR) Aeromonas recovered from the metropolitan area of Valencia (Spain): diseases spectrum and prevalence in the environment, Eur J Clin Microbiol Infect Dis 34:137, 2015.
Janda J, Abbott S: The genus Aeromonas: taxonomy, pathogenicity, and infection, Clin Microbiol Rev 23:35–73, 2010.
McAuliffe GN, Hennessy J, Baird RW: Relative frequency, characteristics, and antimicrobial susceptibility patterns of Vibrio spp., Aeromonas spp., Chromobacterium violaceum, and Shewanella spp. in the Northern Territory of Australia, 2000–2013, Am J Trop Med. Hyg 92(3):605–610, 2015.
Teunis P, Figueras MJ: Reassessment of the enteropathogenicity of mesophilic Aeromonas species, Front Microbiol 7:1395, eCollection, 2016.
Buss SN, Leber A, Chaplin K, et al: Multicenter evaluation of the BioFire FilmArray gastrointestinal panel for etiological diagnosis of infectious gastroenteritis, J Clin Microbiol 53:915–925, 2015.
Shah N, DuPont HL, Ramsey DJ: Global etiology of travelers’ diarrhea: systematic review from 1973 to the present, Am J Trop Med. Hyg 80:609–614, 2009.
Bizzarro MJ, Shabanova V, Baltimore R.S., et al: Neonatal sepsis 2004–2013: the rise and fall of coagulase-negative staphylococci, J Pediatr 166(5):1193–1199, 2015.
Carmeli Y, Armstrong J, Laud PJ, et al: Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated. urinary tract infections or complicated. intra-abdominal infections (REPRISE): a randomized. pathogen directed. phase III study, Lancet Infect Dis 16:661–673, 2016.
Centers for Disease Control and Prevention: Melioidosis treatment. http://www.cdc.gov/melioidosis/treatment/index.html
Logan LK, Gandra S, Mandal S, et al: Multidrug- and carbapenem-resistant Pseudomonas aeruginosa in children, United. States, 1999–2012, J Pediatr Infect Dis 6:352–359, 2017.
Planquette B, Timsit JF, Misset BY, et al: Pseudomonas aeruginosa ventilator-associated. pneumonia, Am J Respir Crit Care Med. 188:69–76, 2013.
Saiman L, Siegel JD, LiPuma JJ, et al: Infection prevention and control guideline: update for cystic fibrosis 2013, Infect Control Hosp Epidemiol 35:S1–S67, 2014.
Sawa T, Shimizu M, Moriyama K, et al: Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review, Crit Care 18:668–679, 2014.
Serisier DJ, Martin ML, McGuckin MA, et al: Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non–cystic fibrosis bronchiectasis: the BLESS randomized. controlled. trial, JAMA 309(12):1260–1267, 2013.
Burkholderia cepacia Complex David J, Bell RE, Clark GC: Mechanisms of disease: host-pathogen interactions between Burkholderia species and lung epithelial cells, Front Cell Infect Microbiol 5:80, 2015.
Mahenthiralingam E, Vandamme P: Taxonomy and pathogenesis of the Burkholderia cepacia complex, Chron Respir Dis 2:209–217, 2005.
Saiman L, Siegel JD, LiPuma JJ, et al: Infection prevention and control guideline: update for cystic fibrosis 2013, Infect Control Hosp Epidemiol 35:S1–S67, 2014.
Burkholderia mallei and B. pseudomallei Anderson EW, Mackay MT, Ryan MM: Neurologic melioidosis: case report of a rare cause of acute flaccid paralysis, J Pediatr 170:319–321, 2016.
Centers for Disease Control and Prevention: Melioidosis: treatment.
Currie BJ, Haslam A, Pearson T, et al: Identification of melioidosis outbreak by multilocus variable number tandem repeat analysis, Emerg Infect Dis 15:169–174, 2009.
McLeod C, Morris PS, Bauert PA, et al: Clinical presentation and medical management of melioidosis in children: a 24-year prospective study in the Northern Territory of Australia and review of the literature, Clin Infect Dis 60:21–26, 2015.
Amin R, Waters AR: Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis, Cochrane Database Syst Rev (14):1–14, 2016.
Hand E, Davis H, Kim T, et al: Monotherapy with minocycline or trimethoprimsulfamethoxazole for treatment of Stenotrophomonas maltophilia infections, J Antimicrob Chemother 71:1071–1075, 2016.
Boisset S, Caspar Y, Sutera V, Maurin M: New therapeutic approaches for treatment of tularaemia: a review, Front Cell Infect Microbiol 4(40):1–8, 2014.
Carvalho CL, Lopes de Carvalho I, Ze-Ze L, et al: Tularaemia: a challenging zoonosis, Comp Immunol Microbiol Infect Dis 37:85–96, 2014.
Centers for Disease Control and Prevention: Tularemia—United. States, 2001–2010, MMWR Morb Mortal Wkly Rep 62:963–966, 2013.
Maurin M, Gyuranecz M: Tularaemia: clinical aspects in Europe, Lancet Infect Dis 16:113–124, 2016.
Pedati C, House J, Hancock-Allen J, et al: Notes from the field. Increase in human cases of tularemia—Colorado, Nebraska, South Dakota, and Wyoming, January–September 2015, MMWR Morb Mortal Wkly Rep 64(47):1317–1318, 2015.
Taglom H, Rodriguez E, Gaither M, et al: Fatal pneumonic tularemia associated. with dog exposure—Arizona, June 2016, MMWR Morb Mortal Wkly Rep 66(33):891, 2017.
Ulu-Kilic A, Doganay M: An overview: tularemia and travel medicine, Travel Med Infect Dis 12:609–616, 2014.
Whitten T, Bjork J, Neitzel D, et al: Francisella tularenis type B infection from a fish hook injury—Minnesota, 2016, MMWR Morb Mortal Wkly Rep 66(7):194, 2017.
Ahmed. W, Zheng K, Liu ZF: Establishment of chronic infection: Brucella’s stealth strategy, Front Cell Infect Microbiol 6:30, 2016.
Al-Tawfiq JA, Memish ZA: Antibiotic susceptibility and treatment of brucellosis, Recent Pat Antiinfect Drug Discov 8:51–54, 2013.
De Figueiredo P, Ficht TA, Rice-Ficht A, et al: Pathogenesis and immunobiology of brucellosis: review of Brucella-host interactions, Am J Pathol 185:1505–1517, 2015.
Eskazan AE, Dal MS, Kaya S, et al: Two cases of autoimmune hemolytic anemia secondary to brucellosis: a review of hemolytic disorders in patients with brucellosis, Intern Med. 53:1153–1158, 2014.
Mussalam II, Abo-Shehada MN, Hegazy YM, et al: Systematic review of brucellosis in the Middle East: disease frequency in ruminants and humans and risk factors for human infection, Epidemiol Infect 144:671–685, 2016.
Roushan MRH, Amiri MJS: Update on childhood brucellosis, Recent Pat Antiinfect Drug Discov 8:42–46, 2013. Mussalam II, Abo-Shehada MN, Hegazy YM, et al: Systematic review of brucellosis in the Middle East: disease frequency in ruminants and humans and risk factors for human infection, Epidemiol Infect 144:671–685, 2016.
Roushan MRH, Amiri MJS: Update on childhood brucellosis, Recent Pat Antiinfect Drug Discov 8:42–46, 2013.
Centers for Disease Control and Prevention.
Centers for Disease Control and Prevention: Legionellosis—United. States, 2000–2009, MMWR Morb Mortal Wkly Rep 60:1083–1086, 2011.
Correia AM, Goncalves J, Gomes JP, et al: Probable person-to-person transmission of legionnaires disease, N Engl J Med. 374(5):497–498, 2016.
Cunha BA, Burillo A, Bouza E: Legionnaire’s disease, Lancet 387:376–385, 2016.
Gershengorn HB, Keene A, Dzierba AL, et al: The association of antibiotic treatment regimen and hospital mortality in patients hospitalized. with Legionella pneumonia Clin Infect Dis 60(11):e66–e79, 2015.
Granseth G, Bhattarai R, Sylvester T, et al: Two cases of legionnaires’ disease in newborns after water births—Arizona, 2016, MMWR Morb Mortal Wkly Rep 66(22):590–591, 2017.
Jain S, Self WH, Wunderink RG, et al: Community-acquired. pneumonia requiring hospitalization among U.S. adults, N Engl J Med. 373(5):415–427, 2015.
Phin N, Parry-Ford F, Harrison T, et al: Epidemiology and clinical management of legionnaires’ disease, Lancet Infect Dis 14:1011–1021, 2015.
Soda EA, Barskey AE, Shah PP, et al: Vital signs. Health care–associated. legionnaires disease surveillance data from 20 states and a large metropolitan area — United States, 2015, MMWR Morb Mortal Wkly Rep 66(22):584–589, 2017.
Yiallouros P, Papadouri T, Karaoli C, et al: First outbreak of nosocomial Legionella infection in term neonates caused. by a cold mist ultrasonic humidifier, Clin Infect Dis 57(1):48–56, 2013.
Blazes DL, Mullins K, Smoak BL, et al: Novel Bartonella agent as cause of verruga peruana, Emerg Infect Dis 19:1111–1114, 2013.
Vayssier-Taussat M, Moutailler S, F?m?nia F, et al: Identification of novel zoonotic activity of Bartonella spp., France, Emerg Infect Dis 22:457–462, 2016.
Angelakis E, Rraoult D: Pathogenicity and treatment of Bartonella infections, Int J Antimicrob Agents 44:16–25, 2014.
Anyfantakis D, Kastanakis M, Papdomichelakis A, Bobolakis E: Cat-scratch disease presenting as a solitary splenic abscess in an immunocompetent adult: case report and literature review, Infez Med. 21:130–133, 2013.
Arisoy ES, Correa AG, Wagner ML, et al: Hepatosplenic cat-scratch disease in children: selected. clinical features and treatment, Clin Infect Dis 28:778–784, 1999.
Bass JW, Freitas BC, Freitas AD, et al: Prospective randomized. double blind placebocontrolled. evaluation of azithromycin for treatment of cat-scratch disease, Pediatr Infect Dis J 17:447–452, 1998.
Batts S, Demers DM: Spectrum and treatment of cat-scratch disease, Pediatr Infect Dis J 23:1161–1162, 2004.
Carithers HA, Margileth AM: Cat scratch disease: acute encephalopathy and other neurologic manifestations, Am J Dis Child 145:98–101, 1991.
Centers for Disease Control and Prevention: 2017.
Florin TA, Zaoutis TE, Zaoutis LB: Beyond cat scratch disease: widening spectrum of Bartonella henselae infection, Pediatrics 121:e1413–e1425, 2008.
Fournier PE, Lelievre H, Ekyn SJ, et al: Epidemiologic and clinical characteristics of
Bartonella quintana and Bartonella henselae endocarditis: a study of 48 patients, Medicine (Baltimore) 80:245–251, 2001.
Jacobs R, Schutze G: Bartonella henselae as a cause of prolonged. fever and fever of unknown origin in children, Clin Infect Dis 26:80–84, 1998.
Metzkor-Cotter E, Kletter Y, Avidor B, et al: Long-term serological analysis and clinical follow-up of patients with cat scratch disease, Clin Infect Dis 37:1149–1154, 2003.
Oksi J, Rantala S, Kilpinen S, et al: Cat scratch disease caused. by Bartonella grahamii in an immunocompromised. patient, J Clin Microbiol 51:2781–2784, 2013.
Maguisa C, Garcia P, Gotuzzo E, et al: Bartonellosis (Carri?n’s disease) in the modern era, Clin Infect Dis 33:772–779, 2001.
Angelakis E, Rraoult D: Pathogenicity and treatment of Bartonella infections, Int J Antimicrob Agents 44:16–25, 2014.
Bonilla DL, Kabeya H, Henn J, et al: Bartonella quintana in body lice and head lice from homeless persons, San Francisco, California, USA, Emerg Infect Dis 15:912–915, 2009.
Florin TA, Zaoutis TE, Zaoutis LB: Beyond cat scratch disease: widening spectrum of Bartonella henselae infection, Pediatrics 121:e1413–e1425, 2008.
Inoue K, Maruyama S, Kabeta H, et al: Exotic small mammals as potential reservoirs of zoonotic Bartonella spp, Emerg Infect Dis 15:526–532, 2009.
Raoult D, Fournier PE, Vandenesch F, et al: Outcome and treatment of Bartonella endocarditis [original investigation], Arch Intern Med. 163:226–230, 2003.
Rolain JM, Brouqui P, Koehler JE, et al: Recommendations for the treatment of human infections caused. by Bartonella species, Antimicrob Agents Chemother 48:1921–1933, 2004.
Burke P, Needham M, Jackson BR, et al: Outbreak of foodborne botulism associated with improperly jarred. pesto—Ohio and California, 2014, MMWR 65:175–177, 2016.
Cassir N, Benamar S, La Scola B: Clostridium butyricum: from beneficial to a new emerging pathogen, Clin Microbiol Infect 22:37–45, 2016.
Castor C, Mazuet C, Saint-Leger M, et al: Cluster of two cases of botulism due to Clostridium baratii type F in France, November 2014, Euro Surveill 20(6):2015.
Maslanka SE, Luquez C, Dykes JK, et al: A novel botulinum neurotoxin, previously reported. as serotype H, has a hybrid-like structure with regions of similarity to the structures of serotypes A and F and is neutralized. with serotype A antitoxin, J Infect Dis 213:379–385, 2016.
McCarty CL, Angelo K, Beer KD, et al: Large outbreak of botulism associated. with a church potluck meal—Ohio, 2015, MMWR 64:802–803, 2015.
McCrickard L, Marlow M, Self JL, et al: Notes from the field. Botulism outbreak from drinking prison-made illicit alcohol in a federal correctional facility—Mississippi, June 2016, MMWR 65:1491–1492, 2017.
Moodley A, Quinlisk P, Garvey A, et al: Notes from the field. Infant botulism caused by Clostridium baratii type F—Iowa, 2013, MMWR 64:400, 2015.
Qureshi IA, Qureshi MA, Rauf Afzal M, et al: Black tar heroin skin popping as a cause of wound botulism, Neurocrit Care 27:415–419, 2017.
Shelley EB, O’Rourke D, Grant K, et al: Infant botulism due to C. butyricum type E toxin: a novel environmental association with pet terrapins, Epidemiol Infect 143:461–469, 2015.
Trehard H, Poujol I, Mazuet C, et al: A cluster of three cases of botulism due to Clostridium baratii type F, France, August 2015, Euro Surveill 21(4):2016.
Tsai HJ, Liang WC, Wang CH, et al: Botulism with unusual rapid progression to complete paralysis in a child, Pediatr Neonatol 56:425–428, 2015.
Centers for Disease Control and Prevention: Tetanus surveillance—United. States, 2001–2008, MMWR Morb Mortal Wkly Rep 60:365–369, 2011.
Fowkes FJ, McGready R, Johnstone-Robertson S, et al: Antibody boosting and longevity following tetanus immunization during pregnancy, Clin Infect Dis 56:749–750, 2013.
Grund JM, Toledo C, Davis SM, et al: Tetanus cases after voluntary medical male circumcision for HIV prevention—Eastern and Southern Africa, 2012–2015, MMWR
Morb Mortal Wkly Rep 65(2):36–37, 2016.
Hassel B: Tetanus: pathophysiology, treatment, and the possibility of using botulinum toxin against tetanus-induced. rigidity and spasms, Toxins (Basel) 5:73–83, 2013.
Johnson MG, Bradley KK, Mendus S, et al: Vaccine-preventable disease among homeschooled. children: two cases of tetanus in Oklahoma, Pediatrics 132(6):e1686–e1689, 2013.
Rossetto O, Scorzeto M, Megighian A, et al: Tetanus neurotoxin, Toxicon 66:59–63, 2013.
Sequist TD: Eliminating maternal and neonatal tetanus and closing the immunity gap, Lancet 389:1380–1381, 2017.
Skuby SO, Rhee E, Thilo EH: Tetanus and Occam’s razor: almost forgotten but not gone: a case report, Pediatrics 138(5):e20160298, 2017.
Thwaites CL, Beeching NJ, Newton CR: Maternal and neonatal tetanus, Lancet 385(9965):362–370, 2015.
Yaffee AQ, Day DL, Bastin G, et al: Notes from the field. Obstetric tetanus in an unvaccinated. woman after a home birth delivery—Kentucky, 2016, MMWR Morb Mortal Wkly Rep 66(11):307–308, 2017.
Goldenberg JZ, Ma SSY, Saxton JD, et al: Probiotics for prevention of Clostridium difficile-associated. diarrhea in adults and children, Cochrane Database Syst Rev (5):CD006095, 2013.
Horton DB, Strom BL, Putt ME, et al: Epidemiology of Clostridium difficile infection–associated. reactive arthritis in children: an underdiagnosed, potentially morbid condition, JAMA Pediatr 170:e160217, 2016.
Khanna S, Baddour LM, Huskins WC, et al: The epidemiology of Clostridium difficile infection in children: a population-based. study, Clin Infect Dis 56:1401–1406, 2013.
Kronman MP, Nielson HJ, Adler AL, et al: Fecal microbiota transplantation via nasogastric tube for recurrent Clostridium difficile infection in pediatric patients, J Pediatr Gastroenterol Nutr 60:23–26, 2015.
Lamouse-Smith ES, Weber S, Rossi Hb, et al: Polymerase chain reaction test for Clostridium difficile toxin B gene reveals similar prevalence rates in children with and without inflammatory bowel disease, J Pediatr Gastroenterol Nutr 57:293–297, 2013.
Lessa FC, Mu Y, Bamberg WM, et al: Burden of Clostridium difficile infection in the United. States, N Engl J Med. 372:825–834, 2015.
Lo Vecchio A, Cohen MB: Fecal microbiota transplantation for Clostridium difficile infection: benefits and barriers, Curr Opin Gastroenterol 30:47–53, 2014.
Martinelli M, Strisciuglio C, Veres G, et al: Clostridium difficile and pediatric inflammatory bowel disease: a prospective, comparative, multicenter, ESPGHAN study, Inflamm Bowel Dis 20:2219–2225, 2014.
McDonald LC, Gerding DN, Johnson S, et al: Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases
Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA), Clin Infect Dis 66(7):e1–e48, 2018.
Russell GH, Kaplan JL, Youngster I, et al: Fecal transplant for recurrent Clostridium difficile infection in children with and without inflammatory bowel disease, J Pediatr Gastroenterol Nutr 58:588–592, 2014.
Schutze GE, Willoughby RE: AAP Committee on Infectious Diseases: Clostridium difficile infection in infants and children, Pediatrics 131:196–200, 2013.
Tschudin-Sutter S, Tamma PD, Naegeli AN, et al: Distinguishing community-associated
Clostridium difficile from hospital-associated. Clostridium difficile infections in children: implications for public health surveillance, Clin Infect Dis 57:1665–1672, 2013.
Van Nood E, Vrieze A, Nieuwdorp M, et al: Duodenal infusion of donor feces for recurrent Clostridium difficile, N Engl J Med. 368:407–414, 2013.
Brook I: Clostridial infections in children: spectrum and management, Curr Infect Dis Rep 17(11):47, 2015.
Brook I: Spectrum and treatment of anaerobic infections, J Infect Chemother 22(1):1–13, 2016.
Centers for Disease Control and Prevention: Multidrug-resistant Bacteroides fragilis—Seattle, Washington, 2013, MMWR 62:694–696, 2013.
De Keukeleire S, Wybo I, Naessens A, et al: Anaerobic bacteraemia: a 10-year retrospective epidemiological survey, Anaerobe 39:54–59, 2016.
Johannesen KM, Bodtger U: Lemierre’s syndrome: current perspectives on diagnosis and management, Infect Drug Resist 9:221–227, 2016.
Kaide CG, Khandelwal S: Infectious diseases in emergency medicine hyperbaric oxygen: applications in infectious disease, Emerg Med. Clin North Am 26:571–594, 2008.
King E, Chun R, Sulman C: Pediatric cervicofacial necrotizing fasciitis: a case report and review of a 10-year national pediatric database, Arch Otolaryngol Head Neck Surg 138:372–375, 2012.
Rodriguez-Sanchez B, Alcala L, Marin M, et al: Evaluation of MALDI-TOF MS (matrixassisted. laser desorption-ionization time-of-flight mass spectrometry) for routine identification of anaerobic bacteria, Anaerobe 42:101–107, 2016.
Shaw JJ, Psoinos C, Emhoff TA, et al: Not just full of hot air: hyperbaric oxygen therapy increases survival in cases of necrotizing soft tissue infections, Surg Infect 15(3):328–335, 2014.
Blumberg HM, Burman WJ, Chaisson RE, et al: American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis, Am J Respir Crit Care Med. 167:603–662, 2003.
Centers for Disease Control and Prevention: Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis, MMWR Recomm Rep 62(RR–09):1–12, 2013.
Dooley KE, Sterling TR: Treatment of latent tuberculosis infection: challenges and prospects, Clin Chest Med. 26:313–326, vii, 2005.
Duncan K, Barry CE: Prospects for new antitubercular drugs, Curr Opin Microbiol 7:460–465, 2004.
Fortun J, Martin-Davila P, Navas E, et al: Linezolid for the treatment of multidrugresistant tuberculosis, J Antimicrob Chemother 56:180–185, 2005.
Furin J, Tommasi M, Garcia-Prats AJ: Drug-resistant tuberculosis: will grand promises fail children and adolecents?, Lancet 2:237–238, 2018.
Marshall JD, Abdel-Rahman S, Johnson K, et al: Rifapentine pharmacokinetics in adolescents, Pediatr Infect Dis J 18:882–888, 1999.
McNeill L, Allen M, Estrada C, et al: Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved. completion rates but more hepatotoxicity, Chest 123:102–106, 2003.
Rieder HL: Fourth-generation fluoroquinolones in tuberculosis, Lancet 373:1148–1149, 2009.
Samigun M, Santoso B: Lowering of theophylline clearance by isoniazid in slow and rapid acetylators, Br J Clin Pharmacol 29:570–573, 1990.
Sotgiu G, Tiberi S, D’Ambrosio L: WHO recommendations on shorter treatment of multidrug-resistant tuberculosis, Lancet 387:2486–2487, 2016.
Van Scoy RE: Wilkowske CJ: antimycobacterial therapy, Mayo Clin Proc 74:1038–1048, 1999.
Xavier AS, Lakshmanan M: Delamanid: a new armor in combating drug-resistant tuberculosis, J Pharmacol Pharmacother 5(3):222–224, 2014.
Anderson ST, Kaforou M, Brent AJ, et al: Diagnosis of childhood tuberculosis and host RNA expression in Africa, N Engl J Med 370:1712–1722, 2014.
Arora S, Prakash TV, Carey RA, Hansdak SG: Poncet’s disease: unusual presentation of a common disease, Lancet 387:617–618, 2016.
Bekker A, Schaaf HS, Draper HR, et al: Pharmacokinetics of rifampin, isoniazid, pyrazinamide and ethambutol in infants dosed according to revised WHO-recommended treatment regimens, Antimicrob Agents Chemother 60(4):2171–2179, 2016.
Berwal A, Chawla K, Vishwanath S, Shenov VP: Role of multiplex polymerase chain reaction in diagnosing tubercular meningitis, J Lab Physicians 9(2):145–147,2017.
Blumberg HM, Kempker RR: Interferon-? release assays for the evaluation of tuberculosis infection, JAMA 312:1460–1461, 2014.
Boehme CC, Nicol MP, Nabeta P, et al: Feasibility, diagnostic accuracy, and effectiveness of decentralized use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study, Lancet 377:1495–1505, 2011.
Borisov AS, Morris SB, Njie GJ, et al: Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection, MMWR Morb Mortal Wkly Rep 67(25):723–726, 2018.
Carruth L, Roess AA, Mekonnen YT, et al: Zoonotic tuberculosis in Africa: challenges and ways forward, Lancet 388:2460–2461, 2016.
Centers for Disease Control and Prevention: Reported tuberculosis in the United States, 2015, Atlanta, 2015, US Department of Health and Human Services.
Chiang SS, Khan FA, Milstein MB, et al: Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis, Lancet Infect Dis 14(10):947–957, 2014.
Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB Treatment–2017: Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis, Lancet 392:821–834, 2018.
Cruz AT, Starke JR: Completion rate and safety of tuberculosis infection treatment with shorter regimens, Pediatrics 141(2):e20172838, 2017.
Cruz AT, Starke JR, Lobato MN: Old and new approaches to diagnosing and treating latent tuberculosis in children in low-incidence countries, Curr Opin Pediatr 26:106–113, 2014.
Dodd LE, Wilkinson RJ: Diagnosis of paediatric tuberculosis: the culture conundrum, Lancet 13:3–4, 2013.
Detjen AK, DiNardo AR, Leyden J, et al: Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis, Lancet Respir Med 3(6):451–461, 2015.
Diallo T, Adjobimey M, Ruslami R, et al: Safety and side effects of rifampin versus isoniazid in children, N Engl J Med 379(5):454–462, 2018.
Donald PR, Van Toorn R: Use of corticosteroids in tuberculous meningitis, Lancet 387:2585–2587, 2016.
Farmer PE: Better and safer treatment for multidrug-resistant tuberculosis, Lancet 392:798–800, 2018.
Feder HM Jr, Rigos L, Teti K: Pott’s disease in a Connecticut toddler, Lancet 388:504–505, 2016.
Frieden TR, Brudney KF, Harries AD: Global tuberculosis: perspectives, prospects, and priorities, JAMA 312:1393–1394, 2014.
Gaensbauer J, Gonzales B, Belknap R, et al: Interferon-gamma release assay-based screening for pediatric latent tuberculosis infection in an urban primary care network, J Pediatr 200:202–209, 2018.
Gupta-Wright A, Corbett EL, van Oosterhout JJ, et al: Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicenter, parallel-group, double blind, randomized controlled trial, Lancet 392:292–300, 2018.
Harausz EP, Garcia-Prats AJ, Seddon JA, et al: New/repurposed drugs for pediatric multidrug-resistant tuberculosis: practice-based recommendations, Am J Respir Crit Care Med 195(10):1300–1310, 2017.
Hatzenbuehler LA, Starke JR, Graviss EA, et al: School-based study to identify and treat adolescent students at risk for tuberculosis infection, Pediatr Infect Dis J 35(7):733–738, 2016.
Hsu DC, Faldetta KF, Pei L, et al: A paradoxical treatment for a paradoxical condition: infliximab use in three cases of mycobacterial IRIS, Clin Infect Dis 62(2):258–261, 2016.
Jenkins HE, Tolman AW, Yuen CM, et al: Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates, Lancet 383:1572–1578, 2014.
Jenkins HE, Yuen CM, Rodriguez CA, et al: Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis, Lancet Infect Dis 17(3):285–295, 2017.
Jones-Lopez EC, Acu?a-Villaorduna C, Ssebida?di M, et al: Cough aerosols of Mycobacterium tuberculosis in the prediction of incident tuberculosis disease in household contacts, Clin Infect Dis 63:10–20, 2016.
Kay Aw, Islam SM, Wendorf K, et al: Interferon-? release assay performance for tuberculosis in childhood, Pediatrics 141(6):e20173918, 2017.
Klopper M, Warren RM, Hayes C, et al: Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa, Emerg Infect Dis 19:449–455, 2013.
Koh WJ, Lee SH, Kang YA, et al: Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis, Am J Respir Crit Care Med 188:858–864, 2013.
LaCourse SM, Cranmer LM, Njuguna IN, et al: Urine TB lipoarabinomannan (LAM) predicts mortality in hospitalized HIV-infected children, Clin Infect Dis 66(11):1798–1801, 2018.
Lekhak SP, Sharma L, Rajbhandari R, et al: Evaluation of multiplex PCR using MPB64 and IS6110 primers for rapid diagnosis of tuberculosis meningitis, Tuberculosis (Edinb) 100:1–4, 2016.
Lewisohn DM, Leonard MK, LoBue PA, et al: Official American Thoracic Society/Infectious Diseases Society of America/CDC clinical practice guidelines: diagnosis of tuberculosis in adults and children, Clin Infect Dis 64(2):e1–e33, 2017.
Mandalakas AM, Kirchner HL, Walzl G, et al: Optimizing the detection of recent tuberculosis infection in children in a high-tuberculosis-HIV burden setting, Am J Respir Crit Care Med 191(7):820–830, 2015.
Martinez L, le Roux DM, Barnett W, et al: Tuberculin skin test conversion and primary progressive tuberculosis disease in the first 5 years of life: a birth cohort study from Cape Town, South Africa, Lancet 2:46–54, 2018.
McClintock AH, Eastmnet M, McKinney CM, et al: Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid,4 months of rifampin and 3 months of isoniazid and rifapentine, BMC Infect Dis 17:146, 2017.
McMullen SE, Pegues DA, Shofer FS, et al: Performance of QuantiFERON-TB Gold and tuberculin skin test relative to subjects’ risk of exposure to tuberculosis, Clin Infect Dis 58:1260–1266, 2014.
Menzies D, Adjobimey M, Ruslami R, et al: Four months of rifampin or nine months of isoniazid for larent tuberculosis in adults, N Engl J Med 379(5):440–452, 2018.
Moonan PK, Teeter LD, Salcedo K, et al: Transmission of multidrug-resistant tuberculosis in the USA: a cross-sectional study, Lancet 13:777–784, 2013.
Moore HA, Apolles P, de Villiers PJ, et al: Sputum induction for microbiological diagnosis of childhood pulmonary tuberculosis in a community setting, Int J Tuberc Lung Dis 15:1185–1190, 2011.
Nahid P, Dorman SE, Alipanah N, et al: Official American Thoracic Society/CDC/Infectious Diseases Society of American clinical practice guideline: treatment of drug-susceptible tuberculosis, Clin Infect Dis 63(7):e147–e195, 2016.
Nemes E, Geldenhuys H, Rozot V, et al: Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination, N Engl J Med 379(2):138–148, 2018.
Oberhelman RA, Soto-Castellares G, Gilman RH, et al: Diagnostic approaches for paediatric tuberculosis by use of different specimen types, culture methods, and PCR: a prospective case-control study, Lancet 10:612–620, 2010.
Paganini H, Gonzalez F, Santander C, et al: Tuberculous meningitis in children: clinical features and outcomes in 40 cases, Scand J Infect Dis 32:41–45, 2000.
Pereira C, Cascais M, Felix M, Salgado M: Scrofula in a child, J Pediatr 189:235, 2017.
Pinero Perez R, Santiago Garcia S, Rodriguez Marroan B, et al: Recommendations for the preparation and administration of antituberculosis drugs in children. Second phase of the Magistral Project of the Spanish Network for the Study of Paediatric Tuberculosis (pTBred), An Pediatr (Barc) 85(6):323.e1–323.e11, 2016.
Posey DL, Naughton MP, Willacy EA, et al: Implementation of new TB screening requirements for US bond immigrants and refugees—2007–2014, MMWR Morb Mortal Wkly Rep 63:234–236, 2014.
Roy A, Harris RJ, Rodrigues LC, et al: Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis, BMJ 349:g4643, 2014.
Shah NS, Auld SC, Brust JCM, et al: Transmission of extensively drug-resistant tuberculosis in South Africa, N Engl J Med 376(3):243–252, 2017.
Sharawat IK: Scrofula, J Pediatr 189:236, 2017.
Starke JR, AAP Committee on Infectious Diseases: Interferon-? release assays for diagnosis of tuberculosis infection and disease in children, Pediatrics 134(6):e1763–e1773, 2014.
Starke JR, Cruz AT: The global nature of childhood tuberculosis, Pediatrics 133: e725–e727, 2014.
Stewart RJ, Tsang CA, Pratt RH, et al: Tuberculosis—United States, 2017, MMWR Morb Mortal Wkly Rep 67(11):317–322, 2018.
Sun L, Tian J-I, Yin Q-Q, et al: Performance of interferon gamma release assays in tuberculosis disease in children five years old or less, PLoS ONE 10(12):e0143820, 2015.
Tameris MD, Hatherill M, Landry BS, et al: Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomized, placebo-controlled phase 2b trial, Lancet 381:1021–1028, 2013.
Tsang CA, Langer AJ, Navin TR, Arnstrong LR: Tuberculosis among foreign-born persons diagnosed ?10 years after arrival in the United States, 2010–2015, MMWR Morb Mortal Wkly Rep 66(11):295–298, 2017.
Villarino ME, Scott NA, Weis SE, et al: Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12 dose regimen of a combination of rifapentine and isoniazid, JAMA Pediatr 169(3):247–255, 2015.
World Health Organization: Global tuberculosis report 2016, Geneva, 2016, WHO.
World Health Organization: Roadmap for childhood tuberculosis, Geneva, 2013, WHO.
World Health Organization: Treatment guidelines for drug-resistant tuberculosis, 2016 update, Geneva, 2016, WHO.
Xie YL, Chakravorty S, Armstrong DT, et al: Evaluation of a rapid molecular drugsusceptibility test for tuberculosis, N Engl J Med 377(11):1043–1054, 2017.
Zlot A, Vines J, Nystrom L, et al: Diagnosis of tuberculosis in three zoo elephants and a human contact—Oregon, 2013, MMWR Morb Mortal Wkly Rep 64(52):1398–1402, 2016.
Zoe HJ, Workman L, Isaacs W, et al: Rapid diagnosis of pulmonary tuberculosis in African children in a primary care setting by use of Xpert MTB/RIF on respiratory specimens: a prospective study, Lancet 1:e97–e104, 2013.
Zumla A, Raviglione M, Hafner R, et al: Tuberculosis, N Engl J Med 368:745–754, 2013.
Araujo S, Freitas LO, Goulart LR, Goulart I: Molecular evidence for the aerial route of infection of Mycobacterium leprae and the role of asymptomatic carriers in the persistence of leprosy, Clin Infect Dis 63(11):1412–1420, 2016.
Ridley DS, Jopling WH: Classification of leprosy according to immunity: a five-group system, Int J Lepr Other Mycobact Dis 34(3):255–273, 1966.
Romero-Montoya M, Beltran-Alzate JC, Cardona-Castro N: Evaluation and monitoring of Mycobacterium leprae transmission in household contacts of patients with Hansen’s disease in Colombia, PLoS Negl Trop Dis 11(1):e0005325, 2017.
Sharma R, et al: Zoonotic leprosy in the southeastern United. States, Emerg Infect Dis 21(12):2127–2134, 2015.
US Department of Health and Human Services, National Hansen’s Disease Program: A summary of Hansen’s disease in the United. States, 2014.
White C, Franco-Paredes C: Leprosy in the 21st century, Clin Microbiol Rev 28(1):80–94, 2015.
Williams Dl, Lewis C: Drug resistance in patients with leprosy in the United. States, Clin Infect Dis 58(1):72–73, 2014.
World Health Organization Expert Committee on Leprosy: Eighth report, World Health Organ Tech Rep Ser 968:1–61, 2012.
World Health Organization: Global leprosy strategy 2016–2020. Accelerating towards a leprosy-free world.
Zhang FR, Huang W, Chen SM, et al: Genomewide association study of leprosy, N Engl J Med. 361(27):2609–2618, 2009.
Bruijnesteijn van Coppenraet LE, de Haas PE, Lindeboom JA, et al: Lymphadenitis in children is caused. by Mycobacterium avium hominis suis and not related. to “bird tuberculosis”, Eur J Clin Microbiol Infect Dis 27:293–299, 2008.
Bryant JM, Grogono DM, Greaves D, et al: Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study, Lancet 381:1551–1560, 2013.
Buss BF, Keyser-Metobo A, Rother J, et al: Possible airborne person-to-person transmission of Mycobacterium bovis—Nebraska, 2014–1015, MMWR 65(8):197–201, 2016.
Edens C, Liebich L, Halpin AL, et al: Mycobacterium chelonae eye infections associated. with humidifier use in an outpatient LASIK clinic, Ohio, 2015, MMWR 64(41):1177, 2015.
Falsey RR, Kinzer MH, Hurst S, et al: Cutaneous inoculation of nontuberculous mycobacteria during professional tattooing: a case series and epidemiologic study, Clin Infect Dis 57:e143–e147, 2013.
Griffith DE, Aksamit T, Brown-Elliot BA, et al: An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases, Am J Respir Crit Care Med. 175:367–416, 2007. Guideline currently being updated.
Kennedy BS, Bedard B, Younge M, et al: Outbreak of Mycobacterium chelonae infection associated. with tattoo ink, N Engl J Med. 367:1020–1024, 2012.
Koh WJ, Jeong BH, Kim SY, et al: Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease, Clin Infect Dis 64(3):309–316, 2017.
Li JJ, Beresford R, Fyfe J, Henderson C: Clinical and histopathologic features of cutaneous nontuberculous mycobacterial infection: a review of 13 cases, J Cutan Pathol epub:1–11, 2017.
Lindeboom JA, Kuijper EJ, Bruijnesteijn van Coppenraet ES, et al: Surgical excision versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children: a multicenter, randomized, controlled. trial, Clin Infect Dis 44:1057–1064, 2007.
Nick JA, Pohl K, Martiniano SL: Nontuberculous mycobacterial infection in cystic fibrosis: to treat or not to treat?, Curr Opin Pulm Med. 22:629–636, 2016.
Oliver KN, Griffith DE, Eagle G, et al: Randomized. trial of liposomal amikacin for inhalation in nonturberculous mycobacterial lung disease, Am J Respir Crit Care Med. 195(6):814–823, 2017.
Sax H, Bloemberg G, Hasse B, et al: Prolonged. outbreak of Mycobacterium chimaera infection after open-chest heart surgery, Clin Infect Dis 61:67–75, 2015.
Tebruegge M, Pantazidou A, MacGregor D, et al: Nontuberculous mycobacterial disease in children: epidemiology, diagnosis, and management at a tertiary center, PLoS ONE 11(1):e147513, 1–14, 2016.
World Health Organization: Buruli ulcer fact sheet, updated. February 2017.
Barbee LA, Centor RM, Goldberger ZD, et al: A history lesson, N Engl J Med. 372:1360–1364, 2015.
Bowen V, Su J, Torrone E, et al: Increase in incidence of congenital syphilis—United. States, 2012-2014, MMWR Morb Mortal Wkly Rep 64:1231–1245, 2015.
Centers for Disease Control and Prevention (CDC): Sexually transmitted. diseases treatment guidelines.
Centers for Disease Control and Prevention (CDC): Sexually transmitted. disease surveillance 2017, Atlanta, 2018. US Department of Health and Human Services.
Centers for Disease Control and Prevention (CDC): Syphilis physician pocket guide (PDF).
Clement ME, Hicks CB: Syphilis on the rise—what went wrong?, JAMA 315:2281–2283, 2016.
deVoux A, Kidd S, Grey JA, et al: State-specific rates of primary and secondary syphilis among men who have sex with men — United. States, 2015, MMWR Morb Mortal Wkly Rep 66(13):349–354, 2017.
Hook E: Syphilis, Lancet 389:1550–1557, 2017.
Hook E, Marra CM: Acquired. syphilis in adults, N Engl J Med. 326:1060–1069, 1992.
Kay NS, Peeling RW, Mabey DC: State of the art syphilis diagnostics: rapid point-ofcare tests, Expert Rev Anti Infect Ther 12:63–73, 2014. www.expert-reviews.com.
Lin JS, Eder ML, Bean SI: Screening for syphilis infection in pregnant women—updated. evidence report and systematic review for the US preventive services task force, JAMA 320(9):918–925, 2018.
McIntosh K: Congenital syphilis—breaking through the safety net, N Engl J Med. 323:1339–1341, 1990.
Newman L, Kamb M, Hawkes S, et al: Global estimates of syphilis in pregnancy and associated. adverse outcomes: analysis of multinational antenatal surveillance data, PLoS Med. 10:e1001396, 2013.
O’Connor CA, Shubin CD: Adolescent STIs for primary care providers, Curr Opin Pediatr 24:647–855, 2012.
Oliver SE, Aubin M, Atwell L, et al: Ocular syphilis—eight jurisdictions, United. States, 2014-2015, MMWR Morb Mortal Wkly Rep 65:1185–1188, 2016.
Onesimo R, Buonsenso D, Gio? C, et al: Congenital syphilis: remember to not forget, BMJ Case Rep 2012:2012.
Patel SJ, Klinger EJ, O’Toole D, et al: Missed. opportunities for preventing congenital syphilis infection in New York City, Obstet Gynecol 120:882–888, 2012.
Patton ME, Su JR, Nelson R, et al: Primary and secondary syphilis—United. States, 2005-2013, MMWR Morb Mortal Wkly Rep 63:402–406, 2014.
Rac MWF, Bryant SN, Cantey JB, et al: Maternal titers after adequate syphilotherapy during pregnancy, Clin Infect Dis 60:686–690, 2015.
US Preventive Services Task Force: Recommendation statement: screening for syphilis infection in nonpregnant adults and adolescents, JAMA 315:2321–2327, 2016.
US Preventive Services Task Force: Screening for syphilis–updated. evidence report and systematic review for the USPSTF, JAMA 315:2328–2337, 2016.
US Preventive Services Task Force: Screening for syphilis infection in pregnancy: reaffirmation recommendation statement, Ann Intern Med. 150:705–709, 2009.
White AC: Treatment of early syphilis in HIV: what do we really know?, Clin Infect Dis 64(76):5–766, 2017.
STD surveillance case definitions
Congenital syphilis case definition
Congenital syphilis newborn treatment guidance
Information about incidence of syphilis among women at state and county levels
Guidelines for taking sexual history
Cejkove D, Zobanikove M, Chen L, et al: Whole genome sequences of three Treponema pallidum ssp, pertenue strains: yaws and syphilis treponemes differ in less than 0.2% of the genome sequence, PLoS Negl Trop Dis 6:e1471, 2012.
Kwayke-Maclean C, Agana N, Gyapong J, et al: A single dose oral azithromycin versus intramuscular benzathine penicillin for the treatment of yaws- a randomized. noninferiority trial in Ghana, PLoS Negl Trop Dis 11(1):e0005154, 2017
Mabey D: Oral azithromycin for treatment of yaws, Lancet 379:295–296, 2012.
Marks M, Goncalves A, Vahi V, et al: Evaluation of a rapid diagnostic test for yaws infection in a community surveillance setting, PLoS Negl Trop Dis 8(9):e3156, 2014. https://doi.org/10.1371/journal.pntd.0003156.
Mitja O, Asiedu K, Mabey D: Yaws, Lancet 381:763–770, 2013.
Mitja O, Godornes C, Houinei W, et al: Re-emergence of yaws after single mass azithromycin treatment followed. by targeted. treatment: a longitudinal study, Lancet 391:1599–1606, 2018.
Mitja O, Hays R, Ipai A, et al: Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomized. trial, Lancet 379:342–347, 2012.
Scolnik D, Aronson L, Lovinsky R, et al: Efficacy of a targeted, oral-penicillin-based. yaws control program among children living in rural South America, Clin Infect Dis 36:1232–1238, 2003.
Antal GM, Lukehart SA, Meheus AZ: The endemic treponematoses, Microbes Infect 4:83–94, 2002.
Farnsworth N, Rosen T: Endemic treponematosis; review and update, Clin Dermatol 24:181–190, 2006.
Cejkove D, Zobanikove M, Chen L, et al: Whole genome sequences of three Treponema pallidum ssp, pertenue strains: yaws and syphilis treponemes differ in less than 0.2% of the genome sequence, PLoS Negl Trop Dis 6:e1471, 2012.
Kwayke-Maclean C, Agana N, Gyapong J, et al: A single dose oral azithromycin versus intramuscular benzathine penicillin for the treatment of yaws- a randomized. non-inferiority trial in Ghana, PLoS Negl Trop Dis 11(1):e0005154, 2017
Mabey D: Oral azithromycin for treatment of yaws, Lancet 379:295–296, 2012.
Marks M, Goncalves A, Vahi V, et al: Evaluation of a rapid diagnostic test for yaws infection in a community surveillance setting, PLoS Negl Trop Dis 8(9):e3156, 2014.
Mitja O, Asiedu K, Mabey D: Yaws, Lancet 381:763–770, 2013.
Mitja O, Godornes C, Houinei W, et al: Re-emergence of yaws after single mass azithromycin treatment followed. by targeted. treatment: a longitudinal study, Lancet 391:1599–1606, 2018.
Mitja O, Hays R, Ipai A, et al: Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomized. trial, Lancet 379:342–347, 2012.
Scolnik D, Aronson L, Lovinsky R, et al: Efficacy of a targeted, oral-penicillin-based. yaws control program among children living in rural South America, Clin Infect Dis 36:1232–1238, 2003
Antal GM, Lukehart SA, Meheus AZ: The endemic treponematoses, Microbes Infect 4:83–94, 2002.
Farnsworth N, Rosen T: Endemic treponematosis; review and update, Clin Dermatol 24:181–190, 2006.
Bharti AR, Nally JE, Ricaldi JN, et al: Leptospirosis: a zoonotic disease of global importance, Lancet Infect Dis 3:757–771, 2003.
Bourhy P, Storck CH, Theodose R, et al: Serovar Diversity of Pathogenic Leptospira Circulating in the French West indies, PLOS Negl Trop Dis 7(3):e2114, 2013.
CDC Health Alert Network: Advice to clinicians about leptospirosis in U.S. travelers returning from Northern Israel. Sept 7, 2018.
Costa F, Hagan JE, Calcagno J, et al: Global morbidity and mortality of leptospirosis: a systematic review, PLOS Negl Trop Dis 9(9):1–19, 2015.
Hartskeeri RA, Collares-Pereira M, Ellis WA: Emergence, control, and re-emerging leptospirosis: dynamics of infection in the changing world, Clin Microbiol Infect 17:494–501, 2011.
Libraty DH, Myint KSA, Murray CK, et al: A comparative study of leptospirosis and dengue in Thai children, PLoS Negl Trop Dis 1(3):e111, 2007.
Picardeau M: Virulence of the zoonotic agent of leptospirosis: still terra incognita? Nature Rev Microbiol 15:297–307, 2017.
Dworkin MS, Schwan TG, Anderson DE Jr, et al: Tick-borne relapsing fever, Infect Dis Clin North Am 22(3):449–468, viii, 2008.
Grosskinsky S, Schott M, Brenner C, et al: Borrelia recurrentis employs a novel multifunctional surface protein with anti-complement, anti-opsonic and invasive potential to escape innate immunity, PLoS ONE 4(3):e4858, 2009.
Hasin T, Davidovitch N, Cohen R, et al: Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever, N Engl J Med. 355:148–154, 2006.
Larsson C, Andersson M, Bergstr?m S: Current issues in relapsing fever, Curr Opin Infect Dis 22:443–449, 2009.
Larsson C, Bergstrom S: A novel and simple method for laboratory diagnosis of relapsing fever Borreliosis, Open Microbiol J 2:10–12, 2008.
Lawaczerk EW, Mead PS, Schreifer ME, et al: Tick-borne relapsing fever in a mother and newborn child–Colorado 2011, MMWR Morb Mortal Wkly Rep 61:174–176, 2012.
Oshaghi MA, Rafinejad J, Choubdar N, et al: Discrimination of relapsing fever Borrelia persica and Borrelia microti by diagnostic species-specific primers and polymerase chain reaction–restriction fragment length polymorphism, Vector Borne Zoonotic Dis 11(3):201–207, 2011.
Parola P, Diatta G, Socolovschi C, et al: Tick-borne relapsing fever Borreliosis, rural Senegal, Emerg Infect Dis 17:883–885, 2011.
Sarih M, Garnier M, Boudebouch N, et al: Borrelia hispanica relapsing fever, Morocco, Emerg Infect Dis 15:1626–1629, 2009.
Vial L, Diatta G, Tall A, et al: Incidence of tick-borne relapsing fever in west Africa: longitudinal study, Lancet 368:37–43, 2006.
Arvikar SL, Steere AC: Diagnosis and treatment of Lyme arthritis, Infect Dis Clin North Am 29:269–280, 2015.
Baldwin KD, Brusalis CM, Nduaguba AM, Sankar WN: Predictive factors for differentiating between septic arthritis and Lyme disease of the knee in children, J Bone Joint Surg Am 98:721–728, 2016.
Berende A, ter Hofstede HJM, Vos FJ, et al: Randomized trial of longer-term therapy for symptoms attributed to Lyme disease, N Engl J Med 374(13):1209–1220, 2016.
Lantos PM: Chronic Lyme disease, Infect Dis Clin North Am 29:325–340, 2015.
Lipsett SC, Pollock NR, Branda JA, et al: The positive predictive value of Lyme ELISA for the diagnosis of Lyme disease in children, Pediatr Infect Dis J 34:1260–1262, 2015.
Marzec NS, Nelson C, Waldron PR, et al: Serious bacterial infections acquired during treatment of patients given a diagnosis of chronic Lyme disease—United States, MMWR Morb Mortal Wkly Rep 66(23):607–609, 2017.
Molloy PJ, Telford SR III, Chowdri HR, et al: Borrelia miyamotoi disease in the Northeastern United States—a case series, Ann Intern Med 163(2):91–98, 2015.
Plotkin SA: Need for a new Lyme disease vaccine, N Engl J Med 375:911–913, 2016.
Robinson ML, Kobayashi T, Higgins Y, et al: Lyme carditis, Infect Dis Clin North Am 29:255–268, 2015.
Sanchez E, Vannier E, Wormser GP, Hu LT: Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review, JAMA 315:1767–1777, 2016.
The Medical Letter: Treatment of Lyme disease, Med Lett Drugs Ther 58:57–58, 2016.
Shapiro ED: Lyme disease in 2018—what is new (and what is not), JAMA 320(7): 635–636, 2018.
Welsh EJ, Cohn KA, Nigrovic LE, et al: Electrocardiographic abnormalities in children with Lyme meningitis, J Pediatric Infect Dis Soc 1:293–298, 2012.
Al-Zaidy SA, MacGregor D, Mahant S, et al: Neurological complications of PCRproven M. pneumoniae infections in children: prodromal illness duration may reflect pathogenetic mechanism, Clin Infect Dis 61(7):1092–1098, 2015.
Atkinson TP, Duffy LB, Pendley D, et al: Deficient immune response to Mycoplasma pneumoniae in childhood asthma, Allergy Asthma Proc 30(2):158, 2009.
Biondi E, McCulloh R, Alverson B, et al: Treatment of Mycoplasma pneumoniae: a systematic review, Pediatrics 133(6):1081, 2014.
Chalker VJ, Stocki T, Mentasti M, et al: Mycoplasma pneumoniae infection in primary care investigated. by real-time PCR in England and Wales, Eur J Clin Microbiol Infect Dis 30(7):915–921, 2011.
Diaz MH, Benitez AJ, Winchell JM: Investigations of Mycoplasma pneumoniae infections in the United. States: trends in molecular typing and macrolide resistance from 2006 to 2013, J Clin Microbiol 53(1):124–130, 2015.
Jain S, Williams DJ, Arnold SR, et al: Community-acquired. pneumonia requiring hospitalization among U.S. children, N Engl J Med. 372(9):835, 2015.
Matsubara K, Morozumi M, Okada T, et al: A comparative clinical study of macrolidesensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients, J Infect Chemother 380–383, 2009.
Simmons WL, Daubenspeck JM, Osborne JD, et al: Type 1 and type 2 strains of Mycoplasma pneumoniae form different biofilms, Microbiology 159(Pt 4):737–747, 2013.
Spuensens EB, Fraaij PL, Visser EG, et al: Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study, PLoS Med. 10:e1001444, 2013.
Waites KB, Xiao L, Liu Y, et al: Mycoplasma pneumoniae from the respiratory tract and beyond, Clin Microbiol Rev 30(3):747–809, 2017.
Bahrat A, Cunningham SA, Scott Budinger GR, et al: Disseminated Ureaplasma infection as a cause of fatal hyperammonemia in humans, Sci Transl Med 7(284):284re3, 2015.
Capoccia R, Greub G, Baud D: Ureaplasma urealyticum, Mycoplasma hominis and adverse pregnancy outcomes, Curr Opin Infect Dis 26(3):231–240, 2013.
Okogbule-Wonodi AC, Gross GW, Sun CC, et al: Necrotizing enterocolitis is associated with ureaplasma colonization in preterm infants, Pediatr Res 69(5 Pt 1):442–447, 2011.
Ureaplasma species: rare or relevant?, Expert Rev Anti Infect Ther 13(2):233–248, 2015.
Viscardi RM, Kallapur SG: Role of Ureaplasma respiratory tract colonization in BPD pathogenesis: current concepts and update, Clin Perinatol 42(4):719–738, 2015.
Viscardi RM: Ureaplasma species: role in neonatal morbidities and outcomes, Arch Dis Child Fetal Neonatal Ed 99(1):F87–F92, 2014.
Waites KB, Schelonka RL, Xiao L, et al: Congenital and opportunistic infections: Ureaplasma species and Mycoplasma hominis, Semin Fetal Neonatal Med 14(4):190, 2009.
Zhang N, Wang R, Li X, et al: Are Ureaplasma spp. a cause of nongonococcal urethritis? A systematic review and meta-analysis, PLoS ONE 9(12):e113771, 2014.
Bastidas RJ, Elwell CA, Engel JN, et al: Chlamydial intracellular survival strategies, Cold Spring Harb Perspect Med. 3:a010256, 2013.
Conklin L, Adjemian J, Loo J, et al: Investigation of a Chlamydia pneumoniae outbreak in a federal correctional facility in Texas, Clin Infect Dis 57:639–647, 2013.
Dowell SF, Peeling RW, Boman J, et al: Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada), Clin Infect Dis 33:492–503, 2001.
Kohlhoff SA, Hammerschlag MR: Treatment of Chlamydial infections: 2014 update, Expert Opin Pharmacother 16(2):205–212, 2015.
Kumar S, Hammerschlag MR: Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods, Clin Infect Dis 44:568–576, 2007.
Pierce V, Elkan M, Leet M, et al: Comparison of the Idaho technology FilmArray system to real-time PCR for detection of respiratory pathogens in children, J Clin Microbiol 50:364–371, 2012.
Roulis E, Polkinghorne A, Timms P: Chlamydia pneumoniae: modern insights into an ancient pathogen, Trends Microbiol 21:120–128, 2013.
Bhosai SJ, Bailey RL, Gaynor BD, et al: Trachoma: an update on prevention, diagnosis and treatment, Curr Opin Ophthalmol 23:288–295, 2012.
Emerson PM, Hooper PJ, Sarah V: Progress and projections in the program to eliminate trachoma, PLOS Negl Trop Dis 11(4):e0005402, 2017. pntd.0005402.
Gebre T, Ayele B, Genet A, et al: Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial, Lancet 379:143–150, 2012.
Grassley NC, Ward ME, Ferris S, et al: The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up, PLoS Negl Trop Dis 2:e341, 2008.
Hammerschlag MR, Kohlhoff SA, Darville T: Chlamydia pneumoniae and Chlamydia trachomatis. In Fratamico PM, Smith JL, Brogden KA, editors: Post-infectious sequelae and long-term consequences of infectious diseases, Washington, DC, 2009, American Society for Microbiology, pp . 27–52.
Black CM, Driebe EM, Howard LA, et al: Multicenter study of nucleic acid amplification ests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in children being evaluated. for sexual abuse, Pediatr Infect Dis J 28:608–613, 2009.
Centers for Disease Control and Prevention (CDC): Recommendations for the Laboratory-Based. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae — 2014, MMWR Recomm Rep 63(RR–#2):1–24, 2014.
Centers for Disease Control and Prevention (CDC): Sexually transmitted. diseases treatment guidelines 2015, MMWR Recomm Rep 64(RR–#3):1–140, 2015.
Darville T: Recognition and treatment of chlamydial infections from birth to adolescence, Adv Exp Med. Biol 764:109–122, 2013.
Girardet RG, Lahoti S, Howard LA, et al: The epidemiology of sexually transmitted infections in suspected. child victims of sexual assault, Pediatrics 124:79–86, 2009.
Hammerschlag MR, Guill?n CD: Medical and legal implications of testing for sexually transmitted. infections in children, Clin Microbiol Rev 23:493–506, 2010.
Hammerschlag MR, Kohlhoff SA, Darville T: Chlamydia pneumoniae and Chlamydia trachomatis. In Fratamico PM, Smith JL, Brogden KA, editors: Post-infectious sequelae and long-term consequences of infectious diseases, Washington, DC, 2009, American Society for Microbiology, pp . 27–52.
Kohlhoff SA, Hammerschlag MR: Treatment of chlamydial infections: 2014 update, Expert Opin Pharmacother 16(2):205–212, 2015.
Centers for Disease Control and Prevention (CDC): Recommendations for the
Laboratory-Based. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae—2014, MMWR Recomm Rep 63(RR–#2):1–24, 2014.
Centers for Disease Control and Prevention (CDC): Sexually transmitted. diseases treatment guidelines 2015, MMWR Recomm Rep 64(RR–#3):1–140, 2015.
Ditkowsky J, Shah KH, Hammerschlag MR, et al: Cost-benefit analysis of Chlamydia rachomatis screening in pregnant women in a high burden setting in the United States, BMC Infect Dis 17(1):155, 2017. doi:10.1186/s12879-017-2248-5.
Hammerschlag MR, Gelling M, Roblin PM, et al: Treatment of neonatal chlamydial conjunctivitis with azithromycin, Pediatr Infect Dis J 17:1049–1050, 1998.
Hammerschlag MR: Chlamydial and gonococcal infections in infants and children, Clin Infect Dis 53(S3):S99–S102, 2011.
Moore DL, MacDonald NE, Canadian Paediatric Society, Infectious Diseases and Immunization Committee: Preventing ophthalmia neonatorum, Paediatr Child Health 20(2):93–96, 2015.
Rours GIJG, Hammerschlag MR, De Faber JTHN, et al: Chlamydia trachomatis as a cause of neonatal conjunctivitis in Dutch infants, Pediatrics 121:e321–e326, 2008.
Backer M, Hammerschlag MR: Case #09011: A teenager with constipation and weight loss. ID Images
Blank S, Schillinger JA, Harbatkin D: lymphogranuloma venereum in the industrialized world, Lancet 365:1607–1608, 2005.
Centers for Disease Control and Prevention (CDC): Recommendations for the Laboratory-Based. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae — 2014, MMWR Recomm Rep 63(RR–#2):1–24, 2014.
Centers for Disease Control and Prevention (CDC): Sexually transmitted. diseases treatment guidelines 2015, MMWR Recomm Rep 64(RR–#3):1–140, 2015.
Leeyaphan C, Ong JJ, Cow EPF, et al: Treatment outcomes for rectal lymphogranuloma venreum in men who have sex with men using doxycycline, azithromycin, or both: a review of clinical cases, Sex Transm Dis 44:245–248, 2017.
Beeckman DSA, Vanrompay DCG: Zoonotic Chlamydophila psittaci infections from a clinical perspective, Clin Microbiol Infect 15:11–17, 2009.
Centers for Disease Control and Prevention (CDC): Case definitions for infectious conditions under public health surveillance. National Notifiable Diseases Surveillance System (NNDSS).
Knittler MR, Sache K: Chlamydia psittaci: update on an underestimated. zoonotic agent, Pathog Dis 73:1–15, 2015.
Moroney JF, Guevara R, Iverson C, et al: Detection of chlamydiosis in a shipment of pet birds, leading to recognition of an outbreak of clinically mild psittacosis in humans, Clin Infect Dis 26:1425–1429, 1998.
National Association of State Public Health Veterinarians (NASPHV): Compendium of Measures To Control Chlamydophila psittaci Infection Among Humans (Psittacosis) and Pet Birds (Avian Chlamydiosis), 2010. • Page last updated: July 7, 2016. (Accessed. 19 May 2017).
Yung AP, Grayson ML: Psittacosis: a review of 135 cases, Med. J Aust 148:228–233, 1988.
Biggs HM, Behravesh CB, Bradley KK, et al: Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted. fever and other spotted. fever group rickettsioses, ehrlichioses, and anaplasmosis—United. States, MMWR Recomm Rep 65:1–44, 2016.
Drexler NA, Dahlgren FS, Heitman KN, et al: National surveillance of spotted. fever group rickettsioses in the United. States, 2008-2012, Am J Trop Med. Hyg 94:26–34, 2016.
Johnston SH, Glaser CA, Padgett K, et al: Rickettsia sp. 364D causing a cluster of eschar-associated. illness, California, Pediatr Infect Dis J 32:1036–1039, 2013.
Paules CI, Marston HD, Bloom ME, Fauci AS: Tickborne diseases—confronting a growing threat, N Engl J Med. 379(8):701–704, 2018.
Shah RG, Sood SK: Clinical approach to known and emerging tick-borne infections other than Lyme disease, Curr Opin Pediatr 25:407–418, 2013.
Straily A, Feldpausch A, Ulbrich C, et al: Rickettsia pakeri Rickettsiosis—Georgia, 2012-2014, MMWR Morb Mortal Wkly Rep 65(28):718–719, 2016.
Alvarez-Hernandez G, Murillo-Benitez C, Candia-Plata Mdel C, Moro M: Clinical profile and predictors of fatal Rocky Mountain spotted. fever in children from Sonora, Mexico, Pediatr Infect Dis J 34:125–130, 2015.
Buckingham SC, Marshall GS, Schutze GE, et al: Clinical and laboratory features, hospital course, and outcome of Rocky Mountain spotted. fever in children, J Pediatr 150:180–184, 2007.
Demma LJ, Traeger MS, Nicholson WL, et al: Rocky Mountain spotted. fever from an unexpected. tick vector in Arizona, N Engl J Med. 353:587–594, 2005.
Holman RC, Paddock CD, Curns AT, et al: Analysis of risk factors for fatal Rocky Mountain spotted. fever: evidence for superiority of tetracyclines for therapy, J Infect Dis 184:1437–1444, 2001.
Mosites E, Carpenter LR, McElroy K, et al: Knowledge, attitudes, and practices regarding Rocky Mountain spotted. fever among healthcare providers, Tennessee, 2009, Am J Trop Med. Hyg 88:162–166, 2013.
Straily A, Drexler N, Cruz-Loustaunau D, et al: Community-based. prevention of Rocky Mountain spotted. fever—Sonora, Mexico, MMWR Morb Mortal Wkly Rep 65(46):1302–2016, 2016.
Todd SR, Dahlgren FS, Traeger MS, et al: No visible dental staining in children treated. with doxycycline for suspected. Rocky Mountain spotted. fever, J Pediatr 166:1246–1251, 2015.
Todd SR, Regan JJ, Humphreys D, et al: Rocky Mountain spotted. fever characterization and comparison to similar illnesses in a highly endemic area—Arizona, 2002-2011, Clin Infect Dis 60(11):L1650–L1658, 2015.
Anton E, Mu?oz T, Traver?a FJ, et al: Randomized. trial of clarithromycin for Mediterranean spotted. fever, Antimicrob Agents Chemother 60:1642–1645, 2015.
Baltadzhiev IG, Popivanova NI, Stoilova YM, et al: Mediterranean spotted. fever—classification by disease course and criteria for determining the disease severity, Folia Med. (Plovdiv) 54:53–61, 2012.
Botelho-Nevers E, Rovery C, Richet H, et al: Analysis of risk factors for malignant Mediterranean spotted. fever indicates that fluoroquinolone treatment has a deleterious effect, J Antimicrob Chemother 66:1821–1830, 2011.
Colomba C, Saporito L, Siracusa L, et al: Mediterranean spotted. fever in paediatric and adult patients: two clinical aspects of the same disease, Infez Med. 19:248–253, 2011.
Mouffok N, Parola P, Abdennour D, et al: Mediterranean spotted. fever in Algerian children, Clin Microbiol Infect 15(Suppl 2):290–291, 2009.
Pishmisheva M, Stoycheva M, Vatev N, Semerdjieva M: Mediterranean spotted. fever in children in the Pazardjik region, South Bulgaria, Pediatr Infect Dis J 33:542–544, 2014.
Blanton LS, Walker DH: Flea-borne rickettsioses and rickettsiae, Am J Trop Med. Hyg 96:53–56, 2017.
Koss T, Carter EL, Grossman ME, et al: Increased. detection of rickettsialpox in a New York City hospital following the anthrax outbreak of 2001: use of immunohistochemistry for the rapid confirmation of cases in an era of bioterrorism, Arch Dermatol 139:1545–1552, 2003.
Bhat NK, Pandita N, Saini M, et al: Scrub typhus: a clinico-laboratory differentiation of children with and without meningitis, J Trop Pediatr 62:194–199, 2016.
Chansamouth V, Thammasack S, Phetsouvanh R, et al: The aetiologies and impact of fever in pregnant inpatients in Vientiane Laos, PLoS Negl Trop Dis 10:e0004577, 2016.
Chanta C, Phloenchaiwanit P: Randomized. controlled. trial of azithromycin versus doxycycline or chloramphenicol for treatment of uncomplicated. pediatric scrub typhus, J Med. Assoc Thai 98:756–760, 2015.
Han DK, Baek HJ, Shin MG, et al: Scrub typhus-associated. severe hemophagocytic lymphohistiocytosis with encephalitis leading to permanent sequelae: a case report and review of the literature, J Pediatr Hematol Oncol 34:531–533, 2012.
Jensenius M, Han PV, Schlagenhauf P, et al: Acute and potentially life-threatening tropical diseases in western travelers—a GeoSentinal multicenter study, 1996-2011, Am J Trop Med. Hyg 88:397–404, 2013.
Lee M, Kim J, Jo DS: Effects of clarithromycin treatment in scrub typhus in children: comparison with chloramphenicol and azithromycin, Korean J Pediatr 60:124–127, 2017.
Reller ME, Bodinayake C, Nagahawatee A, et al: Unsuspected. rickettsioses among patients with acute febrile illness, Sri Lanka, 2007, Emerg Infect Dis 18:825–829, 2012.
Silpapojakul K, Varachit B, Silpapojakul K: Paediatric scrub typhus in Thailand: a study of 73 confirmed. cases, Trans R Soc Trop Med. Hyg 98:354–359, 2004.
Sirisanthana V, Puthanakit T, Sirisanthana T: Epidemiologic, clinical and laboratory features of scrub typhus in thirty Thai children, Pediatr Infect Dis J 22:341–345, 2003.
Taylor AJ, Paris DH, Newton PN: A systematic review of mortality from untreated. scrub typhus (Orientia tsutsugamushi), PLoS Negl Trop Dis 9:e0003971, 2015.
Wang CL, Yang KD, Cheng SN, et al: Neonatal scrub typhus: a case report, Pediatrics 89:965–968, 1992.
Weitzel T, Dittrich S, L?pez J, et al: Endemic scrub typhus in South America, N Engl J Med. 375:954–961, 2016.
Botto C, Basa?ez MG, Escalona M, et al: Evidence of suppression of onchocerciasis transmission in the Venezuelan Amazonian focus, Parasit Vectors 9:40, 2016.
Boussinesq M: Anew powerful drug to combat river blindness, Lancet 392:1170–1172, 2018.
Johnson TP, Tyagi R, Lee PR, et al: Nodding syndrome may be an autoimmune reaction to the parasitic worm Onchocerca volvulus, Sci Transl Med. 9(377):2017. pii: eaaf6953.
Richards F Jr, Rizzo N, Diaz Espinoza CE, et al: One hundred. years after its discovery in Guatemala by Rodolfo Robles, Onchocerca volvulus transmission has been eliminated. from the Central Endemic Zone, Am J Trop Med. Hyg 93:1295–1304, 2015.
World Health Organization: Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis: criteria and procedures, Geneva, 2016, WHO.
Chesnais CB, Takougang I, Pagu?l? M, et al: Excess mortality associated. with loiasis: a retrospective population-based. cohort study, Lancet Infect Dis 17:108–116, 2017.
Geary TG: A step toward eradication of human filariases in areas where Loa is endemic, MBio 7:e00456-16, 2016.
Kamgno J, Nguipdop-Djomo P, Gounoue R, et al: Effect of two or six doses 800 mg of albendazole every two months on Loa loa microfilaraemia: a double blind, randomized, placebo-controlled. trial, PLoS Negl Trop Dis 10:e0004492, 2016.
Dantas-Torres F, Otranto D: Dirofilariosis in the Americas: a more virulent Dirofilaria immitis?, Parasit Vectors 6:288, 2013.
Liu EW, Schwartz BS, Hysmith ND, et al: Rat lungworm infection associated. with central nervous system disease—eight US states, January 2011–January 2017, MMWR Morb Mortal Wkly Rep 67(30):825–828, 2018.
Martins YC, Tanowitz HB, Kazacos KR: Central nervous system manifestations of Angiostrongylus cantonensis infection, Acta Trop 141(Pt A):46–53, 2015.
Ramirez-Avila L, Slome S, Schuster FL, et al: Eosinophilic meningitis due to Angiostrongylus and Gnathostoma species, Clin Infect Dis 48(3):322–327, 2009.
